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SUMMARY
Experiments have been performed on female ferrets (Mustela 
putorius furo, L.) and female rats (Wistar albino) to assess the 
toxicity of the synthetic oestrogens diethylstilboestrol, hexoestrol and 
ethinyloestradiol. Emphasis was given to determining whether the 
observed effects were due to disturbances in endocrine homeostasis or to 
other causes.
Diethylstilboestrol (6mg/kg/day) or hexoestrol (18mg/kg/day) 
administered orally in isopropyl myristate proved lethal to two groups 
of three oestrous ferrets inside a 30-day period. Death was associated 
with agranulocytosis, anaemia, a bleeding syndrome, jaundice, and body 
weight loss. The livers showed periportal fatty change, intrahepatic 
biliary lesions, and early centrilobular necrosis. There was also some 
evidence of renal damage and the bone marrows were hypoplastic or 
aplastic. The changes in the peripheral blood included a neutrophil 
leucocytosis followed by leucopenia, anaemia, and thrombocytopenia. The 
ovaries showed inhibitory, and the uteri stimulatory, changes. The 
heaviest animals tended to survive longest. The toxicity of the 
oestrogens seemed to be related to their hormonal potency.
Though responding in a qualitatively similar manner, the 
anoestrous ferret showed less susceptibility to diethylstilboestrol 
(6 mg/kg/day) than the oestrous animal, both in terms of the hepatic and 
haemopoietic changes and also the uterotrophic effects. Pretreatment 
with the antioestrogen clomiphene citrate (2 mg/kg/day) or with 
phenobarbitone sodium (3GmgAg three times weekly) had no effect on the 
observed changes. The effects of ethinyloestradiol (6 mg/kg/day) were 
similar to those of diethylstilboestrol. There were alterations in 
plasma fibrinogen levels and in the serum proteins.
Oestrogens were less toxic to the female rat than the female 
ferret. Diethylstilboestrol or hexoestrol administered to adult rats 
(c250g) at dose levels of 6 and 60mg/kg/day, respectively, for 42 days, 
provoked a moderate anaemia, inappetance, body weight loss and marked 
gains in the liver, uterine, adrenal and pituitary weights. The liver 
damage was slight, the main finding being fatty change. This affected 
scattered individual cells in the midzonal region. There was a modest 
degree of erythroid hypoplasia in the bone marrow and there were 
stimulatory changes in the reproductive tract. Pretreatment with 
clomiphene citrate (2mg/kg/day) reduced the appetite and body weight, 
losses and the organ weight gains caused by diethylstilboestrol. The 
hexoestrol-treated rats showed disorders in vitamin K-dependent blood
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clotting (Thrombotest time). Subsequent studies showed that 
diethylstilboestrol and ethinyloestradiol at a dose of 60mg/kg/day could 
also cause similar clotting changes. These disorders were not 
associated with overt bleeding and tended to be biphasic and self- 
limiting over a 20-day period. A coumarin-like vitamin K antagonism was 
discounted and it was concluded that the disorders were due to transient 
liver dysfunction. The evidence pointed to the involvement in these 
effects of damage to the hepatic endoplasmic reticulum. The clotting 
defects were unaffected by pretreatment with testosterone or vitamin K 
but were exacerbated by clomiphene citrate, in some cases to lethal 
effect. Death was associated with a bleeding disorder. There appeared 
to be an inverse relationship among animals treated with hexoestrol and 
clomiphene betwen liver size and the Thrombotest clotting time. It was 
concluded that the antioestrogen blocked an adaptive liver enlargement 
by an effect at the hypothalamic-pituitary axis; liver growth in 
response to oestrogens was shown not to be due to direct action but due 
to an increase in pituitary growth hormone secretion. It was postulated 
that the clotting disorders in rats treated with high doses of 
oestrogens were associated with a partial failure of pituitary-mediated 
hepatic adaptation.
In rats treated with hexoestrol at a dose of 60mg/kg/day for 
four days there were the following changes in relative organ weights: 
liver (+37%), spleen (-11%), adrenals (+43%), kidneys (+3%), pituitary 
(+23%), uterus (+49%), and ovaries (+13%). The heart weights were 
generally unchanged. By comparison, the relative organ weights of 
hypophysectomized, hexoestrol-treated rats differed from those of 
hypophysectomized controls thus: liver (+1 1 %), spleen (0 %), heart
(-2%), adrenals (+7%), kidneys (-5%), uterus (+2%), and ovaries (-1%). 
None of these differences was significant. It was concluded that the 
organ weight changes provoked by hexoestrol in intact rats - including 
the uterine weight gains - were mainly mediated through the 
typo thalamic-pituitary axis. The evidence from the present studies and 
the literature is consistent with the existence of a novel pituitary 
hormone necessary for full uterine growth, "uterotrophic factor". It is 
tentatively suggested that this hormone may also have effects outside 
the reproductive system, for example, on hepatic drug and steroid 
metabolism and on haemopoiesis. The uterine growth and also the 
pituitary growth were partially inhibited by an oestrogen-induced 
increase in growth hormone. This latter appeared to be the main cause
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of the increases in the liver and kidney weights and a contributory 
factor in the increase in the adrenal weights. The other influences on 
the organ weights were not determined but presumably involved the other 
trophic hormones of the adenohypophysis. The changes caused by 
hexoestrol were mostly prevented in a dose-dependent manner by 
clomiphene citrate pretreatment (20-60mg/kg/day). It was postulated 
that this effect was due to antagonism at the hypothalamic-pituitary 
axis. In this analysis, the antiuterotrophic activity of clomiphene 
citrate is mainly due to antagonism of the oestrogen-induced pituitary 
contribution to uterine growth.
A decrease in the size of most of the organs, with the exception 
of the adrenals, was observed in rats treated with clomiphene citrate 
alone (60mg/kg/day). The results were as follows: liver (-18%), spleen
(-17%), heart (-16%), kidneys (-11%), adrenals (+7%), pituitary (-13%), 
uterus (-25%), and ovaries (-4%). It was suggested that these effects 
were probably due to action at the lypothalamic-pituitay axis but that 
they may not have been due solely to antagonism of endogenous oestrogen.
A somewhat similar pattern of organ weight changes occurred in 
ferrets treated with hexoestrol at a dose of 60mg/kg/day for four days 
as occurred in rats, though the observed effects were less consistently 
provoked; in some ferrets there were only a few, moderate changes, while 
in others all the organ weights were altered, in some cases (e.g. 
pituitary, uterus) markedly more so than in the rat. It was concluded 
that these effects like those in the rat were probably mediated through 
the hypothalamic-pituitary axis. The mechanism by which the organ 
weight changes were induced in the two species must differ, however, 
because while clomiphene citrate prevented the changes in the rat, this 
compound was without effect in the ferret. The ineffectiveness of 
clomiphene citrate in the ferret included failure to modify an 
oestrogen-induced uterine weight gain. By this criterion, therefore, 
clomiphene citrate did not display antioestrogenic activity in the 
ferret. If the antiuterotrophic activity of clomiphene citrate in the 
rat mainly relates to central effects, then the differences between the 
ferret and rat in the response to this compound may imply species 
variations in the control of the putative pituitary contribution to 
uterine growth.
The oestrogen-induced pituitary enlargements in the ferret and 
rat were due, respectively, to acidophil and chromophobe proliferation 
in the glandular lobe. Ihe proliferative response of the uterine
luminal epithelium of the rat was greater than that of the ferret, but 
among susceptible ferrets of the uterine weight gains and the 
luminal fluid accumulation were more marked than in the rat.
Among untreated oestrous ferrets, the pituitary weights, when 
expressed as a percentage of body weight, were one tenth those of 
untreated rats. The other organ weights were either similar in the two 
species or diverged much less markedly.
It is conjectured (i) that the haematological abnormalities 
caused by oestrogens in the ferret are due in part to progressive 
changes in pituitary function; (ii) that while the changes in the ferret 
pituitary are not well tolerated, the changes in the rat pituitary are 
compatible with, and conducive to, adaptation (e.g. of the liver) and 
hence low toxicity; (iii) that the different responses of the ferret and 
the rat are due to interspecies variations in endocrinology; and (iv) 
that the "toxic" effects of oestrogens appear to be mainly due to 
disturbances in endocrine control mechanisms.
Diethylstilboestrol, hexoestrol, and ethinyloestradiol, when 
administered in high doses have qualitatively similar toxic effects.
Vitamin K-, displayed appreciable oestrogenic activity in the
rat.
The ferret is considered as a potential replacement for the 
beagle dog in toxicity studies. It is concluded that while the ferret 
has considerable cost advantages over the beagle dog, there is less 
background information on its use, and it also lacks the dog's balance 
of practical assets (e.g. ease of phlebotomy). The ferret may thus be 
unsuitable for routine use in safety evaluation, but nevertheless 
represents a useful second non-rodent species where additional 
toxicological characterization of a drug or chemical is required.
ABBREVIATIONS
Acm Adrenocorticotrophic hormone
Anti-GH Monkey antiserum to rat growth hormone
CC Clomiphene citrate
Con A Concanavalin A
DES Diethylstilboestrol
FSH Follicle-stimulating hormone
GH Growth hormone
Hb Haemoglobin
HEX Hexoestrol
Hypox Hypophysectomized
LH Luteinizing hormone
MCV Mean cell volume
MCH Mean cell haemoglobin
MCHC Mean cell haonoglobin concentration
MSH Melanocyte-stimulating hormone
N/L ratio Neutrophil/lymphocyte ratio
PB Phenobarbitone sodium
PCV Packed cell volume
Pltlt Platelets
RBC Red blood cells
Reties Reticulocytes
SD Standard deviation
TSH Thyroid-stimulating hormone
U/l Units/litre
Vit K Vitamin K
WBC White blood cells
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INTRODUCTION
AIMS
The principal aim of the work described in this thesis was to 
investigate the toxicological consequences of administering oestrogens 
in high doses to different mammalian species. Attempts were made to 
determine whether the toxic effects were attributable to disturbances in 
endocrine homeostasis or to an unrelated mechanism. Two structurally 
similar oestrogens (diethylstilboestrol and hexoestrol) were compared at 
oestrogenically equivalent doses in two contrasting species, the ferret 
and the rat. The former is a monoestrous carnivore, a seasonal breeder 
and an induced ovulator. Ihe latter is a polyoestrous rodent, a non- 
seasonal breeder and a spontaneous ovulator. A subsidiary aim of this 
work was to evaluate the ferret as a non-rodent alternative to the dog 
in toxicity studies.
HISTORICAL BACKGROUND
Research on oestrogens began in 1900 when Halban and Knauer 
independently transplanted rabbit ovaries and concluded that these 
organs stimulated uterine growth by secretion of a biologically active 
substance into the blood. Marshall and Jolly in 1905 suggested that 
ovarian cells could secrete a compound that induces oestrus in castrated 
rodents. Other discoveries followed but the final proof that the ovary 
was the source of an oestrus-inducing hormone came with Allen and 
Doisy's demonstration in 1923 that bovine follicular fluid induced 
oestrus and enlargement of the uterus in immature rats. Hiey found, 
too, that the vaginal smear could be used as a quantitative assay of 
oestrogenic activity. At about this time, the interrelations between 
the pituitary and gonads were also described (Zondek and Ascheim, 1926; 
Smith, 1926, 1927). In 1927 Ascheim and Zondek discovered that all 
urine and particularly human pregnancy urine contained large quantities 
of oestrogenic hormones. This together with the bioassay of Allen and 
Doisy opened the way for the full identification of the sex steroids.
In 1929 Doisy's group in the US and Butenaudt in Germany isolated 
oestrone, the first known member, of the steroid group. A year later 
Marrian did the same for oestriol. In 1933 Schwenk and Hildebrandt 
reduced oestrone to oestradiol and by 1935 the structure of all of the 
major sex steroids, including testosterone and progesterone, had been 
established. Around this time also, synthetic compounds with
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oestrogenic activity were described and these together with the natural 
oestrogens rapidly entered medical and veterinary practice in the 
treatent of a variety of disorders.
In view of their recent discovery it is remarkable that the use 
of oestrogens is now so widespread. It is estimated, for example, that 
80 million women worldwide use oestrogen-based contraceptives (WHO,
1978). Recently, however, the use of preparations such as these has 
declined with the appearance of disquietening reports of serious adverse 
reactions. This has renewed interest in the experimental toxicology of 
these compounds.
DESCRIPTION
Oestrogens are a class of substances which, by definition, 
induce 'heat1, behavioural oestrus, in animals, and cause vaginal 
cornification and uterine hypertrophy in animals and man.
Oestrogens form a heterogenous class of compounds: numerous
natural and synthetic compounds, both steroidal and nonsteroidal, have 
been found to possess oestrogenic activity. The diversity of structures 
displaying this activity makes the oestrogens unique among the hormonal 
classes. Furthermore, oestrogenic potency is the commonest biological 
activity encountered among foreign compounds. The synthetic oestrogens 
replicate in the organism the actions of the endogenous hormones, and 
there is no evidence to suggest that their mechanism of action is 
qualitatively different (Emmens, 1970; Eisenfeld, 1976; Lipsett,
1977).
All the natural oestrogens of animal origin so far isolated are 
steroids, that is they possess the cyclopentanoperhydrophenanthrene 
nucleus. The three main mammalian oestrogens are oestradiol (Fig. 1), 
oestrone and oestriol. These are 18-carbon ((4 3 ) steroids. Oestradiol 
is the most biologically active and is the major ovarian oestrogen. The 
organs of origin besides the ovary are the testis, adrenal cortex and 
placenta. The biosynthesis of oestrogens is from cholesterol via 
pregnenolone to the 0 ^ 9 steroids, the androgens, and hence to the C^g 
steroids. The oestrogens circulate in the blood in both the free state 
and bound to albumin and, in humans, to the specific sex hormone-binding 
globulin. They are metabolized predominantly in the liver and the 
structural alterations include hydroxylation at positions 2, 4, 6 , 7 and 
16 on the steroid nucleus, and conjugation with glucuronic and sulphuric
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Fig. 1 Structures of oestradiol, ethinyloestradiol, 
diethylstilboestrol, hexoestrol, and clomiphene citrate
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acids. The conjugates are abundant in the bile but there is an 
extensive enterohepatic circulation (Adlercreutz, 1974). In humans, 
oestrogens are mainly eliminated in the urine, but in the rat and other 
common laboratory animals they are eliminated in the faeces.
The synthetic oestrogens are structurally diverse, but like the 
natural oestrogens all of them possess an aromatic ring though not all 
have a hydroxyl group attached. Those compounds lacking the hydroxyl 
group are metabolized in vivo before showing oestrogenic activity.
These compounds that require conversion are the so-called 'pro- 
oestrogens' (Emmens, 1941, 1942a). Compounds which like oestradiol have 
two hydroxyl groups an appropriate distance apart tend to be the most 
potent oestrogens (Daux and Weeks, 1980).
A number of the synthetic oestrogens are highly active when 
administered orally. This is in contrast to the natural oestrogens 
which are more readily cleared from the blood and inactivated by the 
liver. The first synthetic steroidal oestrogen which was found to be 
highly active when administered orally was ethinyloestradiol (Fig. 1), 
prepared by Inhoffen in 1938. This compound and its 3-methyl ether, 
mestranol, remain the most widely used oestrogens in clinical practice. 
These compounds are metabolized in humans and animals in a similar 
manner to the endogenous hormones, but rather less extensively (Bolt,
1979).
Efforts to identify nonsteroidal compounds of high potency were 
prompted by the report of Cook et al in 1933 that oestrogenic activity 
was not exclusively associated with compounds possessing the steroid 
nucleus. The search culminated in the synthesis of the orally active 
diethylstilboestrol, a stilbene derivative, and hexoestrol, a bibenzyl 
derivative (Dodds et al, 1938). The trans configuration of 
diethylstilboestrol, which bears a superficial resemblance to the 
natural hormones, was found to be a good deal more potent than the cis 
configuration, while meso hexoestrol was found to be the active form of 
that compound (Dodds, 1944). Ihe structures of these oestrogens are 
illustrated in Fig. 1. Many other compounds related to these have been 
investigated for oestrogenic activity, but, any considerable deviation 
from the diethylstilboestrol or hexoestrol structure generally causes a 
marked decrease in activity (e.g. Terenius, 1972).
The metabolic fate of diethylstilboestrol has been determined in 
the rat, hamster and human (Metzler, 1975, 1976). Ihe findings are 
summarized in Fig. 2. The possible pathways are (a) aromatic ring
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hydroxylation and methylation to the resulting catechol, as occur with 
the steroidal oestrogens, both natural and synthetic,
(b) w-hydroxylation at one of the ethyl side chains, and (c) oxidative 
attack at the stilbene double bond giving rise to dienoestrol 
(metabolite E in Fig. 2 - a different stereoisomer from the commercially 
available drug) probably via epoxide and dihydrodiol intermediates.
About 4C% of a -^C diethylstilboestrol dose injected to humans is 
recovered from the first day's urine, with glucuronides representing 90% 
of this activity. About 70% of the glucuroniae fraction is conjugated 
diethylstilboestrol, about 1 0 % dienoestrol, and about 2 0 % w-hydroxy- 
dienoestrol (metabolite J in Fig. 2). In the rat there is predominantly 
faecal excretion, but in this species as in most others there is 
extensive enterohepatic circulation (Bolt, 1979). Fewer studies have 
been reported on hexoestrol. In one experiment, up to 90% of a dose of 
hexoestrol administered to rats was recovered within 96 hours (Dodds et 
al, 1958). Most of this was in the faeces as conjugated material, but 
the identity of the excreted drug was not determined. Total oxidation 
was reported as 2% or less. The metabolism of hexoestrol appears to 
involve, like that of diethylstilboestrol, ring hydroxylation and 
methylation, and w-hydroxylation at the ethyl side chains (Metzler et 
al, 1980). Since hexoestrol lacks the stilbene double bond, however, 
expoxidation in this region does not occur. These findings are 
supported by the results of a study on the metabolism of bifluranol, a 
novel fluorinated bibenzyl structurally related to hexoestrol (Chan et 
al, 1978). The disposition of this compound in the rat is similar to 
diethylstilboestrol but it is significantly less prone to oxidative 
attack. A ring hydroxylated metabolite was identified as the main 
oxidation product.
Many other nonsteroidal oestrogens unrelated to the stilbenes or 
bibenzyls have been described (for reviews see Hogg and Korman, 1956; 
Frieden, 1976). A number of compounds have also been found to 
antagonize the action of oestrogens. These are the so-called 
'antioestrogens1. Use was made in the present work of one of these 
compounds, clomiphene (chloramiphene or MRL-41) - a triphenylethylene 
derivate. This compound is commercially available as clomiphene citrate 
(Fig. 1), a one-to-one racemic mixture of cis and trans isomers. The 
trans isomer (enclomiphene) is antioestrogenic, but the cis isomer 
(zuclomiphene) tends to be oestrogenic (Jordan et al, 1978). When 
clomiphene is administered alone it may act as a weak oestrogen but when
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administered with a fully active compound it acts as an antioestrogen 
and inhibits many of the changes that would normally occur in the 
oestrogen target tissues (Clark and Peck, 1979). This antagonism is due 
not only to direct competition with the oestrogen for the cytosol 
receptors (see below) but also to interference with the process of 
receptor replenishment that is required for full oestrogenic effect.
PHYSIOLOGICAL effects
Endocrinology
Oestrogens constitute a group of hormones which with other 
hormones are responsible for the normal growth and development of female 
mammals. Within this general function they have particular roles in the 
sexual differentiation of the brain, in promoting the development of the 
female reproductive system and the secondary sexual characteristics, and 
in establishing the oestrous cycle of animals and the menstrual cycle of 
humans. Oestrogens, together with progesterone, are thereafter 
responsible for the maintenance of the reproductive cycle, and, in the 
event of conception, of pregnancy. They also act with prolactin to 
stimulate lactation. In humans, the fall in oestrogen production in the 
menopause is responsible for many of the changes that occur at that time 
of life. Oestrogens are also present in the male and evidence is 
accumulating that these hormones may be involved in the regulation of 
the male reproductive system and, in some mammals, in aspects of sexual 
behaviour (Mawhinney and Neubauer, 1979). Oestrogens are antagonistic 
to testosterone, but to progesterone they can be synergistic or 
antagonistic.
The primary purpose of oestrogen is to stimulate the uterine 
cells to increase in size and number. This hypertrophy and hyperplasia 
sets the stage for subsequent modifications induced by progesterone, 
also secreted by the ovaries, which results in a receptive environment 
for blastocyst implantation. The secretion of the ovarian hormones is 
controlled by the pituitary gonadotrophins, FSH and LH, the secretion of 
which is in turn influenced by the gonadal steroids. The female 
reproductive system, therefore, does not remain at a steady level of 
activity but undergoes cyclical changes. In the early part of the cycle 
the ovum or ova develops under the influence of FSH. Oestrogen levels 
rise by virtue of follicular secretion to reach a peak towards the end
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of the first half of the cycle. A positive feedback effect of 
oestrogens at the hypothalamic-pituitary axis then induces a surge in LH 
secretion which in turn triggers ovulation. If fertilization occurs, 
implantation will follow. In animals, sexual activity usually coincides 
with peak plasma levels of LH to ensure fertilization. In induced 
ovulators such as the ferret, LH secretion and hence ovulation are 
reflexly stimulated by coitus.
Oestrogen molecules readily enter all tissues by passive 
diffusion but accumulate preferentially, and remain in a chemically 
unchanged form, in the main target organs - the vagina, uterus, mammary 
glands, anterior pituitary and hypothalamus. The pituitary and 
hypothalamus unlike the other tissues do not grow in response to normal 
oestrogenic stimulation. Originally it was believed that what 
characterized the target organs was the presence of specific 
intracellular oestrogen receptors, but it now seems likely that most, if 
not all, mammalian tissues contain small amounts of these receptors and 
that what differentiates the hormone-dependent tissues is the magnitude 
of their receptor content (Jensen, 1979). The oestrogen receptor is a 
soluble macromolecule found in the cytosol of the cell. The oestrogen 
molecules bind with this to form hormone-receptor complexes which 
undergo an activation step before crossing the nuclear membrane and 
binding to sites on chromatin. This stimulates the transcription of 
mRNA which leads to the synthesis of. specific proteins (enzymes, 
regulatory factors, and structural components) that are responsible for 
the. characteristic response of the target tissues. Ihe receptor itself 
is also replenished during this process and receptors for progesterone 
synthesized. Full uterine growth requires sustained occupancy of 
nuclear-acceptor sites by the oestrogen-receptor complexes. The 
oestrogen receptors like the hormones themselves, increase with the 
onset of sexual maturity, change with cyclical reproductive status 
(Buchi and Keller, 1980), and decline with age (Chang and Roth, 1979). 
Receptor levels are increased by oestrogen administration, and decreased 
by progesterone and antioestrogens (Baulieu et al, 1975), and there 
exists a reasonably good correlation between oestrogenic potency and 
affinity for the receptor (Siiteri, 1979). The receptor concept of 
oestrogen action, however, may be simplistic: additional, low-affinity
receptor sites may exist in the cytosol (Clark and Peck, 1979); there 
may be membrane-bound receptors in the uterine endoplasmic reticulum 
(Parikh et al, 1980); direct effects on the cell membrane have been
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described in the pituitary (Dufy et al, 1980); and blood eosinophils 
have been implicated in the early changes (hyperaemia, histamine 
release, tissue uptake of nutrients and so on) which follow oestrogenic 
stimulation of the uterus (Tchernitchin, 1976). These and other 
observations might suggest that oestrogens are hormones with multiple 
sites of action in their target tissues and elsewhere. Recently, it has 
been shown (Sonnenschein and Soto, 1978) that for a full uterotrophic 
response to oestrogens an intact pituitary is required. The nature of 
this pituitary contribution to uterine growth is uncertain.
Other metabolic effects
Besides having effects on reproduction and development 
oestrogens also have a variety of other roles many of which have only 
recently been established. Thus, these hormones influence body weight 
and composition, and have effects on lipid, carbohydrate and protein 
metabolism, and on other endocrine organs, including the thyroid and 
adrenal glands. Though not as potent as androgens, oestrogens are 
anabolic and as such favour retention of nitrogen, calcium and 
phosphorus. Oestrogens, tend to antagonise many of the effects of 
androgens, for example, in reducing sebaceous gland activity in the 
skin. They also act on the kidney to cause retention of water, sodium 
and chloride. In connective tissue, water content is increased and the 
mucopolysaccharides which bind collagen are altered, rendering the 
tissue more supple. Effects on the cardiovascular system include 
alterations in blood coagulation and wound healing, blood pressure, 
capillary fragility, and the distensibility of blood vessels (Steinetz, 
1973). Oestrogens also appear to retard atherosclerosis. This in part 
may explain the much lower incidence of cardiovascular disease in 
premenopausal women than in men of the same age. This action is in 
contrast to the effect of exogenous oestrogens in enhancing the risk of 
such diseases (see below). Oestrogens increase the hepatic synthesis of 
a number of the specific serum binding proteins and thus may affect the 
blood levels of, for example, thyroxine, cortisol, copper, and iron. 
Stimulation of the reticuloendothelial system (Nicol et al, 1964) and 
actions on the mucous membranes of the nose, mouth, and trachea are some 
of the many other reported effects of oestrogens.
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CLINICAL TOXICOLOGY
Oestrogens have been used in the treatment of many conditions, 
including hypogonadal states, menstrual irregularities, menopausal 
disorders including osteoporosis, cancer (breast and prostate), and 
threatened or recurrent abortion. They have also been given to inhibit 
lactation, to curb excessive growth in tall girls, in pregnancy 
diagnosis, and in various forms of hormonal contraception, notably in 
the combined-type (oestrogen-progestogen) oral contraceptive pill.
Since the various oestrogens elicit the same effects the choice 
of preparation has been largely determined by cost and convenience. 
Latterly, however, because of the alleged teratocarcinogenic effects of 
the nonsteroidal oestrogens (see below), these compounds have been used 
less frequently than their steroidal equivalents. With the possible 
exception of this form of toxicity the various oestrogens have 
qualitatively similar adverse effects (Westerholm, 1980). Though it is 
occasionally stated that the nonsteroidal oestrogens are more toxic than 
the steroidal oestrogens, persuasive evidence of this is lacking.
Oestrogen treatment has been associated with many minor side 
effects such as nausea, depression and so on (Westerholm, 1980), and 
also with many metabolic abnormalities (Briggs, 1976). The clinical 
significance of most of these latter is uncertain. Only the major side 
effects will be considered here.
Cardiovascular disorders
It is now generally accepted that the results of both 
retrospective and prospective epidemiological studies have established 
an association between an increased incidence of various cardiovascular 
diseases and the use of the oral contraceptive pill (review, Westerholm, 
1980). Hie oestrogen component is held to be responsible for these 
effects (Zador, 1975). The disorders include pulmonary embolism, deep 
vein thrombosis, cerebral thrombosis, myocardial infarction, and 
hypertension. Estimates put the excess risk among oral contraceptive 
uses of thromboembolic disorders in particular at 4 - 5 times that of 
non-users (Rakoff, 1978). There is also an increased incidence of 
thromboembolic disorders among several other groups treated with 
oestrogens: in women in whom lactation has been suppressed after
childbirth (Suppressing Lactation, 1977); in men with cancer of the
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prostate (Byar, 1973); and in men receiving these hormones to prevent 
the progression of heart disease (Wessler, 1980). The reason for this 
is not understood though alterations have been described, inter alia, in 
the levels of several of the blood clotting factors (Dixit, 1980), in 
anti thrombin III activity (Zador, 1975) and in factor Xa inhibiting 
activity (Wessler et al, 1976; Gitel and Wessler, 1978), in the 
vascular endothelium (Basdevant et al, 1980; Westerholm, 1980), and in 
platelet aggregation (Hawkins and Elder, 1979).
The hypertension seen in oral contraceptive users and in others 
receiving oestrogens may be due to disturbances in the renin-angiotensin- 
alaosterone system (Westerholm, 1980).
Liver disorders
There is evidence among oral contraceptive users of an increased 
incidence of abnormalities in some liver function tests, notably in 
those tests dealing with bile excretion, such as bromosulphothalein 
retention (Hawkins and Elder, 1979). This is regarded as being due to 
the oestrogen component and to result from a reversible and, in some 
cases, transient reduction in hepatic excretory function. Among pill 
users there is an increased incidence of cholestatic jaundice 
(Adlercreutz and Ikonen, 1964) and gallstones (Royal College of General 
Practitioners, 1974). Serum enzymes (aminotransferases and alkaline 
phosphatase) may also be elevated (Hawkins and Elder, 1979). Elevations 
in serum aminotransferases and serum bilirubin, and a higher incidence 
of intrahepatic cholestasis, have also been reported in patients 
receiving oestrogen therapy for prostatic cancer (Westerholm, 1980).
Neoplasms
Retrospective epidemiological studies have indicated that there 
is probably an increased risk of endometrial cancer in postmenopausal 
women receiving hormone replacement therapy and a similar effect in 
patients with Turner's syndrome treated with oestrogens (Hertz, 1976,
1979). The risk is also higher in conditions in which the endogenous 
hormones are increased: diabetes, obesity, ovarian tumours, and Stein-
Leventhal syndrome (Lipsett, 1977). Most of the data so far collected, 
suggest that it is the oestrogen given without a progestogen (i.e. 
'unopposed') that possesses the carcinogenic effect. This is supported
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by the observation that among oral contraceptive users only those 
receiving sequential therapy have been shown to have an increased risk 
of endometrial cancer (Westerholm, 1980). In the sequential regimen, 
oestrogen-only pills are used in the first half of the cycle, oestrogen- 
progestogen pills in the second. The combined-type contraceptives, on 
the other hand, may decrease by a half the incidence of endometrial 
cancer (Weiss and Sayvetz, 1980).
There is no strong evidence as yet that the use of oestrogens is 
associated with an increased risk of breast cancer. There appears, 
indeed, to be a negative association between benign breast disease and 
oral contraceptive usage (Hertz, 1979).
Liver tumours may be more prevalent among users of conjugated 
oestrogens and oral contraceptives (Westerholm, 1980). The lesions so 
far described range from focal hyperplasia to invasive carcinoma, the 
greatest number, however, being hepatic adenomata (Hertz, 1979). Though 
benign these may be fatal; they are highly vascular and have a tendency 
to rupture. The risk of benign tumours has been put at about 1 - 5  per 
million pill users per year (Huggins and Giuntoli, 1979).
An increase in ovarian cancer has been described among women 
receiving conjugated oestrogens (Hoover et al, 1977). The excess risk 
of ovarian cancer occurred primarily among women who had also taken 
diethylstilboestrol. This study has been criticized and these findings 
await verification (Westerholm, 1980). Benign lesions of the ovary are 
less common in women taking oral contraceptives (Laurence and Bennett,
1980).
It has been suggested that pituitary adenomas are increased by 
oral contraceptive use but recent evidence does not support this 
assertion (Wingrave et al, 1980). Various other neoplastic disorders 
(e.g. malignant melanoma, choriocarcinoma, carcinoma in-situ of the 
uterine cervix) have been reported to be more common among oral 
contraceptive users than non-users but in no case has a causative 
association been established yet (Hoover, 1980).
Foetotoxicity
There is an established link between the use of nonsteroidal 
oestrogens during pregnancy and the development of vaginal and cervical 
adenocarcinomas in female offspring at the age of puberty (Herbst et al, 
1971, . 1974, 1977). Numerous non-neoplastic changes have also been
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identified in the genital tract of exposed females (Herbst, 1976) and 
this is also true, though to a lesser extent, of exposed males (Gill et 
al, 1976). Oestrogens were used from the late 1940s in America and 
elsewhere in the treatment of complications of pregnancy and 
particularly in the prevention of threatened abortion. CVer 300 cases 
of adenocarcinoma have so far been reported in America (Herbst, 1979) 
but only one in Britain (Monaghan and Sirisena, 1978). The exact 
pathogenesis is unknown but appears to involve interference with the 
normal process of differentiation and degeneration of Mullerian 
epithelium in the foetal vagina (Nordqvist, 1976).
The most commonly used oestrogen in the treatment of pregnant 
women was diethylstilboestrol, but hexoestrol, and indeed all 
nonsteroidal oestrogens in use at the time, in some cases in combination 
with progestational agents, have been implicated (Herbst, 1976;
Ulfelder, 1980). Because of their relative cheapness, nonsteroidal 
oestrogens were used in preference to steroidal oestrogens. On current 
evidence, including that from animal studies (see below), it cannot be 
said that steroidal oestrogens could not also cause these cancers 
(Herbst, 1976; Hertz, 1976, 1979).
There are several other circumstances in which a*foetus might be 
exposed to large doses of exogenous oestrogens; after a hormonal 
withdrawal-type pregnancy test, after unsuccessful post-coital 
contraception, and in the event of oral contraceptives being taken 
during pregnancy. Oestrogen administration in early pregnancy may be 
associated with a slightly increased risk in the offspring of limb 
reduction defects, Di George Syndrome (thymus-parathyroid aplasia), the 
Vacteral syndrome (combination of defects), and cardiovascular 
malformations (Nora and Nora, 1973; Lancet, 1974; Browne, 1979; 
Westerholm, 1980).
VETERINARY OSES
Oestrogens find similar applications in veterinary medicine as 
they do in human medicine; they are used in replacement therapy for 
underdeveloped females, in incontinence, for the relief of vaginitis in 
spayed bitches, to induce heat in anoestrus, in uterine inertia, in 
pyometra, to check milk secretion in pseudopregnancy, and to prevent 
conception in mismatched bitches. The most commercially 
significant use, however, is for the growth promotion and fattening of
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poultry and meat animals.
Oestrogens increase fat production in chickens and thus improve 
carcass quality. Though food intake is usually increased (Umberger, 
1975), the body weight only shows a modest rise or no change at all.
Hie response of sheep and cattle is quite different - nitrogen 
retention, feed conversion, and body weight are all increased (Umberger, 
1975 ). This anabolic effect is not observed in many other mammals 
including rodents and swine, and, indeed, the usual observation in these 
animals is a dose-dependent reduction in growth rate. Hie effects of 
oestrogen on metabolic processes related to growth thus vary quite 
markedly. This may be due to species differences in the hypothalamic- 
pituitary system (Trenkle, 1969; Velle, 1978) and is in contrast to the 
rather similar role these hormones play in reproduction in the various 
species.
Hitherto, the most commonly used oestrogen in livestock farming 
has been diethylstilboestrol, but because of the possibility of carcass 
residues and the association between the use of this compound in human 
pregnancy and an increased incidence of cancers of the reproductive 
tract in exposed female offspring, its use has been discontinued in the 
United States and a number of other countries (Walgate, 1980). In 
Britain, the availability of diethylstilboestrol is restricted but 
hexoestrol is on free sale. This compound is probably also a
) teratocarcinogen (Herbst, 1976; Hoover, 1980). A number of other 
oestrogenic substances and some non-oestrogens are also available as 
growth promoters. These remain of considerable economic importance.
EXPERIMENTAL TOXICOLOGY
Species selection
In the United Kingdom, manufacturers of drugs intended for human 
use are required by the Medicines Act (1968, 1971) to provide evidence 
of the safety, quality and efficacy of their products. The customary 
safety evaluations include acute, short-term and long-term toxicity 
studies in animals. Hie acute and short-term studies are performed on 
rodents. The traditional selection for the long-term studies also 
involves a rodent, normally the rat, which is small and has a short life 
span, but also a non-rodent, usually the beagle dog, which is larger and 
more appropriate for individual clinical monitoring. In the present
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work, the ferret is under investigation as a potential replacement for 
the beagle dog in these studies. Ihe latter animal has a number of 
advantages: its pedigree and vigour are well established; in closed
colonies it remains free from disease; it is docile and sociable and 
therefore can be handled easily and need not be housed individually; it 
rapidly achieves a constant adult body weight; the veins are readily 
accessible for the purpose of phlebotomy; and there is extensive 
background knowledge of its physiology, pathology and inherited traits. 
These factors support the continued use of the beagle dog - but it is 
relatively expensive to house and maintain and its use is an emotive 
issue with the general public. Further, it has a tendency to develop 
uterine and mammary disorders which can reduce its usefulness in 
evaluations of reproductive hormones (e.g. Weikel and Nelson, 1977). It 
is possible that the ferret may offer advantages on each of these counts 
and that the balance of advantages and disadvantages may favour the 
introduction of this species into routine toxicology in place of the 
dog. In addition, and of particular significance in the present 
context, is the fact that the dog displays a rather atypical 
haematological response to oestrogens (see below). The ferret may 
differ from the dog in this respect and may thus represent a more 
appropriate model for the human response to these compounds.
Oestrogen toxicity
As oestrogens were introduced into medical and veterinary 
practice in advance of the modern legislative requirement for safety 
evaluation there have been relatively few comprehensive toxicological 
studies on these compounds. Supplementary information can, however, be 
obtained from the extensive literature on the effects of oestrogens on 
specific organs or organ systems. The experimental toxicology of 
oestrogens has recently been reviewed (Heywood and Wadsworth, 1980).
All oestrogens administered chronically in high doses to animals 
are toxic. The synthetic oestrogens have been reported as being more 
toxic than the natural oestrogens (Selye, 1939; Nicol and Helmy, 1951), 
equally toxic (von Pallas, 1940; Morrell and Hart, 1941), and less 
toxic (Castrodale et al, 1941). Few studies, however, have‘attempted to 
compare the synthetic and natural compounds at oestrogenically 
equivalent doses and hence no unequivocal statement can be made as to 
their relative toxicity. They all tend to have qualitatively similar
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effects (Morrell and Hart, 1941; Heywood and Wadsworth, 1980).
Ihe lesions observed in animals treated with oestrogens may be 
divided into those due to endocrine imbalance and those ostensibly due 
to other causes. Effects on the genital tract and endocrine system are 
examples of the first kind, effects on the liver and bone marrow, 
examples of the second.
Chronic oestrogen administration at high doses induces signs of 
persistent oestrus - vaginal cornification and uterine hypertrophy - in 
all species. Secretion of uterine fluid is also increased. In rats and 
mice an initial phase of endometrial hyperplasia may be followed by the 
appearance of squamous metaplasia, adenomyosis, fibroma, and papilloma. 
In the dog, early endometrial hyperplasia, hyperaemia, and myometrial
! hypertrophy, may give way to cystic hyperplasia followed by endometrial
I
| atrophy, necrosis, and pyometra (Jabara, 1962). Proliferative lesions
/ •
of the genital serosa may also occur (Wadsworth, 1978; Heywood and 
Wadsworth, 1980). Ovarian inhibition results from suppression of 
pituitary gonadotrophin secretion. In the male, the testes, seminal 
vesicles and prostate lose weight and become atrophic (Teague, 1942; 
Poppe, 1964).
Numerous studies on rodents have reported pituitary enlargement, 
and an increased incidence of pituitary tumours (Segal and Thompson, 
1956; Gibson et al, 1967). Some strains of mice are particularly 
susceptible to pituitary adenoma formation. Ihese tumours may be lethal 
due to their size and the resultant increase in the intercranial 
pressure, but they are rarely malignant in their histological appearance 
(Leonard, 1974). Dogs are less prone to pituitary enlargement and 
tumours than rodents, and the reason for the pituitary weight gain 
differs. In rodents there is a proliferation of the chromophobes of the 
glandular lobe and possibly also an increase in the acidophils, 
particularly at low doses. In dogs, only the acidophils are increased 
(Jabara, 1962; Heywood and Wadsworth, 1980).
Disturbances in pituitary function are associated with other 
findings such as mammary gland stimulation and mammary tumours, and 
adrenal cortical hypertrophy Ihe adrenals may be haemorrhagic (Page et 
al, 1941) and in rats (Teague, 1942) and mice (Heywood and Wadsworth,
1980) there may be 'brown degeneration1 (ceroid deposition) in the 
juxtamedullary region. Ihe thyroid gland may be increased in size 
(Gibson et al, 1967) or unchanged (Drill, 1974), but the thymus is 
usually found to be diminished in both rats (Russell et al, 1941) and
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dogs (Kramer and Gunzel, 1979).
The susceptibility of various species to liver damage has been 
reported to be, in descending order, cat, rat, mouse, rabbit, guinea 
pig, and dog (Gumbrecht and Loeser, 1940). Ihe reported effects include 
vacuolation, fatty degeneration, cellular infiltration and necrosis. 
Liver damage is usually associated with high doses and may be seen in 
conjunction with renal damage (Gumbrecht and Loeser, 1940; Valenzuela 
and Leaniz, 1945). Liver damage associated with jaundice has been 
reported as the cause of death of rats and mice in one study (Selye, 
1939), but in others on rodents histological evidence of liver damage 
was minimal (e.g. Morrell and Hart, 1941; Gibson et al, 1967, or 
affected only one or two animals (Page et al, 1941; Russell et al,
1941). Gallaher et al (1966) have shown that high doses of oestrogens 
are capable of impairing bromosulphothalein metabolism in rats but 
similar tests in dogs have been less conclusive (Castrodale et al,
1941). In rats, serum enzyme determinations and blood clotting tests 
may indicate liver impairment and serum enzymes may also be elevated in 
rhesus monkeys treated with oestrogens (Heywood and Wadsworth, 1980).
No consistent kidney lesions have been reported in any species 
after oestrogen treatment.
Oestrogens may affect the blood and bone marrow of experimental 
animals but the character of the changes varies with the .species. There 
is a moderate dose-dependent anaemia in both rats (Kramer and Gunzel, 
1979) and mice (Heywood and Wadsworth, 1980) and a mild anaemia is also 
observed in sheep and cattle (Trenkle, 1969), chickens (Pearson and 
Butler, 1978), and rhesus monkeys (Heywood and Wadsworth, 1980). In 
mice, oestrogens produce osteosclerosis and there may be partial or 
complete occlusion of the medullary cavity (Crandall et al, 1980). This 
may be associated with a decrease in some or all of the cellular 
elements in the peripheral blood and extramedullary haemopoiesis may 
also be observed. Bone marrow hypoplasia without osteosclerosis has 
been observed in rats (Macbryde et al, 1940; Von Haam et al, 1941; 
Russell et al, 1941; Stebbins and Blanchard, 1942). Most studies on 
this species have found a decrease in the number of red cells and in 
some cases this was accompanied by a modest decrease in the number of 
platelets (Von Haam et al, 1941) or leucocytes (Teague, 1942). There is 
a report, however, of band neutrophils being elevated in rats (Kettunen, 
1952), and leucocyte levels were increased shortly after oestrogen 
administration in rabbits and, less markedly, in monkeys (Girod et al,
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1956, 1959a, 1959b). This effect in monkeys was not reproduced in 
another investigation (Tyslowitz and Hartman, 1941), but in this case 
blood sampling was initiated later.
The haematological response of the dog is more consistent than 
that of the other species studied and involves irreversible changes in 
the bone marrow and peripheral blood. The changes in the marrow consist 
| of an initial phase of myeloid hyperplasia, followed by hypoplasia. The 
corresponding alterations in the blood consist of leucocytosis followed 
by thrombocytopenia, anaemia, and leucopenia (Hall, 1972). Death is 
usually due to haemorrhage associated with thrombocytopenia and 
increased capillary permeability, or, less frequently, to infection as 
is the case with any aplastic marrow condition. A cyclic 
thrombocytopenia has been reported in one study on ethinyloestradiol 
(Capel-Edwards et al, 1971).
The precise mechanisms underlying the various haematological 
changes induced by oestrogens are unclear. Direct effects on the bone 
marrow have been described (Jepson and Lowenstein, 1966) and there are 
j probably also alterations in erythropoietin production (Mirand and 
1 Gordon, 1966; Piliero et al, 1968).
In most species of mammals oestrogens decrease the growth rate. 
The epidermis and dermis is thinner and there may be alopecia and a 
reduction in the number of sebaceous glands (Jabara, 1962; Gibson et 
al, 1967). Changes in spleen weight, damage to the pancreas, an 
increased incidence of inguinal hernias, and effects on lymph nodes and 
urethra, are some of the many other findings reported after oestrogen 
administration (Jabara et al, 1962; Heywood and Wadsworth, 1980).
Oestrogens are known to induce tumours in a number of common 
laboratory species at a variety of organ sites. The species are mice, 
rat, rabbit, hamster and dog, and the main sites are breast, cervix, 
endometrium, ovary, pituitary, testis, kidney, and bone marrow (Hertz,
1979). In addition, malignant uterine mesotheliomas have been described 
in squirrel monkeys (McClure and Graham, 1973). Tumour induction of 
this kind is a property of all oestrogens, and in this they act as 
hormonal carcinogens. While chemical carcinogenesis is believed to 
involve the binding of the carcinogen or its metabolites to DNA and 
other intracellular macromolecules (Pitot, 1978), hormonal 
carcinogenesis has been attributed to disturbances in endocrine control 
mechanisms, particularly in the feedback relationship of the anterior 
pituitary to its target organs (Furth, 1975). NO one oestrogen is
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consistently more tumorigenic than the others across a number of 
species, or at a number of sites, and the synthetic oestrogens are not 
more tumorigenic than the natural oestrogens (Hertz, 1976). High 
dosages, genetic susceptibility, age and duration of exposure are 
critical factors in these effects, and rodents are more susceptible than 
dogs and primates (Hertz, 1979). For these reasons, the relevance to 
humans of such tumour studies is at present uncertain.
Attempts to reproduce experimentally the teratocarcinogenic 
effects elicited in humans by the nonsteroidal oestrogens have focussed 
on the neonatal mouse as an animal model (e.g. Dunn, 1979). If 
extrapolations from the results of experiments on this animal are valid, 
then steroidal as well as nonsteroidal oestrogens may be effective in 
this regard, though diethylstilboestrol may be more potent than 
oestradiol (Bern et al, 1976; Forsberg, 1976).
Hie present studies were designed to supplement the available 
information on the toxicity of oestrogens in animal species. Hie 
predictiveness of such studies for humans has been somewhat 
disappointing; there are certain effects which occur in animals treated 
with oestrogens (e.g. bleeding disorders in dogs, osteosclerosis in 
mice) which do not occur in humans, and conversely there are effects 
which occur in humans (e.g. thromboembolism) which have not been 
reproduced in the laboratory. Knowledge of the causes of the toxic 
effects of oestrogens in animals, and the reasons for the interspecies 
variations in these effects, might enhance the predictiveness of 
laboratory investigations and aid in the selection of less toxic 
compounds for medical and veterinary use.
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CHAPTER 1
EFFECTS OF 
DIETHYLSTILBOESTRC8L AM) 
HEXOESTRCL ON THE 
FEMALE FERRET 
IN OESTRUS
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INTRCDOCTICN
The dog and cat, both carnivores, display a marked 
susceptibility to high doses of oestrogens but the ultimate lethal 
effects differ in the two species. In the dog, oestrogens induce 
profound changes in the haemopoietic tissue (Hall, 1972). These 
changes are reflected in the peripheral blood successively by 
leucocytosis, thrombocytopenia, anaemia and leucopenia, and are 
associated with the development of a bleeding syndrome. Various 
degrees of liver damage have also been reported but the significance 
of these effects is uncertain (Heywood and Wadsworth, 1980). In the 
cat, on the other hand, there are apparently no significant 
haematological or haemorrhagic abnormalities, but rather, there is 
evidence of distinct hepatic damage (Grumbrecht and Loeser, 1940;
Dow, 1958). The main objective of the present study, therefore, was to 
determine the response to oestrogens of a third species of carnivore, 
the ferret, and hence to compare this response to that of the dog and 
the cat. The second objective was to establish the relationship, if 
any, between the reported potency of two nonsteroidal oestrogens, 
diethylstilboestrol and hexoestrol, and their toxicity when given in 
approximately equipotent doses - that is, in the ratio of 1 to 3, 
respectively.
The experiment reported here was a toxicological investigation 
comprising histopathological and haematological studies together with 
assessments of hepatic and renal function. In this and subsequent 
experiments, the human exposure to oestrogens was simulated by 
administering the test compounds orally according to a repeat-dose 
schedule to sexually mature animals.
The ferret given oestrogens showed the haemopoietic response of 
the dog but the hepatic sensitivity of the cat. The two oestrogens had 
qualitatively similar effects and the degree of toxicity of these 
compounds appeared to be related to their oestrogenic potency.
EXPERIMENTAL DESIGN AND METHODS
Nine female albino ferrets were obtained in early Spring for this 
study. They were aged between nine and twelve months with a weight 
range between 570g and 830g. They were all in a healthy condition and, 
with one exception (Ferret No. 5), they had all entered oestrus (as
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determined by vaginal smear and the appearance of the external 
genitalia) by the commencement of the study.
The nine ferrets were randomly assigned to three groups according 
to the following treatment schedule.
Group Animal Nos. Treatment
2,3,9 Dose vehicle only
(Controls)
B 4, 6 , 7 Diethylstilboestrol
(6mg/kg/day)
1, 5, 8 Hexoestrol
(18mg/kg/day)
The drugs were administered for up to 30 days and the doses were 
adjusted to body weights at weekly intervals. The animals were housed 
singly and maintained under standard conditions. Their food and water 
consumption and their body weights and overall condition were monitored 
daily. 1 ml of blood was taken routinely at intervals during the 
experiment (see tables). A number of early samples, however, were lost 
due to difficulties with the bleeding technique and the initial 
intractability of some of the animals. The haematological 
investigations comprised counts of total red and white cells, 
differential white cells and reticulocytes, estimations of packed cell 
volume, haemoglobin, red cell osmotic fragility and Thrombotest time 
(lOyl whole blood added to 0.5ml reconstituted reagent). The blood 
collection method did not provide sufficient sample to permit reliable 
serial platelet counts, but satisfactory counts were made in the pre­
terminal blood samples. The serum (or, in the case of Ferret No. 8 , 
plasma) from the pre-terminal blood samples was also used for the 
estimation of alkaline phosphatase, alanine aminotransferase and 
isocitric dehydrogenase.
At weekly intervals the animals were transferred to metabolism 
cages and their urine collected over an 8-hour period and its volume 
determined. A simple urinalysis was performed with impregnated reagent 
strips (Ames Co., Stoke Poges, Slough) for pH, protein, glucose,
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ketones, bilirubin and blood. The centrifuged urinary sediment was 
examined microscopically and any crystals identified by solvent studies 
after the manner of Harrison (1957).
After 30 days treatment, or earlier if severe toxic effects 
appeared, the animals were anaesthetised with sodium pentobarbitone 
administered by intraperitoneal injection and exsanguinated from the 
vena cava. After macroscopic examination, the liver, spleen, kidneys, 
heart, ovaries and uterus were removed and weighed. Samples of these 
organs and also of the lungs, adrenals, vagina, pancreas, mesenteric 
lymph nodes, stomach, duodenum, ileum, colon, sternum, and of tissues 
other than these showing macroscopic abnormalities, were preserved in 
10% buffered formal-saline. These tissues were then subjected to a full 
histological analysis. Femoral marrow smears were prepared during 
autopsy.
Full details of the materials and methods used in this and 
subsequent experiments are given in an appendix to this thesis.
RESULTS
General observations
The condition of all ferrets treated with oestrogens eventually 
deteriorated to the point where, with one exception, they were 
electively killed for humane reasons before the end of the 30-day study 
period. The exception (No. 1) died after a sudden and rapid collapse 
while preparations were in hand for terminal examination. 
Diethylstilboestrol was markedly more toxic than hexoestrol: the mean
survival time of the animals receiving diethylstilboestrol was 18 days, 
and the mean lethal cumulative dose 108 mg/kg, while the corresponding 
figures for those animals treated with hexoestrol were 24 days and 432 
mg/kg respectively. The survival times and total cumulative doses are 
shown in Table 1. There was some tendency for the heavier animals to 
survive longer (Fig. 1). Though the rapidity of onset of oestrogen- 
related toxic effects differed between the two groups, the reactions 
were qualitatively similar. All controls remained in general good 
health throughout the experiment.
All the ferrets except No. 5 were in oestrus on Day 1 with vaginal 
cornification, and vulval enlargement and hyperaemia. These signs
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Table 1 Mortalities among female ferrets given 
oral oestrogens
Treatment Ferret No. Survival time 
(days)
Total cumulative 
dose (mg/kg)
DES 4 15 90
DES 7 16 96
HEX 8 17 306
DES 6 23 138
HEX 1 26 468
HEX 5 29 522
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Fig. 1 Survival times and initial body weights of female 
ferrets given oral oestrogens: O, diethylstilboestrol;
• , hexoestrol. Numbers identify individual animals.
intensified with oestrogen treatment and in these animals an occasional 
pale, viscous, or bloody discharge was seeru The pelage of the 
urinogenital region became soiled and minor infections were common. By 
Day 8 , Ferret No. 5 displayed changes which indicated oestrus induction. 
Two of the controls remained in oestrus but with little qualitative 
change in status. The third (Ferret No. 3) showed slight vulval 
inflammation by about Day 17, which condition, however, did not 
deteriorate. Some degree of mammary enlargement was noted in all the 
treated animals.
Morbidity in Groups B and C was associated with some or all of 
the following signs:
Loss of physical activity (all)
Decreased body weight (all)
Decreased food consumption (all)
Tarry stools or diarrhoea (all)
Nasal bruising (Nos. 1, 4, 6 and 8 )
Oedema (No. 6 )
Alopecia (all except No. 4)
Yellow pigmentation of exposed skin (all)
Poor wound healing (venepuncture site) (Nos. 1, 4 and 7) 
Nasal bleeding (No. 8 )
After routine venepuncture, the bleeding of one animal (Ferret 
No. 8) could not be arrested and this animal was put down. The blood 
which was taken for serum remained incoagulable. After the death of 
Ferret No. 1 the blood of this animal also proved incoagulable. A 
sample of this was therefore collected from the vena cava and subjected 
to a full analysis.
Body weights
The changes in body weights are presented in Fig. 2. All 
animals showed an initial decline in body weight associated with an 
anorectic response to oral dosing. The weights of the control animals 
subsequently recovered to around their initial values. In contrast, all 
the treated animals showed a net reduction in body weight, though the 
majority also showed gains at some stage during the study.
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Fig. 2 Body weights of female ferrets given oral oestrogens, 
and of controls. Numbers identify individual animals.
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Food and water consumption
Food intake was lower in all animals during the study than before. 
Ihe figures were lower in the treated animals than in controls, and 
lowest in those treated animals receiving diethylstilboestrol. Food 
consumption was variable for each animal but generally changes in this 
paralleled changes in body weight: the figures were stable for controls
after an early decline, whereas in the treated animals an initial 
inappetance gave way to a modest recovery prior to a second, 
progressive, decline.
Water consumption figures were highly variable for each animal 
and between animals and there were no obvious individual or group 
trends.
Haematology •
Red Cells
Tables 2 and 3 show quite clearly that oestrogen treatment 
provoked anaemia associated also with a loss of circulating 
reticulocytes, an effect which in certain animals (Nos. 1, 5 and 6) 
appeared to be biphasic. The depressed reticulocyte count was minimal 
in No. 5, the animal which survived longest. There was in this animal 
some evidence of polychromasia in the terminal blood film but this 
feature was noticeably absent from the other oestrogen treated ferrets. 
Among controls there was a minimal degree of anisocytosis, 
anisochromasia, poikilocytosis and a modest tendency to form rouleaux.
In oestrogen treated ferrets there was gross rouleaux formation 
accompanied by an intensification of the morphological variation noted 
previously in the controls. Normoblasts were rarely seen. In Ferret No.
5 the red cells also showed agglutination. Red cell inclusions were not 
demonstrable. Among controls the only notable feature was a mid-study 
reticulocytosis in Ferret No. 3. Representative blood films are shown 
in Figs. 3 and 4.
White Cells
The control values (Table 4) were unremarkable except for 
slightly elevated mid-study leucocyte counts in two of the animals
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Table 2. Individual and group mean red cell data of female ferrets
given oral oestrogens and of controls
Treatment Ferret 
group No.
Day
No. RBC* •»(10°/mm3)
Reticulocytes 
{%) (10^/mm-3)
Hb
(g/dl)
' PCV 
(%)
1 0.5 49
9 9.4 0.7 67 19.5 55
2 17 10.2 1.0 102 19.8 55
24 10.4 1.1 114 18.6 53
30 9.6 1.0 96 14.0 38
1 8.6 1.5 130 20.1 46
9 8.5 2.1 178 15.9 46
A 3 17 9.2 3.1 286 ' 18.1 48
Controls 24 8.8 2.0 176 16.4 46
30 7.7 1.8 140 15.0 43
1 8.6 1.2 103 18.9 44
9 10.1 1.1 111 19.1 53
9 17 9.7 1.4 136 18.5 49
24 10.1 0.9 91 18.9 52
30 9.9 1.0 99 17.5 50
1 8.6 1.1 117 19.5 47
±0.1 ±0.5 ±19 ±0.9 ±2
9 9.4 1.3 119 18.2 51
±0.8 ±0.7 ±56 ±2.0 ±5
Mean 17 9.7 1.8 175 18.8 51
±SD ±0.5 ±1.1 ±98 ±0.9 ±4
24 9.7 1.3 175 18.0 50
±0.9 ±0.6 ±44 ±1.4 ±4
30 9.1 1.3 112 15.5 44
±1.2 ±0.5 ±23 ±1.8 ±6
1 7.1 1.0 71 15.9 44
4 9 - - - - - -
15 3.0 0.4 12 4.9 11
1 9.1 1.1 100 17.9 50
B 6 9 9.2 0.0 0 16.2 47
DES 17 8.3 1.1 92 13.7 39
23 3.1 0.4 12 5.3 18
.1 8.8 1.1 97 16.9 49
7 9 7.3 0.7 51 14.6 40
16 1.7 0.2 3 2.7 10
1 8.7 1.4 121 - 46
9 - 0.0 0 16.1 44
1 17 6.9 0.4 27 12.9 34
24 4.1 0.5 21 7.6 20
26 0.8 0.2 2 1.3 5
1 9.1 0.8 72 15.0 47
9 8.3 0.0 0 14.7 42
C 5 17 6.6 0.8 53 14.0 33
HEX 24 6.0 1.8 107 10.4 28
26 5.8 1.2 69 7.5 28
29 4.4 1.3 58 6.8 21
1 8.3 1.9 158 19.9 44
8 9 - - - - -
17 6.2 0.3 19 11.8 31
In this table and in subsequent tables and figures, Day 1 data represents that 
obtained before the start of treatment. The terminal blood samples were 
obtained under anaesthesia.
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Table 3. Absolute red cell values of female ferrets given oral oestrogens
and of controls
Treatment Ferret 
group No.
Day
No.
MCV
(fD
MCH
(pg)
MCKC
1%)
9 57.4 20.4 35.6
2 17 54.3 19.4 35.7
24 50.5 17.9 35.4
30 39.5 14.6 36.8
1 53.8 23.3 43.3
9 54.2 18.7 34.6
A 3 17 52.3 19.6 37.5
Controls 24 52.1 18.7 35.8
30 55.5 19.4 34.9
1 51.7 22.1 42.7
9 52.8 18.9 35.8
9 17 50.5 19.1 37.8
24 51.9 18.8 36.1
30 50.6 17.7 35.0
1 52.8 21.9 43.0
±1.5 ±1.5 ±0.4
9 54.8 19.3 35.3
±2.4 ±0.9 ±0.6
Mean 17 52.4 19.4 37.0
±  SD ±1.9 ±0.3 ±1.1
24 51.5 18.5 35.8
±0.9 ±0.5 ±0.4
30 48.5 17.2 35.6
±8.2 ±2.4 ±1.1
4 1
Q
62.9 22.3 35.5
y
15 38.2 16.3 42.7
6 1 55.4 19.7 35.5
B 9 51.5 17.6 34.2
DES 17 46.8 16.4 35.1
23 60.1 17.2 28.6
7 1 56.1 19.2 34.2
9 55.3 20.0 36.1
16 58.8 15.9 27.0
1 1 53.5 - -
9 - - 36.4
17 50. 7 18.8 37.1
24 50.1 18.3 36.5
26 65.5 14.9 22.7
5 1 52.3 16.6 31.6
9 50.6 17.7 35.0
C 17 49.7 21.1 42.4
HEX 24 42.2 17.4 36.9
26 49.5 13.1 26.5
29 49.1 15.4 31.4
8 1
Q
53.7 24.1 44.8
17 51.1 19.0 37.1
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Fig. 3. Blood smear of a ferret (No. 6) treated with 
diethylstilboestrol. Note rouleaux formation, 
anisochromasia, and variation in platelet size. 
May-Grunwald/Giemsa, oil immersion x 500.
Fig. 4. Blood smear of a ferret (No. 1) treated with 
hexoestrol. Note rouleaux formation, anisochromasia, and 
absence of platelets. May-Grunwald/Giemsa, oil immersion 
x 500.
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Total and differential white cell counts of female ferrets given oral oestrogens and of controls
t F e r re t
No.
Day
No.
T o t a l  WBC 
(103/mm3 )
N e u tro p h i ls  
Segmented Non-segmented
E o s in o p h i ls Basophils Lymphocytes 
sm al l  l a r g e
Monocytes U n c l a s s i f i e d
M ono-nuc lear
2 1
9 5 .41 1998 0 0 108 3240 0 0 0
17 1 1 .7 0 7254 117 117 117 3744 351 0 0
24 9 .6 6 - - - - - - - -
30 3 .7 6 • 1938 0 38 0 1729 75 0 0
3 1 12 .03 3360 0 120 0 7680 840 0 0
9 6 .7 5 2028 68 0 0 4590 68 0 0
17 1 3 .9 0 556 0 139 0 0 7228 417 278 0
24 7 .7 0 - - - - - - - -
30 7 .0 2 2590 0 210 0 4130 70 0 0
9 1 5 .9 0 1947 0 118 0 3776 0 59 0
9 5 .0 5 2020 0 101 0 2828 51
0 0
17 6 .8 9 3169 0 207 0 3376 137 0 0 •
24 8 .0 7 2744 0 81 0 4761 484 0 0
30 6 .4 1 2308 0 0 0 4038 64 0 0
1 8 .9 7 2654 0 119 0 57.28 420 30 0
+ 4 .3 4 +999 ±1 - ±2761 ±594 42 -
9 5 .74 2015 23 34 36 3553 40 0 0
+0 .9 0 ±16 - ±58 ±62 ±922 ±35 - -
Mean 17 10.83 5328 85 108 39 4783 302 93 0
±  SD +3 .5 9 ±2052 ±75 ±104 ±68 ±2126 ±146 ±161 -
24 8 .4 8 2744 0 81 0 4761 484 0 0
+ 3 .5 9 - - - - - - - ~
1 11 .80 5546 0 590 0 5664 0 0 0
9
15 0 .4 6 0 0 0 0 460 - - -
1 11 .20 3470 336 112 0 6720 448 0 0
6 9 2 6 .5 0 18550 530 265 0 6360 795 0 0
17 15 .8 0 4164 316 158 0 3160 3002 0 0
23 0 .8 3 0 83 0 0 597 - 0 0 149
1 4 .4 0 1763 132 44 0 1808 441 132 88
7 9 9 .9 8 4597 390 196 0 3521 780 293 0
16 0 .7 9 0 0 0 0 790 0 0 0
1
Q
9 .7 2 3207 97 292 0 5832 292 0 0
1
7
17 9 .7 8 5477 294 98 0 3227 293 0 0
24 4 .0 6 203 0 41 0 3370 41 0 406
26 1.03 0 0 0 0 1030 0 0 0
1 9 .9 1 3168 0 495 0 6237 0 0 0
9 35.80 23628 2864 0 0 9308 0 358 0
5 17 30 .8 0 23408 1540 0 0 4312 1540 0 0
24 12 .7 9 - - - - - - - -
29 3 .2 3 1357 162 0 0 1712 0 0 0
g
1
Q
8 .7 5 2800 0 175 0 5425 262 88 0
7
17 7 .89 4892 553 79 0 2370 0 0 0
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(Nos. 2 and 3), and for a certain inconsistency between the 
neutrophil/lymphocyte ratio of individual animals or indeed the same 
animal on successive occasions. As a general trend, lymphocytes tended 
to outnumber neutrophils. Variations in the relative numbers of these 
cells can probably be related to stress (Crafts, 1941).
Collectively the response to oestrogens amongst the treated 
animals appears to have been a neutrophil leucocytosis with a left shift 
followed by agranulocytosis with circulating cells consisting almost 
entirely of lymphocytes. As is the case with beagle dogs given 
oestrogens, the extent to which this dynamic change is detailed varies 
according to the timing of the blood sampling and the individual 
response of the animal (Capel-Edwards et al, 1971). Leucopenia was 
associated with the terminal condition of all but one of the treated 
animals, Ferret No. 8. This animal was put down because of 
uncontrollable bleeding and showed virtually a near normal leucocyte 
picture.
Blood coagulation
Two parameters were investigated, namely blood platelets and the 
Thrombotest reaction (Tables 5 and 7, respectively). Ihe only reliable 
platelet data was derived from samples obtained from the vena cava under 
anaesthesia. This showed a thrombocytopenia developing in oestrogen 
treated ferrets and is consistent with the observation of tarry stools 
seen very early (week 1 ) and present thereafter in all such animals.
The bleeding syndrome was of dual origin as clearly indicated by the 
prolonged Thrombotest times, a probable function of the degree of liver 
damage.
Serum chemistry
Control values for alkaline phosphatase and isocitric 
dehydrogenase provided a normal range with narrow limits and quite 
clearly oestrogen treatment provoked highly abnormal responses in some 
if not all the ferrets so treated. Ihe values which remained within the 
control range may well reflect merely the problems of interpretation 
which arise from a single estimation performed on a rapidly changing 
system. As the histological evidence shows, there is no doubt about the 
liver damage suffered by all the animals. The serum enzyme values are
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Table 5. Terminal platelet counts of female ferrets given oral oestrogens
and of controls
Treatment
qroup
Ferret
No.
Platelets 
(lO^/mm^)
2 420
A 3 _
Controls
9 355
4 76
B 6 128
DES
7 33
1 3
C 5 67
HEX
8 50
Table 6. Serum enzvmes (U/l) in terminal blood samples of female ferrets
aiven oral oestroaens and of controls
Treatment
group
Ferret
No.
Alkaline
phosphatase
Isocitric
dehydrogenase
Alanine
aminotransferase
2 59 17 44
A
Controls
3 61 27 124
9 60 15 24
60 20 64
Mean
+ SD ±1 ±6 ±53
4 367 74 10
B 6 72 88 36DES
7 90 13 36
1 63 284 428
C 5 222 115 65
HEX
8 21 14 177
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Table 7. Thrombotest times of female ferrets given oral oestrogens and of controls
Treatment
group
Ferret
No.
Day
No.
Thrombotest
(sec)
1
9 -
2 17 66
24 47
30 56
1 _
9 49
A 3 17 70
Controls 24
30 46
1 _
9 -
9 17 64
24 61
30 52
1 -
9 49
Mean 17 67
+ SD ±3
24 54
±10
30 51
±5
-
1
4 9 -
15 900
1 57
B 6 9 -
DES 17 57
23 128
1
7 9 44
16 61
1 -
9 -
1 17 60
24 45
26 900
1 _
9 49
C 5 17 51
HEX 24 57
26 79
29 295
1 _
8 9 -
17 900
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shown in Table 6 .
The occurrence of isolated elevations of alanine 
aminotransferase in control animals in toxicity tests is well known 
(Street, 1970) and diminishes the value of single estimations such as 
the ones performed in this study. The result obtained for control 
Ferret No. 3 may well reflect concurrent latent disease, a view 
consonant with the histological evidence. Notwithstanding this apparent 
inherent variation at least two oestrogen treated ferrets showed 
abnormal levels of this enzyme (Nos. 1 and 8).
With hindsight the quantitative measurement of serum bilirubin 
would have been valuable, though ordinarily this estimation is far less 
reliable in rats and dogs than it is in humans. There was, however, no 
doubt about the observable degree of icterus in serum from oestrogen- 
treated ferrets.
Urinalysis
The urine from oestrogen treated ferrets yielded a sediment rich 
in epithelial cells and casts, protein, red and white blood cells, 
triple phosphate and oxalate crystals. In three animals (Nos. 4, 5 and 
8) there was a strong positive reaction for bilirubin. The controls 
voided urine with a similar sediment but by comparison reduced in 
quantity - though that of Ferret No. 3 was suggestive of some minor 
degree of renal dysfunction.
Organ weight analysis
The results of both absolute and relative organ weights have 
been tabulated (Tables 8a and b). With one exception the values 
obtained from the control animals provided relatively narrow ranges for 
comparative purposes. The exception was the high uterine weight of 
Ferret No. 2 which rendered comparisons between the control animals and 
the treated animals difficult. However, this said, the reproductive 
organs of two of the hexoestrol treated animals (Nos. 1 and 5) appeared 
to have become enlarged and possibly those of two animals from the other 
test group (NOs. 4 and 6) also responded with weight gains. It is 
noticeable that diethylstilboestrol had less of an effect in this 
respect than did hexoestrol though it may be that the important 
consideration here is survival time, as this factor, the weights of the
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Table 8 a & b. Organ weights of female ferrets given oral oestrogens and of controls
a. Absolute organ weights (q)
Treatment
group
Ferret
No.
Terminal 
body weight
Heart Liver Spleen Kidneys Sex
organs
2 697 4.27 28.10 5.10 4.22 6.84
3 673 2. 59 24.00 4.60 4.39 3.95
A
Controls
9 588 3.49 22.20 3.90 3.65 3. 39
Mean 653 3.45 24.77 4.53 4.09 4. 73
± SD + 57 +0. 84 +3.02 ±0.60 ±0. 39 ±1. 85
4 382 2.63 31. 78 1.62 4.00 2.89
6 770 3.88 51.10 - 5.27 7. 46
B 7 605 3.34 27.56 2.30 3.82 3.50
DES
Mean 586 3.28 36. 81 1.96 4.36 4.62
+ SD +194 +0.63 +12.55 +0.48 +0. 79 ±2.48
1 500 3.52 37.20 1.47 5.88 7.61
5 642 4.04 31.60 2.07 4.65 12.63
C 8 510 2.71 25.00 2.35 4.06 _
HEX
Mean 551 2.42 31.27 1.96 4.86 10.12
± SD ±79 +0.67 ±6.11 ±0.45 ±0.93 ±3.55
b. Relative oraan weiahts (% of bodv weiaht)
Treatment
group
Ferret
No.
Heart Liver Spleen Kidneys Sex Organs
2 0.61 4.03 0.73 0.61 0.98
3 0.39 3.57 0.68 0.65 0.59
A
Controls
9 0.59 3.78 0.66 0.62 0.50
Mean 0.53 3.79 0.69 0.63 0.72
± SD ±0.13 ±0.23 ±0.04 ±0.02 ±0.23
4 0.69 8.32 0.42 1.05 0.76
6 0.51 6.64 - 0.68 0.97
7 0.55 4.56 0.38 0.63 0.58
DES Mean 0.58 6.50 0.40 0.79 0.77
± SD ±0.09 ±1.89 ±0.03 ±0.23 ±0.20
1 0.70 7.44 0.29 1.18 1.52
5 0.63 4.92 0.32 0.72 1.97
C 8 0.53 4.90 0. 46 0.80 -
HEX
Mean 0.62 5. 76 0.38 0.90 1.75
± SD ±0.09 ±1.46 ±0.09 ±0.25 ±0.32
Sex organs = ovaries, oviducts and uterus weighed together
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reproductive organs and the histopathological changes (see below) 
appeared to be closely related. Such a relation to survival time may 
also be evident for the splenic weights; the values of these were 
reduced in all the treated animals but most notably in the longest lived 
(Nos. 1 and 5). Ihe livers of all the treated animals were larger than 
those of controls but there was no relationship with time of exposure to 
oestrogens. Renal enlargement was gross in two animals (Nos. 1 and 4) 
and also present in at least two of the other treated ferrets (Nos. 5 
and 8). Ihe heart weights of two of the treated ferrets (Nos. 1 and 4) 
were also somewhat above those of controls.
Histopathological changes
Oestrogen treatment provoked the expected changes in the 
reproductive organs. Ihe ovaries of the treated animals compared to 
those of controls, showed an absence of mature follicles and in one case 
(No. 4) atretic follicles. Ihe histopathological changes in the uteri 
of the treated ferrets depended upon the individual survival times 
rather than the actual compound administered. Thus, the uterine changes 
in the shorter-lived animals (Nos. 4, 7 and 8) consisted of moderate 
hypertrophy of the luminal epithelium, glandular dilatation, some 
hypertrophy of the stromal cells, and myometrial hypertrophy. The 
changes in the uteri of the longer-lived animals (Nos. 1, 5 and 6) 
comprised an increase in size with distension due to fluid accumulation, 
varying in extent from modest (up to 5ml) (No. 1) to gross (15-20ml)
(Nos. 5 and 6), a loss of mucosal folding, some luminal epithelial 
hyperplasia, and endometrial oedema. Ihe uterine luminal epithelium of 
one animal (No. 6 ) showed dystrophic changes. A light bacterial flora 
was also evident in the uterine fluid of the treated animals. Hiere 
were moderate stromal round cell infiltrations in the vaginae of two 
animals (Nos. 5 and 6 ).
The livers of treated animals revealed fatty change (all), 
varying but modest degree of centrilobular necrosis (all), cholestasis 
with bile duct proliferation, dilatation and hyperplasia (Nos. 1, 4 and 
5) and a periportal inflammatory round cell infiltrate (Nos. 1, 5, 7 and 
8). An abundant positive Perl's reaction was seen in the livers of four 
animals (Nos. 1, 4, 5 and 8) but was present to a lesser degree in the 
other two (Nos. 6 and 7). Livers from control ferrets showed only a 
weak diffuse positive reacion for fat and occasional flecks of Perl's-
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positive material. In one case (No. 3) a marked periportal round cell 
infiltrate was seen but otherwise the histology was unremarkable. Liver 
sections from a treated animal and a control are shown in Figs. 5 and 6 .
Ihe spleen and lymph nodes of oestrogen treated ferrets were 
indistinguishable from those of controls apart from a marked increase in 
stainable iron. This material was also demonstrable in the sternal 
marrow sections of these animals, and in addition these sections and the 
femoral marrow smears showed varying degrees of bypocellularity ranging 
from mild (Nos. 5 and 6) to severe (Nos. 1 and 4) and affecting myeloid 
and erythroid tissue equally. Megakaryocytes were scarce or absent 
except in Ferret No. 1 where they displayed polyploid and distorted 
nuclei.
The kidneys of all treated animals showed evidence of cloudy 
swelling in the epithelial cells of the proximal convoluted tubules.
The lumen of both the proximal tubules and the loops of Henle in the 
kidneys of Ferret No. 4 contained yellowish brown casts (H and E 
sections) whilst the unprocessed or wax-embedded unstained tissue turned 
bright green. This phenomenon has been described in animals with 
obstructive icterus or severe liver disease and is known as cholemic 
nephrosis (Smith, Jones and Hunt, 1972, pp. 1270), the green 
pigmentation being attributed to the re-oxidation of bilirubin to the 
green intermediate haem breakdown pigment biliverdin.
Seven of the nine ferrets (one control, No. 2, the remainder 
treated with oestrogens) showed evidence of low grade lung infection as 
distinguished by some degree of peri-bronchiolar round cell infiltration 
and areas of collapsed sub-pleural alveoli, visible externally as small 
white plaques on the pleural surface. Such lesions in ferrets have been 
reported elsewhere (Hammond and Chesterman, 1976).
At post-mortem the intestinal contents of one animal (No. 1) 
were found to be black and coated with blood, indicating occult 
bleeding. In two other animals (Nos. 5 and 6) haemoperitoneum was noted 
at termination, with 5-7ml of fluid being present in the body cavity.
All other tissues examined were considered to be normal in 
appearance
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Fig. 5. Fatty change in the liver of a ferret (Mo. 4) treated 
with diethylstilboestrol. H & E, x 100
Fig. 6 . Liver of a control ferret (Mo. 9). H & E, x 100
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DISCUSSION
Potency and toxicity
At the dosages administered diethystilboestrol was more toxic 
than hexoestrol to the female ferret in oestrus, though the two 
oestrogens had qualitatively similar effects. The analysis of the 
mortality data must of necessity be tentative in view of the small 
numbers of animals used in this study, but two observations can be made: 
first, regarding the total lethal dose, that of hexoestrol was four 
times that of diethylstilboestrol; and, second, regarding the survival 
times, it is probable that had a higher dosage of hexoestrol been given, 
say, 5-10 times that of diethylstilboestrol, the survival times of the 
animals in the two groups might well have been more nearly equal. These 
two approaches yield a similar conclusion, namely, that the relative 
toxicity of diethylstilboestrol and hexoestrol reported in the present 
study (i.e. 1:>4) approximates to the relative potency of the two 
oestrogens as determined by bioassay in various species (i.e. 1:3-10) 
(Fyden, 1951; Heftman, 1970; Walgate, 1980). tIt appears, therefore, 
that in the female ferret oestrogens may be toxic in proportion to their 
hormonal potency. This may also be the case in the dog (MacBryde et al, 
1942; Chiu, 1974, pp. 30).
Susceptibility
There have been no toxicity studies of hexoestrol in the dog or 
cat but there have been several of diethylstilboestrol. These make 
possible an assessment of the relative susceptibility of the ferret to 
oestrogens.
Generally, below a daily dose of about O.lmg/kg mortalities only 
occur in dogs and cats given oestrogens by whatever route after a 
protracted period or not at all (Castrodale et al, 1941; Tyslowitz and 
Dingemanse, 1941; Dow, 1959), though this is not invariably the case 
(Arnold and Hamperl, 1939). ■ Above this dose and up to about 
2 or 4mg/kg/day the animals tend to survive for an average period of 25- 
75 days (Crafts 1941, 1948; MacBryde et al, 1942). At the highest 
doses of about 4-lQmg/kg/day the survival times are usually below 25 
days (Castrodale et al, 1941; Dow, 1958), though there are no reports 
of animals dying in under 10 days. The highest total lethal doses (i.e.
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over lOOmg/kg) tend to be associated with these high dose studies, 
whilst the lethal doses reported in most studies fall within the range 
10-7Gng/kg.
The ferrets in Group B of the present study survived for up to 
23 days and received total doses of diethylstilboestrol of 90mg/kg/day 
or more. Comparable figures in dogs and cats would imply daily dosages 
of about 4-lQmg/kg. As in fact the ferrets received 6mg/kg/day this 
species would appear to be as susceptible to oestrogens as the other two 
carnivores.
Toxicoloqical findings
The picture that has emerged from the present work of the 
effects of high doses of oestrogen in the female ferret involves 
stimulation of the reproductive and endocrine systems, marked changes in 
the blood and bone marrow, and hepatic and renal damage.
The changes in the reproductive tract were those usually 
associated with hyperoestrogenism - ovarian inhibition and uterine 
stimulation. The character of the uterine changes, however, appeared to 
depend upon the time of exposure to oestrogens. Ihe changes in the uteri 
of the shorter-lived animals were indicative of moderate stimulation but 
the changes in the uteri of the longer-lived animals were more aberrant 
and included gross luminal fluid accumulation. Rather similar effects 
to these have been observed in dogs treated with oestrogens (Jabara, 
1962). There was some tendency towards infective disorders of the 
reproductive tract and in this the ferret appears also to resemble the 
dog. Mammary stimulation and alopecia, both noted in the present study, 
are common findings in experimental animals treated with oestrogens 
(Heywood and Wadsworth, 1980).
From the toxicological viewpoint the most interesting aspect of 
the ferret's response to oestrogens is that it displayed the 
haematological reaction previously regarded as an idiosyncrasy of the 
dog. Ihe composite picture drawn from the results of this experiment is 
one of peripheral blood leucocytosis followed by agranulocytosis, 
accompanied by thrombocytopenia and anaemia. The anaemia may have been 
a combined effect of haemorrhage and bone marrow erythroid hypoplasia 
but was not haemolytic in nature and unlikely therefore to account for 
the jaundice, since three cardinal features of haemolysis were not 
present - reticulocytosis, splenomegaly and altered osmotic fragility.
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Moreover,, extram edullary haemopoiesis was not seen. Ihe altered 
distribution in stainable iron might be regarded as a possible 
redirection to the tissues in a storage form, of iron which would 
ordinarily be taken up by erythropoiesis and which, in these animals, 
was depressed by oestrogen treatment. Abnormal accumulation of iron in 
the livers of dogs given oestrogen has been reported elsewhere (e.g. 
Mulligan et al, 1943).
In the dog, the successive changes in the peripheral blood 
mirror changes in the bone marrow consisting of an initial phase of 
myeloid hyperplasia, followed by hypoplasia (Castrodale et al, 1941).
As the terminal marrows of the animals in the present study were 
hypoplastic it is likely that the changes in the marrow of the ferret 
follow the same course of events. An early reticulocytopenia in the 
ferret followed, in some animals, by regeneration prior to a terminal 
decline, presumably correspond to parallel changes in the erythroid 
elements of the bone marrow. Early decreases in the number of 
reticulocytes have also been observed in the dog in response to 
oestrogens and indeed these cells are generally the first to show marked 
changes in number (Arnold, 1939; Arnold and Hamperl, 1939).
Blood coagulation and liver damage
The bleeding syndrome in the ferret seems to involve both a 
thrombocytopenia and, latterly, a clear liver-dependent clotting defect. 
In contrast, in the dog the bleeding is usually attributed to 
thrombocytopenia alone. This, however, may be an insufficient 
explanation as the animals in one study recovered from haemorrhages 
while still thrombocytopenic (Chiu, 1974). An additional factor may be 
alterations in capillary fragility; oestrogens are known to increase 
this in the dog (Skelton et al, 1946). Such effects may also occur in 
the ferret though the data from the present study do not bear directly 
on this point. Compared to the ferret, the dog shows less striking 
hepatic changes in response to oestrogens (Heywood and Wadsworth, 1980). 
Such changes as do occur tend to be inconsistent between animals, modest 
in extent and associated with the highest doses though not in a clear 
dose-dependent manner. In dogs given the lower doses 
(i.e. 0 .1-lmg/kg/day, depending on the oestrogen) several reports note a 
neutrophil leucocytosis as the only major haematological finding but no 
disturbance of liver function. At dose levels above these the full
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haematological picture emerges, mortalities result, and histological 
changes in the liver are observed. These latter usually involve fatty 
degeneration (Arnold and Hamperl, 1939; Li Voti and Mutolo, 1947) often 
with varying degrees of inflammatory round cell infiltration (Arnold et 
al, 1937; Bareuther and Schabbel, 1937; Chiu, 1974), and possibly some 
foci of centrilobular necrosis (Castrodale et al, 1941) or hydropic 
degeneration (Macbryde et al, 1942). Functional impairment as judged by 
liver function tests is usually absent (Castrodale et al, 1941; 
Steinberg, 1970; Capel-Edwards et al, 1971). It should be noted that 
the prothrombin test is less sensitive than Thrombotest (and hence the 
use of the latter in the present study) so it is possible that an effect 
may have been missed, though this seems unlikely in view of the limited 
histological and functional evidence of hepatic damage. It has, in 
fact, been suggested that the various hepatic changes reported in the 
dog may be secondary to the severe haematological disorders (Castrodale 
et al, 1941; Roberts et al, 1944). However, MacBryde et al (1942) 
reported that hepatic damage preceded profound changes in the blood 
indices, suggesting a direct effect on the hepatic parenchyma.
The position is less equivocal in the cat. When this animal is 
given oestrogens it is found in comparative studies to be more 
susceptible to liver damage than the dog and indeed than any of the 
other common laboratory species (Grumbrecht and Loeser, 1940). The 
reported changes in the liver include fatty degeneration, round cell 
infiltration, and necrosis. A later and somewhat more comprehensive 
study showed that there is no evidence of bone marrow aplasia or anaemia 
in this animal (Dow, 1958). The overall picture of hepatic change was 
confirmed but in addition there were extensive abnormalities in the 
intrahepatic biliary system consisting of 'acute cholangitis', 
epithelial thickening and necrosis, and luminal congestion with cellular 
debris and bile. Jaundice and a raised level of serum alkaline 
phosphatase were other pathological findings. In its hepatic response 
to oestrogens, then, the cat appears to differ from the dog in three 
ways: in the nature of some of the changes - notably those in the
biliary system - and in the extent of the others; in the fact that 
these changes prove lethal, and that the liver must therefore be 
regarded as a primary site of toxicity; and in the way in which the 
toxic response of the liver is clearly dependent on dose and duration of 
exposure. In fact, in the character of its hepatic response the cat 
more clearly resembles the ferret than the dog, while ostensibly lacking
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the haematological sensitivity of either.
Renal pathology
The ferrets in the present study show some susceptibility to 
renal damage, dysfunction and enlargement. Renal changes have been 
noted in dogs given oestrogens (Kunde et al, 1930; Balo and Purjez, 
1937; Mulligan et al, 1943; Mulligan and Becker, 1947) and in cats 
(Dow, 1958), though the extent and histological appearance of the 
reported lesions varies considerably. The significance of the present 
findings therefore is uncertain.
Body weight and survival time
There may have been some relation between the initial body 
weights of the ferrets and their survival times: the heaviest animals
in each group tended to survive longest. The exception to this 
generalisation was Ferret No. 8 , but this animal was electively killed 
because of a failure to arrest bleeding after routine venepuncture and 
not because it became moribund, That is to say, in the absence of 
venepuncture is animal would undoubtedly have survived longer. This 
correlation between body weight and survival time must remain tentative 
in view of the small size of the study but it is probably not an age- 
related effect; the variations amongst the experimental animals in body 
weight were not caused by age differences.
Background pathology
In one control animal, No. 3, there were abnormalities in 
hepatic histology, in the levels of serum alanine aminotransferase, in 
the blood picture and in renal function. These observations may reflect 
underlying disease, and, indeed, seven of the other ferrets showed 
evidence of a low-grade intercurrent lung infection. Comparisons can be 
made here with the extensive pathological lesions seen in mongrel dogs 
of indeterminate origin and the paucity of comparable lesions seen in a 
colony of pure bred beagles (Pick and Ewbanks, 1965). Although no other 
evidence of active viral, bacterial, parasitic or fungal infection was 
seen the potential is there since ferrets for all practical purposes 
must be categorised as of wild origin. The interpretation of
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pathological data from such studies as the present one must be made with 
these possibilities in mind.
ABSTRACT
Diethylstilboestrol and hexoestrol were administered orally to 
two groups of three oestrous female ferrets at dosage levels of 
6 and 18mg/kg/day, respectively. Three animals acted as controls.
All the treated animals died within the 30-day study period. 
Death was associated with agranulocytosis, anaemia, a bleeding syndrome 
and jaundice. There was liver damage and the bone marrows were 
hypoplastic or aplastic. The changes in the peripheral blood comprised a 
neutrophil leucocytosis followed by leucopenia, anaemia and 
thrombocytopenia. There was some evidence of renal damage and 
dysfunction.
The histological changes in the uterus and ovaries were 
indicative of stimulation and inhibition, respectively.
The two oestrogens had qualitatively similar effects and the 
degree of toxicity of these compounds appeared to be related to their 
oestrogenic potency.
The ferret proved to be as susceptible to oestrogens as the dog 
and cat - but more closely resembled the dog in the character of its 
haematological response and the cat in its hepatic sensitivity.
Among the treated ferrets the heaviest tended to survive
longest.
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CHAPTER 2
EFFECTS OF 
DIETBYLSmBOESTRQD 
AND ETHINYLOESTRADIOL 
ON TBE FEMALE 
FERRET IN ANOESTEDS
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INTRCDDCnCN
Species with a well-defined breeding season usually respond more 
readily to exogenous hormones such as oestrogens just before or during 
the normal breeding period than at other times (e.g. Fletcher and 
Lindsay, 1971). While this is well established, it appears that there 
are no reports in the literature of attempts to discern such seasonal 
effects on the toxicity of hormonal compounds. One of the main 
intentions of this study, therefore, was to evaluate the response to 
oestrogens of the anoestrous ferret in order to compare this response to 
that of the oestrous ferrets of the previous study. In the oestrous 
ferret the main toxicological findings comprised damage to the liver and 
bone marrow (Chapter 1). The mechanism of toxicity remained unclear, 
however, so in order to elucidate this the attempt was made here to 
determine if these effects could be modified or eliminated by the prior 
administration of either clomiphene citrate, an antioestrogen, or 
phenobarbitone sodium, an inducer of the hepatic microsomal enzymes. 
Ihere are no reports on the use of either of these compounds in high- 
dose toxicity studies on oestrogens. Since the oestrogens used in the 
earlier experiment were nonsteroidal compounds, one animal in the 
present study was given ethinyloestradiol to determine if the ferret 
displayed a similar response to this, a steroidal oestrogen.
Several attempts have been made to elucidate the mechanism of 
oestrogen toxicity in the dog by the administration of other active 
compounds or tissue extracts, but for the most part no changes have 
resulted from such procedures. Thus, vitamin C (Bareuther and Schabbel, 
1931), androgens (Tyslowitz and Dingemanse, 1941? Skelton et al, 1946), 
liver extracts (Tyslowitz and Dingemanse, 1941), vitamins A, D, K and 
histamine (Cruz et al, 1948), nicotinic acid (Schrade, 1938), and 3- 
methylcholanthrene (Mulligan, 1947), all appear to be without effect on 
the haematological and haemorrhagic changes. However, Skelton et al 
(1946) reported that purpura induced in dogs by diethylstilboestrol 
could be reversed by treatment with vitamin E, which restored platelet 
counts and capillary fragility to normal. This result, though, could 
not be reproduced by Richtsmeir et al (1947).
In the toxicological investigation reported here the changes 
observed in the anoestrous ferrets given oestrogens resembled in 
character, though generally not in extent, those reported in the 
oestrous animals. Ihe prior administration of either clomiphene citrate
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or of phenobarbitone sodium was largely without effect on these changes.
EXPERIMENTAL DESIGN AND METHODS
Thirteen female albino ferrets were obtained in early Autumn for 
this study. They were aged between nine and fifteen months and weighed 
from 650g to 1300g. At the commencement of the study all the animals 
were in anoestrus (as determined by vaginal smear and the appearance of 
the external genitalia) and in a healthy condition.
Twelve of the ferrets were randomly assigned to the four main 
experimental groups according to the following treatment schedule.
Group Animal Nos. Treatment Dose
(mg/kg/day)
A 10, 11, 21 Dose vehicle only
(controls)
B 12, 17, 19 Diethylstilboestrol
C 14, 18, 22 Clomiphene citrate
D 15, 16, 20 Phenobarbitone sodium 30
+
Diethylstilboestrol 6
Drug dosages were adjusted to body weights at weekly intervals 
during the 32-day study period. Both the pretreatment compounds were 
given one hour before the oestrogen: clomiphene citrate (dissolved in
isopropyl myristate) daily by oral intubation; and phenobarbitone sodium 
(dissolved in water) on three days prior to the start of the study and 
on three days per week thereafter by intraperitoneal injection. One 
other animal (Ferret No. 13) received ethinyloestradiol at a dose level 
of 6 mg/kg/day for a short-study period of 18 days.
The animals were housed singly and maintained under standard 
conditions. Their food and water consumption and their overall 
condition were monitored daily, and their body weights were determined 
weekly.
Blood (1ml) was taken routinely at intervals during the 
experiment (see tables). The serial haematological investigations
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comprised counts of platelets and reticulocytes, and total and 
differential white cells, and estimations of packed cell volume, 
haemoglobin and fibrinogen. The Thrombotest time (10yl whole blood 
added to 0.5ml reconstituted reagent) was determined in the pre­
terminal blood samples. The serum from these samples was also used for 
the estimation of bilirubin, total and fractional proteins (Biuret and 
cellulose acetate electrophoresis, respectively) and glycoproteins 
(Concanavalin A Laurell rocket electrophoresis).
At the termination of the study, or earlier if severe toxic 
effects appeared, the animals were anaesthetised with pentobarbitone 
sodium by intraperitoneal injection and exsanguinated from the vena 
cava. After macroscopic examination, the liver, spleen, heart, kidneys, 
adrenals, ovaries and uterus were removed and weighed. Samples of these 
organs and also of the lungs, vagina, pancreas, mesenteric lymph node, 
stomach, duodenum, ileum, colon, sternum, and of any tissue other than 
these showing macroscopic abnormalities, were preserved in 1 0 % buffered 
formal-saline. These tissues were then subjected to a standard 
histological analysis. Femoral marrow smears were prepared during 
autopsy.
RESULTS
General observations
Two of the ferrets given diethylstilboestrol died before the 
termination of the study. The first, No. 20, failed to emerge fully 
from phenobarbitone-induced anaesthesia, showed subcutaneous bleeding 
and putrefaction in the intraperitoneal dosing area, and was passing 
tarry stools. It was electively killed for humane reasons on Day 12.
The total cumulative doses of phenobarbitone sodium and 
diethylstilboestrol received by this animal were 180mg/kg and 72mg/kg, 
respectively. The second animal, No. 22, died on the morning of the 
final day of the study just prior to termination. Morbidity in this 
animal was associated with a loss of physical activity, nasal bruising, 
a bloody discharge around the eyes, and incontinence. It was brought to 
autopsy approximately one hour after death, and examination revealed 
severe haemothorax. The blood had not clotted by this time and the 
serum from this was grossly icteric. In total, this ferret received 
64mg/kg body weight of clomiphene citrate and 192mg/kg of
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diethylstilboestrol. Oestrogen treatment induced some degree of vaginal 
cornif ication and vulval, oedema in all the animals so treated and a 
clear pattern of group responsiveness emerged: the animals of Group C 
(diethylstilboestrol and clomiphene citrate) showed the earliest and 
most pronounced vulval swelling (by Day 14), followed by those of Group 
D (diethylstilboestrol and phenobarbitone sodium), with enlargement by 
Day 21, and then those of Group B (diethylstilboestrol alone), with mild 
enlargement by Day 28. No treated animal showed the full vulval 
enlargement characteristic of the oestrous animal though some approached 
this condition. Ferret No. 22 showed the earliest response in the 
genital tract (Day 4) and a viscous discharge from the vulva was noted 
subsequently in this animal between Days 18 and 22. Slight vulval 
inflammation was noted in Ferret No. 18 around Day 16, but otherwise 
there was no tendency among the treated animals to develop any disorders 
of the genital tract. The control animals showed no changes in 
reproductive status. Mammary stimulation (as judged by nipple 
enlargement ) was noted in all the treated animals, but most notably in 
Ferret No. 22 (by Day 14) and, to a lesser extent, Ferret Nos. 15 and 21 
(by Day 28).
The overall condition of the treated animals was generally 
inferior to that of controls and there was a particularly marked 
deterioration in the health of a number of these animals during the 
third week of the study. This was followed by a recovery in all cases, 
but Ferret No. 22 subsequently relapsed after Day 27 and its condition 
deteriorated thereafter. Morbidity in Groups B, C and D was associated 
with the following signs:
Decreased food consumption (all)
Nasal bruising (after Day 27) (Nos. 15, 16, 17, 19, and 22)
Prolonged clotting times (after venepuncture)
(Nos. 12 and 14, Day 23)
Poor wound healing (venepuncture site) (No. 15, Day 30)
Incontinence (Nos. 16, 19, 21, and 22)
Oedema (Nos. 12, 15, 18, 19, 21, and 22)
All controls remained in general good health throughout the experiment.
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Body weights
The control animals gained weight steadily throughout the 
experiment, and showed net gains by termination of about 15%. The 
majority of the treated animals showed changes similar to these though 
in the case of No. 12 the increase was 33%. Four of the treated 
ferrets, however, showed a net loss in body weight. In two of these 
animals (Nos. 13 and 20) the decline in weight was progressive, while in 
the others (Nos. 19 and 22) it occurred after initial gains.
Food consumption
The treated animals consumed less food than controls, and Group 
D animals consumed least of all. Probably due to the stress of oral 
dosing the figures were lowest in the first week in all animals. Food 
consumption then increased progressively up to termination.
Haematology
The haematological findings are presented in Tables la and lb, 
and the data from one ferret (No. 19) are also illustrated in Fig. 1.
Red cells
Oestrogen treatment resulted in a moderate anaemia in all the 
test animals. This was progressive over the entire study period in some 
animals (Nos. 13, 14, 17 and 19) but showed a tendency to stabilise in 
the others. The anaemia was associated with a disappearance of 
circulating reticulocytes, an effect which in most cases was biphasic. 
There were also variations in control reticulocyte values somewhat 
similar in appearance though only similar in degree in Ferret No. 21. 
Among the treated ferrets there was a modest degree of rouleaux 
formation, but little morphological variation in the red cells. 
Normoblasts were few and red cell inclusions were not demonstrable.
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Aa. Individual and group mean haematological data of female ferrets given oral oestrogens and of controls
ment F e r re t  
No.
Day
No.
PCV
(X)
Hb
( g /d l )
R et ies
(X)
MCHC
(X)
WBC 
( lO^/mm^)
N/L
r a t i o
P l a t e l e t s  
( lO^/mm^)
1 45 16.5 2.1 36.7 17.7 1 .2 _
9 49 16.5 0 .6 33.7 19.3 1 .2 505
10 16 49 18.0 0 .7 37.1 18.4 1.1 -
23 52 18.3 1 .3 35.0 20.4 1.4 -
30 51 17.3 1.1 33 .7 19.6 1 .0 440
1 53 17.8 2 .0 33 .8 19.4 0 .8 428
9 53 17.4 1.0 33.1 20.0 1.9 190
o ls  H 16 53 17.9 0 .8 34.1 18.4 1.0 245
23 51 17.9 1 .0 35.0 15.2 0 .8 265
30 55 19.7 1 .5 35.5 16.2 1 .9 280
1 49 17.1 1 .8 35.2 9 .5 1.1 -
9 47 15.1 0 .1 32.5 14.1 1.4 245
21 16 51 17.0 1.8 33 .0 9 .7 1 .4 275
23 50 17.1 2 .1 34.1 12.7 1 .2 -
30 so 16.7 0 .6 33.4 11.0 0 .6 -
1 49 17.1 to o 35 .2 15.5 1 .0 428
±4 +0 .7 +0.1 + 1 .5 + 5 .3 + 0 .2 -
9 49 16.3 0 .6 33.1 17.8 1 .5 313
Mean +3 + 1 .2 +0 .5 +0 .6 +3 .2 + 0 .3 ±168
±  SD 16 51 17.6 1.1 34.7 15.5 1 .2 260
±2 + 0 .5 + 0 .6 ± 2 .1 + 5 .0 ± 0 .2 ±21
23 51 17.8 1.5 34.7 16.1 1.1 265
+ 1 +0 .6 + 0 .5 + 0 .5 + 3 .9 ± 0 .3 -
30 52 17.9 1.1 34.2 15.6 1 .2 440
+ 3 + 1.6 + 0 .5 + 1.1 + 4 .3 ±0 .  7 -
1 46 16.0 0 .9 34.4 16.6 1 .2 313
9 43 15.0 0.4 34.5 ' 30 .2 1 .5 85
12 16 38 13.7 1.0 36.1 39.0 1.9 -
23 36 11.4 4 .5 32.0 25.3 1.3 640
30 35 12.0 1.1 34.3 26.3 1.4 240
1 49 - - - 0 .6 -
9 49 16.6 0 .0 34.2 30.1 2.6 295
17 16 43 14.7 0 .7 33.8 34.9 1.6 145
23 41 14.5 2 .2 35.1 15.0 1 .9 345
30 37 12.4 0 .8 33.1 16.8 1 .4 180
1 56 19.4 0.4 34.5 12.5 0 .7 310
9 45 14.9 0 .0 33.1 45.7 2 .7 320
19 16 42 14.1 0 .9 33.5 37.5 2 .3 315
23 36 13.1 1 .3 36.4 27.9 1.4 100
30 33 11.8 0 .2 35.8 24.9 1 .2 110
1 50 17.7 0 .7 34.5 14.5 0 .8 311
±5 ±2.4 +0.3. +0.0 ±2 .9 ± 0 .3 ±  2
9 46 15.5 0.1 33.9. 35.3 2 .3 233
±3 ± ) .9 +0.2 +0.7 . +9.0 ± 0 .7 ±129
Mean 16 41 14.2 0 .9 34.5 37.1 1.9 230
±  SD ±3 •40.7 +0.1 +1.4 ±2 .1 ± 0 .3 ±120
23 38 12.9 2 .7 34.5 22.7 1.5 493
±3 +2.2 +1.7 +2.3 +6 .8 ± 0 .4 ±209
30 35 12.1 0 .7 34.4 22.7 1 .3 177
±2 ±0.3 +0.5 ±1.3 +5.1 ± 0 .1 ±65
s t a b le  and i n  Table  
s were ob ta ined  under
l b , Day 1 data  
a naesth es ia .
rep resents  th a t ob ta ined  before the  s t a r t  o f t re a tm e n t . The te rm in a l  blood
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able lb. Individual and group mean haematological data of female ferrets given oral oestrogens and of controls
eatment F e r r e t  
oup No.
Day
No.
PCV
(X)
Hb
( g / d l )
Ret ies
(X)
MCHC
(X)
WBC 
( 10^/mm^)
N/L
r a t i o
P la t e l e t s  
( lO-Vmm^)
1 51 14.4 _ 28. 1 14. 1 0 .7 _
9 43 15.0 0.1 35.3 40.1 2.4 1190
14 16 36 12.1 0 .9 33.3 41.5 1.2 12S
23 36 15 .7 3.3 43.5 27.2 1.7 85
30 35 10.5 2 .0 30.0 19.3 1.0 35
1 47 17.4 1 .5 37.0 9 .8 1.1 -
9 47 15 .2 0 .1 32.7 31.4 2.8 135
18 16 43 14 .9 1.0 34.4 39.3 3.1 85
23 31 13 .2 1.6 42.4 18.1 1.6 310
30 35 12.1 1-5 34.9 18.0 2.1 170
1 51 17 .1 1.7 33.4 11.8 0 .8 328
9 45 15.4 0 .0 33.8 36.1 2.4 515
22 16 38 13 .2 0 .1 34.8 25.2 3 .9 280
23 41 12 .7 0 .1 31.4 - 1 .0 95
30 40 13.2 0 .9 33.0 12.4 0 .6 _
1 50 16.3 1.6 32.8 11.9 0 .9 328
+ 3 +1.7 f ) . l ± 4 .5 ± 2 .1 + 0 .2 -
9 45 15.2 0 .1 33 .9 35.9 2 .6 613
±2 +0 .2 +0.1 ± 1 .3 + 4 .3 +0 .2 + 534
Mean 16 39 13.4 0 .7 34.2 35.3 2 .7 163
±  SD ±4 ± 1 .4 ±0 .5 ±0 .8 ± 8 .8 ± 1 .3 + 103
23 36 13 .9 1 .7 39.0 22.7 1 .4 163
+5 +1.6 +1.6 +6.6 +6.4 +0.4 +127
30 36 11.9 1 .5 32.6 16.6 1 .3 103
±3 +1.4 +0.6 ±2 .5 ± 3 .7 +0 .8 ±95
1 57 18.9 - 33.5 13.0 0 .7 -
9 45 15.4 0 .0 34.6 33.0 2 .8 215
15 16 44 14.6 0 .0 33.3 39.6 1.3 70
23 32 12.1 1 .5 38.1 22.6 l . S 95
30 37 13.8 1 .4 36.8 19.8 1 .6
1 50 16.6 1.8 33.1 9 .9 1.3
9 40 13.5 0 .0 33.8 23.0 3 .8 335
16 16 39 13.8 1.2 34.9 29.6 2.0 390
23 36 11.6 1 .9 32.3 21.2 1.6 380
30 35 12.5 0 .6 35.2 23.0 0 .8 200
1 50 17 .7 - 35.4 13.6 0 .8 560
20 9 45 15 .2 0 .0 33.4 35.4 3.3 210
12 49 17.2 0 .0 34.7 19.8 1 .0 106
1 52 17 .7 1.8 34.0 12.2 0 .9 560
±4 ± 1 .2 - ±1 .2 +2 .0 +0.4 -
9 43 14 .7 0 .0 33.9 30.5 3.3 253
+ 3 +1.0 - +0.6 +6.6 +0 .5 ±71
Mean3 16 42 14.2 0.4 34.1 34.6 1 .7 230
+ SD ±3 +0.5 +0.7 ± 1 .1 ± 7 .1 + 0 .5 +226
23 34 11.9 1 .7 35.2 21.9 1.5 237
+3 +0.4 +0.3 ±4 .1 +1.0 +0.1 +201
30 37 13.2 1.0 36.0 21.4 200
+ 1 +0 .9 +0.6 ±1 .1 +2.3 -
1 58 19.3 0 .7 33.5 18.4 0 .8 125
n y l  - 13 9 53 18.6 0 .0 35.3 22.3 1 .9 250
r a d io l 16 50 16.8 0 .0 33.7 19.3 0 .8 170
x c lud ing  F e r r e t  No. 20 a f t e r  Day 9
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(103/mm3) (103/mm3 
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300_
2 0 0 _
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0
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Day of treatment
Fig. 1 Haematological changes in a ferret (No. 19) given 
diethylstilboestrol: 0, platelets (Pltlt); A, white blood
cells (WBC); O , haemoglobin (Hb).
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White cells
There was a marked neutrophil leucocytosis in all the treated 
ferrets. The extent and duration of this varied between animals but in 
most cases the pre-*terminal blood sample yielded a leucocyte count 
within the normal range. There was some variation among controls in the 
neutrophil/lymphocyte ratio but otherwise control values were 
unremarkable.
Blood coagulation
Some degree of thrombocytopenia was evident by Day 30 in all the 
treated animals, and this appeared to be progressive in five cases (Nos. 
14, 15, 19, 20, and 22) and biphasic in two (Nos. 12 and 18). The 
platelet counts are given in Tables la and lb. By Day 23 the. plasma 
fibrinogen levels of the animals which received oestrogens were over 
twice those of controls. By Day 30, however, these values had fallen to 
control levels or below. The Thrombotest times of the treated animals 
were within normal limits. These results and those of the fibrinogen 
estimations are presented in Table 2.
Serum chemistry
Total bilirubin levels were elevated in the terminal serum of 
two of the treated animals (Nos. 14 and 20), and probably also in a 
third (No. 22) (Table 3).
The changes in the serum proteins showed no clear group trends 
(Table 4). Compared to controls, the total serum proteins of four of 
the test animals were elevated (Nos. 12, 13, 19, and 22), while those of 
five were depressed (Nos. 14, 16, 17, 18, and 20). These changes were 
reflections, respectively, of increases or decreases in albumin, and 
there were also alterations in the globulin fractions. Two changes were 
evident in all the treated animals: a fall in the a^-globulins and
a rise in the $i*-globulins. This latter was associated with the 
clear differentiation of a second band in this region (Fig. 2). The 
character of the other changes in the globulin components depended on 
the direction of change of the total proteins. Animals showing 
elevations in the latter tended to show increased a2 8 2 ”an^
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Table 2. Plasma fibrinogen levels and Thrombotest times of female ferrets
given oral oestrogens and of controls
Treatment
group
Ferret
No.
Fibrinocen
(g/l)
Day 23 Day . 30
Thrombotest time 
(sec)
Day 30
A 10
- 1.8 43
Controls 11 2.0 1.9 45
21 1.5 1.2
Mean I-7 1.6 44
± SD ±0.3 ±0.4 ±1
12 4.0 2.5 41
B 17 4.8 1.4 45
DES 19 4.3 2.4 40
Mean 4.4 2.1 42
± SD ±0.4 ±0.6 ±3
C 14 5.6 1.0 36
CC 18 5.1 1.7 43
DES 22 1.4 —
Mean 5.3 1.3 40
± SD ±0.4 ±0.3 ±5
D 15 4.4 0.6 36
PB 16 4.1 0.8 38
DES 20 — — 44
Mean 4.2 0.7 39
± SD ±0.2 ±0.1 ±4
Ethinyl-
oestradiol 13 5. 2b 1.0C 42c
a Day 12 b Day 9 c Day 16
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Table 3. Total bilirubin in the terminal serum
of female ferrets given oral oestrogens and of controls
Treatment Ferret Bilirubin
group No. (mg/dl)
10 0.11
A
11 0.14
Controls
21 0.10
Mean 0.12
± SD ±0.02
B
12 0.08
17 0.03
DES 19 0.11
Mean 0.07
± SD ±0.04
C 14 0.23
CC
DES 18 0.13
22
Mean 0.18
± SD ±0.07
D 15 0.07
PB 16 0.07
DES
20 0.38
Mean 0.17
± SD ±0.18
Ethinyl- 13 0.01
oestradiol
The blood of Ferret No. 22 was collected after death. The serum 
was grossly icteric but a reliable value for bilirubin could not be 
obtained.
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Fig. 2 Cellulose acetate electrophoresis of serum from a 
female ferret given diethylstilboestrol (No. 19, unbroken 
line) and from a control (No. 10, broken line).
Alb = albumin; c^-y = globulin fractions.
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y-globulins. Animals showing decreased total proteins generally had 
lower levels of g2 “9 l°bulins and unchanged levels of o^- and 
Y-globulins.
The serum glycoproteins were raised in all the treated ferrets 
(Table 4).
Organ weight analysis
Oestrogen treatment had little effect on the weights of the 
ovaries and uteri of the majority of the test animals with the notable 
exceptions of those of Nos. 13 and 22, where massive increases occurred, 
and No. 20, where the gains were less marked. There also appeared to 
have been an increase in the ovarian weight of Ferret No. 12. With two 
exceptions, the relative liver weights of the treated animals were 
between 20% and 60% greater than those of controls. The two 
exceptions were those of Nos. 20 and 22, in which no changes were, 
evident. Decreases in the splenic weights occurred in all the treated 
animals except Ferret No. 13 in which there appears to have been the 
opposite effect. > Some of the adrenal weights were raised (Nos. 12, 15, 
17, 18, and 2 0 ), and there may also have been slight increases in the 
renal weights of some of the treated ferrets (Nos. 13, 15, and 18). The 
absolute and relative organ weights are given in Tables 5 and 6 , 
respectively.
The ovaries and uteri of the control animals in the present 
study were appreciably smaller than those of the oestrous ferrets of a 
previous experiment (Chapter 1). Temporal changes in the size of the 
reproductive organs of the ferret have been reported elsewhere (Thornton 
et al, 1979), and these changes are reflections of seasonal differences 
in reproductive activity.
Histopathological changes
There were no obvious group trends in the morphological changes 
that occurred in the treated animals.
The changes in the reproductive system broadly consisted of 
ovarian inhibition and uterine stimulation. In the ovaries of the 
treated ferrets there was a decrease in the number of advanced follicles 
and in one case (No. 22) there were follicular cysts. The uterine 
changes were of the two main types noted in the earlier study on
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ferrets; thus, the uteri of six animals (Nos. 14, 15, 16, 17, 18, and 
2 0 ) showed modest changes - moderate endometrial hyperplasia, glandular 
dilatation and, in some cases, myometrial hypertrophy (Fig. 4). One of 
these animals (No. 20) also showed areas of endometrial oedema at the 
apices of the mucosal folds. The changes in the uteri of two of the 
other animals (Nos. 13 and 22) were more extensive and comprised 
gross luminal distension due to fluid accumulation (10 and 40ml, 
respectively), endometrial oedema, loss of mucosal folding, epithelial 
hyperplasia, and in some cases cystic glandular dilatation (Fig. 5).
Ihe uteri of the remaining treated animals, Nos. 12 and 19, represented 
intermediate forms, with modest endometrial and myometrial changes and 
some fluid accumulation. A section from the uterus of a control animal 
is shown in Fig. 3.
Ihe liver of one treated ferret (No. 22) showed gross periportal 
fatty change, early centrilobular necrosis, cholestasis, bile duct 
dilatation and epithelial proliferation, and a marked increase in Perl's 
stainable iron. Ihe livers of all the treated animals, in fact, showed 
more fat than those of controls, with the degree of fatty change being 
moderate and diffuse in Nos. 13, 19, and 20, and modest in the others. 
The livers of the treated animals also tended to show more glycogen than 
did those of controls. Ihe intrahepatic bile ducts of several ferrets 
(Nos. 13, 17, and 19) had eosinophilic contents and in these animals 
there may also have been some early bile duct epithelial hyperplasia.
A moderate degree of inflammatory round cell infiltration, mainly 
periportal, was noted in the livers of a number of treated animals 
(Nos. 13, 14, 15, 16 and 20) and, to a lesser extent, in one control 
(No. 10). Focal haemorrhagic necrosis was observed in the caudal lobe 
of the liver of Ferret No. 16.
The kidneys of two animals showed signs of extensive fatty 
change. In one case (No. 20), this was primarily confined to the 
proximal and distal convoluted tubules, while in the other (No. 22) this 
occurred in the epithelial cells of the collecting ducts. Cloudy 
swelling of the cells of the proximal and distal convoluted tubules was 
also evident in this latter animal as was an increase in Perl's positive 
material. This last observation also applied to the kidneys of Ferret 
No. 13. Purple deposits were noted in the tubules of the renal pelvis 
in two animals (Nos. 15 and 22) and these may have been parasitic cysts. 
In a third animal (No. 14) there was a papillary round cell infiltrate 
that may be suggestive of some urinary tract infection.
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Fig. 3. Uterus of a control ferret (No. 11). H & E, x 25
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Fig. 4. Stimulatory changes in the uterus of a ferret 
(No. 17) treated with diethylstilboestrol. Note endometrial 
hyperplasia, glandular dilatation, and myometrial hypertrophy. 
H & E, x 25.
Fig. 5. Gross changes in the uterus of a ferret (No. 22) 
treated with clomiphene citrate and diethylstilboestrol. Note 
increase in size, luminal epithelial hyperplasia, luminal 
fluid accumulation, and endometrial oedema. H & E, x 25
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The bone marrows of the treated ferrets showed varying degrees 
of erythroid and megakaryocyte hypoplasia but only in the case of 
Ferret No. 22 were these effects severe. There were no obvious changes 
in the myeloid cells.
The spleens and mesenteric lymph nodes of all the animals given 
oestrogens showed a marked increase in Perl's positive material. This 
was particularly obvious in Nos. 13, 17, 18, 19 and 22.
The adrenal weight gains noted in several animals were due to 
cortical enlargement but there was little evidence of hyperplasia.
The stomach of Ferret No. 22 showed mucosal calcification, a 
phenomenon which may be suggestive of previous leptospiral infection.
In addition, the gastric and intestinal epithelium of this and another 
animal (No. 20) showed some degree of erosion. These findings may 
correlate with the observation of tarry stools in one (No. 20) and a 
bleeding syndrome in the other (No. 22).
Several animals (Nos. 13, 14, 16, and 21) showed signs of the 
low-grade lung disease observed in the ferrets of the earlier study and 
elsewhere (Hammond and Chesterman, 1976). This was evident 
macroscopically as discreet white plagues on the pleural surface. In 
the lungs of a number of the treated animals (Nos. 13, 14, 15, 16, 18, 
and 2 2 ) there were also areas of peribronchiolar round cell 
infiltration.
DISCUSSION
The results of this experiment and the previous one taken 
together indicate that the female ferret is markedly less susceptible to 
oestrogens when in anoestrus than when in oestrus, but that the toxic 
changes in the two states are essentially similar. This would appear to 
be the first report detailing a seasonal effect on oestrogen toxicity. 
All the ferrets in the previous study succumbed to diettylstilboestrol 
at a dosage level that in the present experiment proved lethal to only 
two of the ferrets so treated. Moreover, while both of these latter 
animals, in extremis, showed signs of the bleeding and other disorders 
associated with oestrogen toxicity in the earlier study, neither 
mortality was uncomplicated. That of the first, Ferret No. 11, was 
associated with a failure to revive from anaesthesia and the presence of 
a serious abdominal lesion which was probably due to septic changes 
around the intraperitoneal dosing area. That of the second, Ferret
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No. 22, may have been partly due to the poor general health of the 
animal, though this was not obvious externally; there was histological 
evidence of previous leptospiral infection and there were what appeared 
to be parasitic cysts in the collecting ducts of the renal tubules. 
Crafts (1948) has noted that the survival times of dogs given oestrogens 
is related to their general state of health, lhat Ferret No. 22 (and 
Mo. 15) may have harboured renal parasites and that a number of other 
animals showed evidence of the low-grade lung infection observed in the 
oestrous ferrets, reinforces the caveat that pathological 
interpretations should be made with particular care in animals bred 
outside the laboratory.
Among the other treated animals that which probably displayed 
the greatest incipient toxicity was Ferret No. 13. Ihe ethinyl- 
oestradiol which this ferret received caused qualitatively similar 
toxicological changes to those seen in the other treated animals. It 
seems likely, therefore, that in general the steroidal oestrogens have 
the same toxic effects in the female ferret as the nonsteroidal 
oestrogens. Ibis is also the case in the dog (MacBryde et al, 1942).
Toxicological findings
As consistent differences between the treatment groups were few, 
the treated animals can be considered together for the purposes of 
obtaining an overall assessment of the toxicological consequences of 
administering oestrogens to the anoestrous ferret. Ihe observed changes 
included effects in the reproductive tract and on the mammary glands, 
alterations in the blood and bone marrow, and some degree of hepatic and 
renal damage. In a number of the treated animals (Mbs. 13, 20, and 22, 
and to a lesser extent, Nos. 12 and 19) these various effects were 
markedly more severe than in the others.
Ihe changes in the peripheral blood consisted of a prolonged 
neutrophil leucocytosis, a moderate anaemia, and a more or less 
progressive thrombocytopenia. Ihe anaemia was either progressive or 
showed a tendency to stabilise, and was usually associated with a cyclic 
reticulocytopenia such as was observed in the previous ferret study 
(Chapter 1). Ihe bone marrows of the treated animals showed varying 
degrees of hypoplasia, and the increase in stainable iron in several 
tissues probably indicates a reduction in the bone marrow utilisation of 
this material. Histological evidence of liver damage was for the most
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part modest and comprised fatty change and some degree of damage to the 
intrahepatic biliary system.
There were marked increases followed by decreases in the plasma 
fibrinogen levels in all the treated ferrets. As the liver is the major 
site of fibrinogen production and disposal this finding may indicate 
sequential changes in the hepatic functions relating to this clotting 
factor. Elevations in plasma fibrinogen levels have been reported after 
oestrogen treatment in humans (Song et al, 1969), monkeys (Barbosa et 
al, 1970) and dogs (Bhargava et al, 1979) but decreases have not. 
Fibrinogen may be raised in inflammatory states and in conditions of 
tissue injury (Spector, 1977). These rises may be superseded by 
reductions to abnormally low levels.
Striking changes also occurred in the serum proteins: the total
protein was elevated markedly in most of the susceptible ferrets (Nos. 
12, 13, 19 and 22) but decreased in the other animals. As the 
various protein fractions were affected to different extents this 
probably indicates that the observed changes were not caused by 
haemodilution or haemoconcentration. Changes in liver function seem a 
more likely explanation; the liver is the major site of synthesis of 
serum proteins. The results of the protein analysis might therefore 
indicate an opposite effect on liver function in the susceptible animals 
compared to the remainder. That the animals which tended to display the 
greatest histological evidence of liver damage also showed raised levels 
of most of the serum proteins was an unexpected finding: such damage
usually leads to a decrease in albumin and possibly also in the a- and 
3-globulins (Walter and Israel, 1979). The extent of the serum protein 
changes reported here, like the fibrinogen results, are more severe than 
the effects usually encountered in oestrogen toxicity studies in other 
species.
There were increases in serum glycoproteins - as indicated by 
enhanced binding to the plant lectin Concanavalin A - in all the treated 
animals. This probably indicates an increase in the acute phase 
reactants in response to tissue damage. Concanavalin A binds and 
precipitates the predominant glycoproteins present in serum including 
haptoglobin, orosomucoid, a^-antitrypsin, a2“macro9 l°kulin, transferrin, 
C} esterase inhibitor, Cg, C4 , antichymotrypsin and caeruloplasmin 
(literature cited in Warren et al, 1980). These display acute phase 
characteristics. Changes in the levels of some of these proteins may 
explain the raised 3p-globulins in the serum of the treated animals, as
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these include, inter alia, the complement components, which run in the 
second band of this fraction. These behave as acute phase proteins 
albeit slow reacting (Gray and Howarth, 1979, pp. 71). Transferrin is 
another major constituent of the 3 -^-globulins detectable by zonal 
electrophoresis and this too displays acute phase characteristics. The 
levels of this protein are augmented in humans treated with oestrogens 
(Briggs, 1979), and, furthermore,a possible rise in transferrin would 
correlate with a low bone marrow utilisation of iron, as this 
iron-binding protein is raised in conditions of excess plasma iron 
(Keyser, 1979, pp. 144). The cg_-globulins also include a number of the 
acute phase reactants notably oj-antitrypsin, and might thus have been 
expected to rise in the treated animals. The significance of a decline 
in this fraction is therefore problematical.
Seasonal effects
Most of the haematological and histopathological changes noted 
above resembled those observed in the oestrous animals of the previous 
study. Many other changes were also similar. These included decreased 
food consumption, nasal bruising, delayed wound healing at the 
venepuncture site, incontinence, oedema, mammary enlargement, decreased 
splenic weights, and, in some cases, increased adrenal and renal 
weights.
The most obvious difference between the oestrous and the 
anoestrous ferret was the lower sensitivity of the latter to 
reproductive stimulation. The relative refractoriness of the anoestrous 
animal was perhaps predictable: sexual activity is seasonal in the
ferret, and photoperiod, not oestrogen, is the major factor controlling 
its onset (Herbert et al, 1975). A less predictable result of the 
current experiment is that the susceptibility of the female ferret to 
the toxic effects of oestrogens on the liver and bone marrow, and to 
oestrogen-induced liver and kidney enlargements, also appears to be 
influenced by season. In addition, those anoestrous animals which 
showed the greatest toxic effects also invariably showed the most marked 
reproductive stimulation - a correlation which might suggest a more 
general endocrine contribution to oestrogen toxicity than has hitherto 
been recognised.
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Body weights
Ihe ferrets most susceptible to the reproductive and toxic 
effects of oestrogens also showed the greatest changes in body weight. 
Two patterns emerged: either a progressive decline in the lighter
animals (Nos. 13 and 20), or a rise followed by a decline in the heavier 
ones (Nos. 19 and 22). Similar patterns of body weight changes emerged 
in the earlier study? the lighter animals showed more rapid reductions 
in weight and had shorter survival times than the heavier animals. The 
results of the current experiment indicate that in the anoestrous ferret 
the initial body weight is not predictive of susceptibility - but if an
animal proves susceptible then the character of the weight changes it
displays will bear some relation to its initial body weight.
The oestrous ferrets in the previous experiment weighed about a 
third less than the anoestrous animals used here. This difference 
probably relates to the weight loss associated with the onset of oestrus 
in this species (Thornton et'al, 1979).
Pretreatment compounds
Prior administration of clomiphene citrate or phenobarbitone 
sodium was largely without consistent effect on the character, onset, or 
duration of the toxic changes provoked by diethylstilboestrol. The 
pretreatment compounds also appeared not to alter the reproductive 
response-of the treated animals. In view of the antioestrogenic
activity of clomiphene, this result at least was unexpected.
Phenobarbitone pretreatment, however, has also been reported to decrease 
the uterotrophic activity of orally administered diethylstilboestrol, 
probably by increasing the hepatic metabolism of this oestrogen (Levin 
et al, 1968). The absence of an obvious antiuterotrophic effect in the 
present experiment may have been due to the high dose of 
diethylstilboestrol used. Phenobarbitone also had no effect on the 
changes in the peripheral blood. The corresponding changes in the blood 
of oestrogen-treated dogs are not affected by 3-methylcholanthrene, 
another potent inducer of hepatic drug metabolism (Mulligan, 1947).
These results may indicate that the metabolism of oestrogens in the 
liver and at other sites is not involved in the haematological changes.
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ABSTRACT
Diethylstilboestrol was administered orally at a dose level of 
6mg/kg/day to three groups of three female ferrets in anoestrus over a 
32-day study period. The animals in two of these groups were pretreated 
with either clomiphene citrate (daily at a dose level of 2mg/kg/day) or 
phenobarbitone sodium (three times a week at a dose level of 
3Qmg/kg/day). One further animal received ethinyloestradiol at a dose 
level of 6 mg/kg/day. for a short-study period of 18 days. Three animals 
acted as controls.
Though responding in a qualitatively similar manner to the 
oestrous ferret, the anoestrous animal proved to be markedly less 
susceptible to the toxic effects of oestrogens on the liver and bone 
marrow and also tended to show more modest enlargements of the liver and 
kidneys and less intense signs of reproductive stimulation. No 
consistent group trends emerged and the pretreatment compounds were 
generally without effect on the observed changes. Those animals 
displaying the most reproductive changes also tended to show the most 
severe toxic effects. There were alterations in the peripheral blood 
which included a neutrophil leucocytosis accompanied by anaemia and 
thrombocytopenia. Two ferrets died during the study. There were signs 
in these animals of bleeding disorders but both mortalities were 
complicated by incidental pathology, relating in one case to a 
pretreatment compound (phenobarbitone sodium) and in the other to pre­
existing disease.
All the treated animals showed changes in plasma fibrinogen 
levels and in the serum proteins.
The single ferret given ethinyloestradiol showed an essentially 
similar pattern of response to that seen in the animals treated with 
diethylstilboestrol.
78
CHAPTER 3
EFFECTS OF 
DIEraYLSTIIBOESTRCL 
AND HEXOESTROL 
ON THE FEMALE 
RAT
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INTRODUCTION
There have been a number of investigations into the effects of 
high doses of oestrogens on the rat (Grumbrecht and Loeser, 1940;
Russell et al, 1941; Page et al, 1941; Von Haam et al, 1941; Teague, 
1942; Blanchard and Stebbins, 1945; Gibson, 1967). These have shown that 
in this species the major haematological finding is a stable, low-grade 
anaemia (e.g. Gibson et al, 1967) and that this is so even at dosages 
which in the dog provoke extensive and often irreversible alteration of 
the bone marrow and formed elements of the peripheral blood (Hall,
1972). As with the dog, liver damage in the rat is inconsistently 
reported as to incidence, character, and severity - though in one 
comparative experiment the rat was found to be second only to the cat in 
its susceptibility to liver damage in terms of histological 
abnormalities (Grumbrecht and Loeser, 1940). Other reported effects of 
oestrogens include changes in the endocrine and reproductive organs, 
alterations in the body and organ weights, and increases in mammary and 
pituitary tumours (Heywood and Wadsworth, 1980).
The experiment reported here was a toxicological investigation 
encompassing haematological, histopathological, and other, studies. The 
results support the view that in the rats oestrogens have a low 
toxicity. The dosage of diethylstilboestrol used (6 mg/kg/day) was such 
as to permit comparisons with the ferrets of the two previous studies, 
while that of hexoestrol (6 Qmg/kg/day) was selected to provide an 
assessment of the toxicity of the two oestrogens at equipotent doses - 
hexoestrol has usually been found to have about one tenth of the 
oestrogenic activity of diethylstilboestrol in rodent bioassays (Kemp 
and Pedersen-Bjergaard, 1943; Harmer and Broom, 1948; Pedersenr- 
Bjergaard and Tonnesen, 1954; Hogg and Korman, 1956; Heftman, 1970). 
The animals in one other treatment group also received clomiphene 
citrate each day prior to diethylstilboestrol. This was in order to 
determine the effects of antioestrogen pretreatment on the development 
and character of any oestrogen-related toxic effects.
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EXPERIMENTAL DESIGN 2ND METHODS
Fifty female rats weighing between 220g and 285g were randomly 
assigned to five groups according to the following protocol.
Group Treatment Dose
(mg/kg/day)
A Diethylstilboestrol 6
B Hexoestrol 60
C Dose vehicle once -
(controls)
D Clcmiphene citrate 2
+
Diethylstilboestrol 6
E Dose vehicle twice
(controls)
The drugs were administered for up to 42 days and the doses were 
adjusted to body weights at weekly intervals. The animals of Group D 
received clomiphene citrate (dissolved in isopropyl myristate) one hour 
prior to diethylstilboestrol.
The animals were caged in groups of five and they were 
maintained under standard conditions. Their food and water consumption 
and their overall condition were monitored daily, while their body 
weights were determined weekly. Their reproductive status was assessed 
by vaginal smear at four-day intervals. Blood samples were taken 
routinely during the experiment (see tables). The samples from half the 
rats in each group were used to measure the Thrombotest time (lOpl whole 
blood added to 0 .5 ml reconstituted reagent), while those from the other 
half were subjected to a haematological investigation consisting of a 
total white cell count, estimations of haemoglobin and packed cell 
volume, and assessment of blood films. Differential white cell counts 
and reticulocyte counts were performed electively. The serum from the
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pre-terminal blood samples was used for the estimation of total proteins 
and albumin.
At the end of the study, or earlier if severe toxic effects 
appeared, the animals were anaesthetised with pentobarbitone sodium by
intraperitoneal injection and exsanguinated from the vena cava. After 
macroscopic examination, the heart, liver, spleen, kidneys, adrenals, 
uterus, ovaries, and pituitary, were removed and weighed. Samples of 
these organs and also of the lungs, vagina, pancreas, mesenteric lymph 
nodes, stomach, duodenum, ileum, colon, sternum, and of tissues other 
than these showing macroscopic abnormalities were preserved in 1 0 % 
buffered formal-saline. Ihese tissues were subjected to a standard 
histological analysis. Femoral marrow smears were also prepared.
RESULTS
General observations
One death occurred in Group A. Ihis animal survived 26 days and 
had received 156mgAg diethylstilboestrol. It was electively killed 
after developing uncontrollable bleeding. Post-mortem examination 
revealed haemothorax and haemoperitoneum. Ihe animal was also found to 
have a massive anaemia and leucocytosis. Ihe bone marrow showed myeloid 
and megakaryocyte hyperplasia while the blood film showed rouleaux, 
morphological variation among the red cells, an increase in normoblasts 
and reticulocytes, and an absence of platelets. Ihere was also 
extensive damage to the liver. No other mortalities occurred among the 
control or test groups.
The adverse effects among the other treated animals were few.
All tended to show a decline in physical activity and overall condition 
from late in the first week of treatment until the second or third week 
of the study. This effect was manifested earliest and was of the 
greatest severity in those rats given hexoestrol.
All the treated animals showed signs of persistent oestrus and 
stimulation of the mammary glands. Gross observation revealed no 
obvious infective disorders of the genital tract.
Body weights
The control animals showed reductions in body weight during the
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first week of the experiment. This was presumably related to the stress 
associated with handling and oral dosing. A subsequent recovery was 
less marked in those controls which received the dose vehicle twice 
daily (Group E). The treated animals showed a similar pattern of early 
changes, but thereafter in the rats given oestrogens alone the weights 
showed a progressive decline. This effect was partially prevented by 
antioestrogen pretreatment. The body weight changes are illustrated in 
Fig. 1.
Food and water consumption
The food intake of all animals was lowest during the first week 
of dosing than subsequently (Table 1). The treated rats ate less than 
controls, the loss of appetite being least marked in the animals given 
clomiphene citrate. Among the controls food consumption was lowest in 
the animals of Group E.
Water intake was variable. There were no consistent differences 
between the control and test animals, or between treatment groups.
Haematology
r The haenatological findings are presented in Tables 2a and 2b.
Red cells
A stable, moderate, normocytic, normochromic anaemia was 
provoked in all the animals given oestrogens. Though the onset and 
extent of this phenomenon showed some individual variation no consistent 
differences emerged between the three treatment groups. The blood and 
reticulocyte films showed no evidence of any changes in the numbers of 
reticulocytes or of any morphological variation among the red cells.
White cells
Transitory elevations in the total numbers of white cells 
occurred in one animal from each of Groups A and B, and in two controls. 
These changes were due to increases in the neutrophils. Otherwise there 
were no leucocyte changes of note.
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Table 1. Food consumption of female rats given oral oestrogens and of
controls
Treatment
group
Food consumption 
(g/rat/day)
Week No.
1 2 ' 3 4 5 6
A
DES
7.1
±2.2
10.5 
+ 1.8
11.2
±0.8
10.6
±1.1
11.4
±1.1
10.8
±1.6
B 6.0 8.9 13.5 13.3 11.2 10.7
HEX
±1.1 ±1.6 ±1.5 ±2.0 ±1.3 ±1.6
C
Controls
10.1
±1.3
14.7
±3.5
16.4
±1.2
15.7
±0.8
16.1
±1.4
16.2
±1.2
D
CC 5.6 9.0 14.3 13.8 14.3 14.3
DES
±1.9 ±2.5 ±2.9 ±2.6 ±1.2 ±2.2
E
Controls
10.0 11.3 14.1 15.5 15.1 15.1
+ 1.8 ±2.1 + 1.4 +2.8 ±2.0 ±1.8
Figures represent mean ±SD of data from ten animals.
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Table 2a. Haematological data of female rats given oral oestrogens
and of controls
Treatment
group
Day
No.
Hb 
(g/di)
PCV
(%)
MCHC
(£)
WBC
(103/mm3)
1 17.1 48 35.5 11.0
+0.5 + 1 +0.7 + 1.8
8 14.5 42 35.1 9.8
+0.5 ±2 +0.4 +2.2
16 13.9 39 35.6 10.8
A + 1.6 ±3 + 3.1 + 1.0
DES 24 12.9 38 33.8 14.1
+0.3 + 1 +0.9 +8.6
31 12.7 39 32.3 10.3
+0.5 ±2 +0.4 ±1.7
39 13.3 39 33.9 10.0
+0.2 ±1 +0.6 + 1.8
1 15.6 45 34.4 8.9
+0.7 ±2 ±0.7 ±2.2
8 14.2 40 35.1 11.7
+0.9 ±3 ±0.2 ±2.4
16 13.2 41 34.0 9.2
B + 1.5 ±7 ±0.8 ±2.7
HEX 24 13.3 39 33.8 17.5
+0.7 ±1 ±0.7 ±9.7
31 14.0 41 34.4 10.1
+0.3 ±1 ±1.0 ±1.4
39 12.9 37 34.4 10.6
±1.3 ±4 ±0.8 ±1.2
1 15.7 46 34.4 9.8
±0.6 ±1 ±1.3 ±2.1
9 15.7 46 34.3 10.4
±0.6 ±2 ±1.5 ±3.1
15 14.6 43 33.8 12.4
C ±0.3 ±1 ±0.9 ±1.9
Controls 23 16.1 47 34.7 7.4
±0.6 ±2 ±i.i ±1.0
31 15.6 47 33.3 9.6
±0.8 ±1 ±1.3 ±0.7
39 15.5 48 32.7 9.8
±1.3 ±2 ±1.5 ±2.6
Figures represent mean ±SD of data from five animals. In this table and in Table 2b, 
and in Figure 1, Dayldata represents that obtained before the start of treatment.
The terminal blood samples were obtained under anaesthesia.
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TaDle 2b. Haematological aata of female rats given oral oestrogens
and of controls
Treatment
group
•Day
No.
Hb 
(g/dl)
PCV
(%)
MCHC
(X)
WBC
(10 /mm2)
1 15.4 43 35.8 10.5
+0.6 + 1 + 1.5 ±1.4
9 14.9 43 33.5 11.9
+ 1.0 ±1 +0.9 +0.5
D 15 13.1 39 31.7 16.4
CC
DES + 1.1 ±3 +3.1 ±1.5
23 13.0 38 33.8 12.4
+0.8 ±2 +1.0 ±2.6
30 13.6 41 33.3 13.8
+0.7 ±3 +0.6 ±3.1
38 13.1 41 32.4 11.8
+0.2 ±2 + 1.6 ±2.3
1 15.7 45 34.3 9.3
±0.6 ±3 ±1.1 ±2.0
9 15.8 46 34.5 10.1
±0.7 ±1 ±1.0 ±3.1
15 14.7 45 33.9 11.8
E
Controls ±0.4 ±1 ±2.6 ±2.8
23 15.0 47 33.7 12.4
±0.7 ±2 ±0.8 ±5.0
30 15.4 45 33.8 15.4
±0.9 ±2 ±1.9 ±3.5
38 15.7 47 33.3 10.7
±0.6 ±1 ±0.9 ±2.0
Figures represent mean ±SD of data from five animals.
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Blood coagulation
The only changes in the Thrombotest times occurred in the 
animals given hexoestrol (Table 3). In these, the clotting times were 
markedly prolonged by the second week, but had almost reverted to normal 
values by the end of the study. There were no overt signs of bleeding 
associated with these clotting changes.
Serum proteins
The results of the serum protein analysis are shown in Table 4. 
There may have been a slight increase in the globulin fraction in the 
rats treated with hexoestrol (Group B) but these changes were non­
significant. In the rats treated with diethylstilboestrol (Group A), 
compared to controls (Group C), there was a modest, non-significant, 
increase in albumin and a significant decrease in globulin (p<0.05).
The albumin/globulin ratio reflected these changes and was above control 
values. The total proteins of the rats of Group D (DES + CC) were 
moderately elevated compared to controls (Group E) and this was due to a 
significant increase in albumin (p<0 .0 1 ).
Organ weight analysis
The interpretation of the organ weight changes is complicated by 
the body weight loss that occurred in all the treated animals. However, 
there appeared to be real as distinct from artefactual increases in the 
liver, uterine, adrenal, and pituitary weights of the Groups A and B 
rats, most notably in the latter. The renal weights also tended to be 
above control values but the differences were non-significant. Similar 
alterations in the organ weights occurred in those animals pretreated 
with clomiphene citrate, though the increases in the liver, uterine, and 
pituitary weights were much less marked than in those animals which 
received diethylstilboestrol alone. The adrenal weights, however, 
tended to be heavier in the former animals than the latter. The ovarian 
weights of the diethylstilboestrol-treated animals, in contrast to those 
of the other treated animals, were significantly increased in size 
(p<0.01) compared to controls. The absolute and relative organ weights 
are presented in Table 5.
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Table 3. Thrombotest times of female rats aiven oral oestroaens
and of controls
Treatment
group
Day
No.
Thrombotest 
(sec)
Treatment
group
Day
No.
Thrombotest 
(sec)
11 51 11 49
+3 ±8A D
DES
17 51
CC
DES 17 48
±6 ±6
25 43 25 50
Mean Mean
±5 ±1±  SD ±  SD
37 42 37 42
±3 ±5
n 121 11 51
±25 ±9
B E
17 88 17 51
HEX Controls
+50 ±5
25 49 25 50
Mean
±  SD ±7 ±2
37 49 37 43
±12 ±6
11 54
±5
C
17 48
Controls
±7
25 55
Mean
±5
±  SD
37 44
±4
Figures represent mean ±SD of data from five animals.
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Table 4. Pre-terminal serum proteins of female rats given oral oestrogens
and of controls
Treatment Total protein Albumin Globulin Albumin/
group (g/1) (g/1) (*) (g/1) (*0 globulin ratio
A 66.4 38.8 58.4 27.6 41.6 1.5
DES + 1.5 + 7.7 ±11.6 ±7.0 ±10.5 ±0.7
B 70.3 33.0 46.9 37.3 53.1 0.9
HEX +6.7 ±1.7 ±2.4 ±6.5 ±9.2 ±0.2
C 68.0 33.0 48.5 34.8 51.1 1.0
Controls +5.0 ±2. 7 ±4.0 ±6.9 ±10.1 ±0.2
D
CC 73.3 40.8 55.6 32.5 44.4
1.3
DES + 4.6 ±3.9 ±5.3 ±1.9 ±2.6 ±0.1
E 64.2 33.4 52.0 33.7 52.6 1.0
Controls +7.3 ±3.9 ±6.1 ±6.4 ±10.0 ±0.2
% = % of total protein 
Globulin = total protein-albumin.
Figures represent mean ±SD of data from ten animals.
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Table 5. Organ weights of female rats given oral oestrogens and of controls 
a. Absolute organ weights (a)
Treatment
group
Heart Liver Spleen Kidneys Adrenals Uterus Ovaries Pituitary
A 0.70 11.41 0.46 1.48 0.12 1.18 0.13 0.053
DES +0.07 ±1.33 ±0.09 ±0.33 ±0.04 ±0.18 ±0.02 ±0.013
B 0.69 12.04 0.40 1.38 0. 19 1.27 0.10 0.090
HEX ±0.11 ±1.08 ±0.05 ±0.16 ±0.21 ±0.31 ±0.04 ±0.047
C 0. 85 9.86 0.57 1.63 0.08 0.91 0.12 0.017
Controls +0.14 ±1.14 ±0.06 ±0. 10 ±0.02 ±0.25 ±0.03 ±0.004
D 0.86 11.33 0.49 1.57 0.15 0.98 0.10 0.022
CC
DES +0.21 ±0.75 ±0.05 ±0.13 ±0.08 ±0.37 ±0.04 ±0.006
E 0.80 8.68 0.50 1.49 0.07 0.91 0.12 0.014
Controls +0.15 ±0.55 ±0.10 ±0.14 ±0.02 ±0.31 ±0.03 ±0.004
b. Relative oraan weiahts 1% of bodv weiaht)
Treatment Heart Liver Spleen Kidneys Adrenals Uterus Ovaries Pitui tary
group
A 0. 32 5.14 0.21 0.67 0.052 0.54 0.059 0.024
DES ±0.03 ±0.32 ±0.05 ±0.15 ±0.019 ±0.09 ±0.001 ±0.004
B 0.31 5.59 0.19 0.64 0.093 0.61 0.048 0.042
HEX ±0.03 ±0.41 ±0.02 ±0.11 ±0.010 ±0.22 ±0.027 ±0.022
C 0. 31 3.70 0.21 0.61 0.030 0.34 0.045 0.007
Controls ±0.06 ±0.46 ±0.02 ±0.05 ±0.009 ±0.09 ±0.010 ±0‘.001
D 0.36 4.76 0.21 0.66 0.063 0.41 0.042 0.009
CC
DES ±0.09 ±0.29 ±0.02 ±0.06 ±0.036 ±0.16 ±0.017 ±0.002
E 0.31 3.38 0.20 0.58 0.028 0.36 0.048 0.005
Controls ±0.06 ±0.27 ±0.04 ±0.03 ±0.005 ±0.14 ±0.013 ±0.001
Figures represent mean +SD of data from ten animals.
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Histopatholoaical changes
Post-mortem examination revealed haemorrhagic pituitaries, uteri 
which were hyperaemic and distended with secretion, and cystic ovaries. 
These effects often occurred together and were much more common in the 
rats of Group B than in those of Groups A or D. The histological 
changes seen in these tissues were consistent with the altered physical 
appearance of the organs. The uteri of the diethylstilboestrol-treated 
animals of both Groups A and D, compared to controls, showed hypertrophy 
and hyperplasia of the luminal epithelium, some hypertrophy of the 
stromal cells, myometrial hypertrophy, and an increase in leucocytes in 
the endometrial stroma (Fig. 3). There was some tendency towards 
glandular cyst formation, and in addition, the uterine and glandular 
lumina of the Group D animals contained desquamated cells, mucoid 
material, and leucocytes. The uteri of one or two of the rats given 
hexoestrol showed rather similar changes to those described above but 
the majority showed a response which included luminal distension and 
fluid accumulation and loss of mucosal folding. There was some oedema 
of the endometrial stroma and a moderate degree of epithelial 
.hyperplasia in all these, and in several there was also marked cystic 
dilatation of the more superficial endometrial glands (Fig. 4). Among 
, all the treated animals there were abnormalities of the luminal 
epithelium: the cells were often vacuolated and variable in size, there 
were occasional hyperplastic polypoid projections, and areas of 
pseudostratification. The controls showed the usual variation in uterine 
histology seen among normal rats. A section of uterus from a control is 
shown in Fig. 2.
The ovaries of most of the treated animals showed atretic 
follicles and a decrease in mature follicles. There was also a decrease 
in interstitial cells and a generally inactive appearance compared to 
controls. The corpora lutea were mostly reduced in size and number, 
occasionally haemorrhagic, and their constituent cells showed variations 
in size and staining characteristics. The exceptions to these 
observations were the corpora lutea in the ovaries of the 
diethylstilboestrol-treated rats. These tended to be larger and 
possibly more numerous than those of controls.
The pituitary changes induced by oestrogens consisted of a 
massive proliferation of the chromophobe cells with a consequent
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Fig. 2. Uterus of a control rat. H & E, x 25
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Fig. 3. Stimulatory changes in the uterus of a rat treated 
with diethylstilboestrol. Note hyperplasia and hypertrophy of 
luminal epithelium. H & E, x 25
Fig. 4. Gross changes in the uterus of a rat treated with 
hexoestrol. Note glandular cyst formation, and luminal fluid 
accumulation. H & Ef x 25
decrease in the relative proportions of the acidophils and basophils.
Ihe pituitaries of a number of the rats treated with hexoestrol and of 
several others appeared haemorrhagic. Ihe adrenals of a number of the 
treated animals also appeared haemorrhagic and enlarged. This latter 
effect was due to cortical hypertrophy and in some cases hyperplasia.
The liver of the diethylstilboestrol-treated animal which died 
during the study showed extensive haemorrhagic necrosis. In the livers 
of the Group A and B animals, and particularly in the latter, there were 
isolated cells showing evidence of fatty change. There was an increase 
in dark cells in the livers of the Group D animals. The hepatocytes in 
the Group B rats showed variable increases in cell and nuclear size.
This effect was particularly marked around the centrilobular veins.
There were no other obvious abnormalities in the treated animals or the 
controls.
The bone marrows of the treated animals showed a moderate degree 
of erythroid hypoplasia. The other cell lines were unaffected.
There were some increases in Perl's stainable iron in the 
spleens, kidneys, and mesenteric lymph nodes of the rats given 
oestrogens, but otherwise these tissues, like the others examined, were 
normal in appearance.
DISCUSSION
The results of this study indicate that the female rat responds 
to oestrogens in a qualitatively different manner to the female ferret; 
at the dosages administered, the oestrogens were largely without lethal 
effect in the rat and there were only modest changes in the haemopoietic 
tissue and liver. These findings, therefore, provide evidence for the 
lower toxicity of oestrogens in the rat compared to the ferret, cat, and 
dog.
Haematological effects
The only significant haematological finding among the majority 
of the treated animals was a normocytic, normochromic anaemia. Such an 
anaemia is the commonest finding in rats given oestrogens (MacBryde et 
al, 1940; Von Haam et al, 1941; Teague, 1942; Gibson et al, 1967) and, 
as in the present study, this may be associated with some degree of 
erythroid hypoplasia (Russell et al, 1941; Piliero et al, 1968). The
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aetiology of these changes in the rat probably differ from that of the 
anaemia in the dog. In the latter species the bone marrow alterations 
are more severe and the associated changes in the peripheral blood are 
usually progressive. Ihe precise mechanism by which oestrogens depress 
erythropoiesis in the rat is uncertain and may depend on dose - high 
doses may decrease erythropoietin production,, possibly due to an effect 
on the liver synthesis of the precursor protein (Mirand and Gordon,
1966; Gordon and Zanjani, 1971), while smaller doses may depress the 
stem cell response to erythropoietin just as androgens stimulate it 
(Jepson and Lowenstein, 1966). More recent studies, however, have 
indicated that even low doses of oestradiol (2.5 - 10.Qil/day) do 
inhibit erythropoietin production in female rats exposed to hypoxia 
(Peschle et al, 1973).
Transient leucocytoses occurred in two treated and two control 
animals. Ihese effects may have been due to stress or infection rather 
than - in the case of the treated rats - with drug administration. 
Oestrogens generally do not induce striking changes in the leucocytes in 
the peripheral blood of rats (Von Haam et al, 1941; Vollmer and Gordon, 
1941; Okubo, 1965; Gibson et al, 1967). A leucocytosis was also 
observed, however, in the diethylstilboestrol-treated rat which died in 
the present experiment. This appeared to be a post-haemorrhagic effect, 
the .animal developing a bleeding disorder related to severe liver 
damage. Liver damage associated with jaundice has been reported as a 
major cause of death in mice given diethylstilboestrol (Selye, 1939), 
but in most studies in rodents either no serious liver abnormalities 
have been observed (Blanchard and Stebbins, 1945; Gibson et al, 1967), 
or only one or two animals were affected (Russell et al, 1941; Page et 
al, 1941; Von Haam et al, 1941).
Reproductive findings
The uterine and ovarian changes observed in the treated animals 
were indicative of stimulation and inhibition, respectively. Such
♦
effects are the usual findings in rats treated with oestrogens 
(Benirschke et al, 1978). Less predictable, however, were the group 
differences: the uterine changes in the hexoestrol-treated animals -
which included marked enlargement and fluid accumulation - corresponded 
in type though not in degree to the changes seen in ferrets given 
oestrogens and regarded as being dependent on time of exposure rather
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than dosage. Since these changes were not seen in the animals treated 
with diethylstilboestrol for the same period - and at a dosage, 
moreover, which like that of hexoestrol was well above the minimum 
effective dose for the induction of oestrus - these alterations would 
appear to be more dependent in the rat on dosage than time of exposure. 
Also unlike the ferret, the rat treated with oestrogens invariably shows 
uterine weight gains. This is presumably a reflection of the fact that 
in this species oestrogens will usually induce oestrus regardless of 
seasonal photoperiodic factors.
Organ weights
The changes in the absolute and relative organ weights were 
largely as expected (Teague, 1942). The gains were particularly 
striking in the pituitary gland; this was due to a massive 
proliferation of chromophobe cells in the anterior pituitary, and a 
relative decline in the acidophils and basophils. These are the usual 
findings in rats treated with large doses of oestrogens (Heywood and 
Wadsworth, 1980), and for this reason no detailed histometric analysis 
was attempted. Pituitary weights are readily induced by oestrogens in 
the rat, as are pituitary tumours (El Etreby et al, 1979). Alterations 
in pituitary function probably account for the observed mammary and 
adrenal enlargements (Benirschke et al, 1978). This latter effect is 
due to hypertrophy of the adrenal cortex. This not only occurs after 
oestrogen treatment but also during oestrus (Turner and Bagnara, 1971). 
The pituitaries and adrenals of several of the treated animals were 
haemorrhagic. These are common observations in rats exposed to 
oestrogens (e.g. Page et al, 1941).
Group differences (Groups A and B)
The results of the present investigation support the view that 
hexoestrol and diethylstilboestrol have qualitatively similar effects in 
the rat (Teague, 1942). Differences did emerge, however, between the 
two groups. Tie diethylstilboestrol-treated rats (Group A) showed more 
changes in the serum proteins and ovarian weights than the hexoestrol- 
treated rats (Group B). The former, however, did not display the 
alterations in Thrombotest times noted in the latter. Such changes have 
also been reported in rats given ethinyloestradiol at a dose of
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0.5mg/kg/day (Heywood and Wadsworth, 1980) and probably reflect 
alterations in liver function. Ihe histological evidence of liver 
damage was, in fact, somewhat greater in the rats treated with 
hexoestrol than in those given diethylstilboestrol - as were the 
clinical signs of toxicity, the uterine changes, and the extent of the 
liver, adrenal, and pituitary weight gains. In general, therefore, the 
level of toxicity was higher in the Group A animals than in those of 
Group Bw This indicates that in the rat, unlike the ferret (Chapter 1), 
the toxic effects of oestrogens are mainly related to the dosage rather 
than the potency of the compounds administered.
Body weights
One exception to the foregoing generalisation was the body 
weight loss which was similar in the two experimental groups. Ihis 
effect of oestrogens has, in fact, been reported to be dependent upon the 
potency of the test compounds (Gibson et al, 1967). Body 
weight reduction is usually regarded as an index of toxicity (Balazs, 
197G), but in the present case pharmacological effects are indicated; 
the weight loss is mainly due to an anorexia which is probably mediated 
through the hypothalamic-pituitary axis, but there may also be an 
adjustment of the regulated body weight (Wade, 1975). This latter 
contention is supported by the present results which showed a partial 
recovery of appetite but a progressive reduction in body weight.
Antioestroaen pretreatment
Clomiphene reduced the losses in appetite and body weight caused 
by diethylstilboestrol and also the gains in the pituitary, liver and 
uterine weights. In antagonising the appetite and body weight changes, 
clomiphene is probably acting centrally; in the rat, this antioestrogen 
can reduce the uptake of oestradiol by the anterior pituitary and 
hypothalamus (Kato et al, 1968). This probably accounts for the lower 
pituitary weights and may also account for the lower liver weights, as 
there is some evidence that the hepatotrophic effects of oestrogens are 
mediated through the hypothalamic-pituitary axis (Fraenkel-Conrat et al, 
1941). The antiuterotrophic activity of clomiphene is the usual 
finding in the rat (Clark and Peck, 1979).
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ABSTRACT
Diethylstilboestrol and hexoestrol were administered orally to 
two groups of ten female rats at dose levels of 6 and 60mg/kg/day, 
respectively. Che further group of ten animals received clomiphene 
citrate at a dose of 2mg/kg/day followed one hour later by 
diethylstilboestrol at a dose of 6 mg/kg/day. Twenty animals acted 
as controls.
One animal treated with diethylstilboestrol died within the 
42-day study period. Death was associated with a bleeding disorder 
related to severe liver damage. Ihe remaining treated animals showed 
little overt toxicity.
Ihe major haematological finding in the treated animals which 
survived was a moderate, stable, normocytic, normochromic anaemia. The 
terminal bone marrows of these animals showed a modest degree of 
erythroid hypoplasia.
There were stimulatory changes in the reproductive tract and 
there were gains in the liver, uterine, adrenal, and pituitary weights. 
These various effects were more marked in the rats treated with 
hexoestrol.
The oestrogens caused reductions in appetite and body weight, a 
modest degree of liver damage, and changes in the serum proteins. In 
addition, the Thrombotest times of the hexoestrol-treated rats were 
prolonged.
■ ' The toxic effects of oestrogens were mainly related to the
dosage of the oestrogens administered rather than their potency.
Clomiphene citrate reduced the adverse effects of 
diethylstilboestrol on appetite and body weight and decreased the gains 
in the pituitary, uterine and liver weights.
Oestrogens are less toxic to the rat than the ferret, cat, and 
dog, and the toxic effects are in many respects qualitatively different.
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CHAPTER 4
BLOOD CLOTTING CHANGES 
IN FEMALE RATS 
TREATED WITH 
OESTROGENS
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3KTRODUCTICW
Oestrogens can provoke severe bleeding disorders in the dog 
(Hall, 1972) and in the ferret (see Chapters 1 and 2 of this thesis), 
but such effects do not occur in the rat. Significant increases, 
however, have been described in the prothrombin and Thrombotest times of 
rats receiving ethinyloestradiol at a dose level of 0.5mg/kg/day 
(Heywood and Wadsworth, 1980), and in the Thrombotest times of rats 
receiving hexoestrol at a dose level of 60mg/kg/day (Chapter 3). The 
experiments reported below were designed to reproduce and characterize 
these clotting defects. As the Thrombotest reaction measures the 
activity of three of the vitamin K-dependent liver group of clotting 
factors (II, VII, and X), alterations in this clotting test - and indeed 
in the prothrombin test - mainly arise through changes in vitamin K 
availability or disorders of liver function. The investigations in this 
chapter examined, inter alia, the first possibility, those in the next 
chapter, the second.
It is known that normal female rats are less susceptible to 
dietary vitamin K deficiency, and hence haemorrhagic disorders, than 
either male rats or castrated females (Metta et al, 1959a, 1959b; 
Mellette, 1961). A number of studies have also shown that low doses of 
oestrogens protect rats of either sex against hypoprothrombinaemia due 
to vitamin K deficiency, whereas androgens appear to have the opposite 
effect (e.g. Jolly et al, 1977). Conversely, as outlined above, at high 
doses oestrogens appear to reduce vitamin K-dependent blood coagulation. 
In view of the results of the low dose studies, these clotting changes 
are unlikely to be due to a straightforward coumarin-like vitamin K 
antagonism. In addition, and to complicate any interpretation, vitamin 
K and some of the coumarin derivatives have been shown to possess 
appreciable oestrogenic activity (Mellette, 1961; Frieden, 1976).
Five experiments are described in this chapter. The aims 
of these were as follows: to confirm that other oestrogens besides
hexoestrol can cause the clotting changes; to determine the effects on 
these changes of clomiphene citrate, testosterone, vitamin and 
vitamin K3 ; to ascertain if the changes are age-related; and to 
characterize the coagulation defects in terms of clotting factor or 
clotting inhibitor activity.
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EXPERIMENTAL DETAILS
Adult female rats were used throughout. Each experimental group 
consisted of five animals, and each group was housed together and 
maintained under standard conditions. Unless otherwise stated, the 
compounds were dissolved in isopropyl myristate and administered orally. 
Pretreatment compounds or the dosing vehicle were given one hour before 
the oestrogen or the second dosing vehicle. Blood samples were obtained 
from the tail. Details of the timing of bleeds and the dilution of 
Thrombotest reagent used are given in the appropriate figures and 
tables. Day 1 data throughout represents that obtained before the 
commencement of dosing. The experimental procedures adhered to during 
these investigations were as outlined in the Appendix.
EXPERIMENT 1 Thrombotest times of female rats given oral oestrogens. 
and the effects of pretreatment with testosterone, clomiphene citrate, 
and vitamin Kj^
Thirty-five animals in the weight range 250-30Qg were assigned 
to seven groups as follows.
Group Treatment Dose
(mg/kg/day)
D
B
A
E
C
Dose vehicle only 
(controls)
Hexoestrol
Diethylstilboestrol
Ethinyloestradiol
Testosterone
60
60
60
20
Hexoestrol
Clcmiphene citrate 
+
60
F 20
Hexoestrol
Vitamin Kp 
+
60
G 2
Hexoestrol 60
Vitamin Kp (phytomenadione) was administered by intraperitoneal 
injection one day before the start of dosing and on each day thereafter
for the twenty-day study period. The other pretreatment compounds were 
administered from the first day onwards. Post-mortem examinations were 
performed electively.
RESULTS
Fig. la & b shows clearly that the Thrombotest times were 
prolonged in all the treated animals. Though there was considerable 
individual variation as to the onset and extent of these clotting 
changes they were in many animals biphasic and self-limiting over the 
period of the study. The clotting changes were in all cases significant 
by Day 3 of the study (p<0.02). The second phase of the clotting 
changes was more severe than the first but tended to be more variable 
between individuals and hence less significant. Among the oestrogen-only 
animals the clotting changes were not associated with overt signs of 
bleeding and there were, indeed, few general signs of toxicity. The 
main exceptions to these generalizations were the animals pretreated 
with clomiphene citrate (Group F). In these the clotting changes were 
progressive and the animals showed some bleeding from the nose, eyes, 
and mouth accompanied by reductions in physical activity and body 
weight. One animal from Group F (F2) was found dead on Day 6 prior to 
blood sampling, while two more, F3 and F5, died on Day 7, the latter 
having shown a clotting time of 260 sec on Day 6 . (This clotting time 
has been excluded from Fig lb). The remaining two animals of this group 
were electively killed for humane reasons on Day 7. Post-mortem 
examination reve&led some tarry contents in the intestines of three of 
the rats (FI, F2, and F5), adrenal enlargement and haemorrhage in four 
(FI, F3, F4 and F5), and evidence of fatty change in the livers in two 
(FI and F4). Histological examination confirmed the last-mentioned 
observation and revealed no abnormalities in the livers of the other 
animals. The sternal sections of two rats (FI and F4) showed myeloid 
and megakaryocyte hyperplasia, while that of another (F5) showed the 
latter only. Any cytological changes in the marrows of F2 and F3 were 
obscured by post-mortem autolysis.
Neither testosterone nor vitamin Kj eliminated the increases in 
clotting times caused by hexoestrol, though both pretreatment compounds 
may have caused alterations in these; several of the rats given 
testosterone showed a triphasic pattern of clotting changes, while 
several of those given vitamin K^ , had greatly prolonged Thrombotest
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Fig. la & b Thrombotest times of female rats treated with 
oral oestrogens and of controls. a: O, controls (Group A);
1, hexoestrol (Group B); diethylstilboestrol (Group C);
•, ethinyloestradiol (Group D) b: #, testosterone and
hexoestrol (Group E); 1, clomiphene citrate and hexoestrol
(Group F); vitamin and hexoestrol (Group G). Points
represent mean + SD of data from five animals except Group F, 
Day 6 (see text). Thrombotest determinations on 20yl whole 
blood added to 0.75ml reconstituted reagent. In this and
subsequent figures, Day 1 data represents that obtained 
before the start of treatment.
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times on Day 13. One of these latter animals (Gl), in fact, showed 
bleeding around the nose and mouth at this time. The significance of 
these effects is somewhat difficult to assess owing to the relative 
infrequency of blood sampling and the extent of the individual variation 
in clotting times among the treated animals.
EXPERIMENT 2 Thrombotest times of female rats given diethylstilboestrol 
and the effects of pretreatment with high doses of vitamin K-^
Thirty animals in the weight range 230-270g were assigned to 
six group as follows.
Group Treatment Dose
(mg/kg/day)
A Dose vehicle twice
(controls)
B Dose vehicle
+
Diethylstilboestrol 60
C Vitamin 6
+
Diethylstilboestrol 60
D Vitamin ^  30
+
Diethylstilboestrol 60
E Vitamin Kj 60
+
Diethylstilboestrol 60
F Vitamin Kj 60
+
Dose vehicle
Vitamin Kj was administered by intraperitoneal injection one day 
before the start of dosing and on each day thereafter for the five-day 
study period. At the termination of the study the animals were 
anaesthetized with ether and exsanguinated from the vena cava. The 
liver, uterus and ovaries were removed and weighed.
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RESULTS
The Thrombotest times were significantly prolonged by Day 3 in 
all the rats treated with diethylstilboestrol, but not in those treated 
with vitamin Kj alone or in the controls (Fig. 2a and b). In most cases 
the clotting times had diminished by Day 5. There were no overt signs 
of bleeding.
Reductions in body weights occurred in most of the controls and 
in all of the test animals (Table 1). Among the latter the losses were 
greatest in the oestrogen-only animals, least in the vitamin K^-only 
animals. Among the animals which received both compounds the reductions 
in weight were more variable and did not depend on the dose of 
vitamin K^ .
The expected stimulation of the reproductive organs was noted in 
all the rats given diethylstilboestrol. In Groups C and D, vitamin 
appeared to reduce somewhat the diethylstilboestrol-induced gains in 
relative uterine weights though these effects were not significant. 
Gonversely, vitamin administered alone caused a significant gain in 
the relative uterine weights (p<0.05) and also increased the size of the 
ovaries (p<0.01). The absolute and relative hepatic weights were 
increased in all the treated animals compared to controls. The gains 
were least marked in the rats which received vitamin alone (Group F). 
The organ weights are presented in Table 1.
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Fig. 2 a & b Thrombotest times of female rats treated with diethyl­
stilboestrol and vitamin K., and of controls. a: 0, controls
(Group A); A, diethylstilboestrol (60mg/kg/day) (Group B);
0, diethylstilboestrol and vitamin I< (6mg/kg/day) (Group C) . 
b: •, diethylstilboestrol and vitamin K (30mg/kg/day) (Group D);
A, diethylstilboestrol and vitamin (6umg/kg/day) (Group E);
■ , vitamin (60mg/kg/day) (F )  Points represent mean + SD of data 
from five animals. Thrombotest determinations on lOyl whole blood 
added to 0.5ml reconstituted reagent. *p<0.05; **p<0.02; ***p<0.01
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Table 1. Body and organ weights of female rats given diethylstilboestrol
and vitamin , and of controls
Treatment Body weight Liver Uterus Ovaries
group Initial Final Abs Rel Abs Rel Abs Rel
(g) (g) (x) (g) (as) (g) .(as)
A
Controls
258 255 8.79 3.45 0.51 0.20 0.13 0.05
±8 ±9 +0.83 +0.33 ±0.09 ±0.04 ±0.02 ±0.01
B
DES 60
254 237 11.92 5.02 0.80 0.34 0.17 0.07
±8 ±11 . +0.76 +0.28 ±0.10 ±0.05 ±0.03 ±0.01
C
DES 60
250 237 12.02 4.97 0.71 0.30 0.17 0.07
Vit K 6 + 12 ±15 +0.97 +0.42 ±0.08 ±0.03 ±0.02 ±0.01
D
DES 60
257 245 12.78 5.23 0.80 0.33 0.19 0.08
Vit K 30 ±14 ±16 +0.89 ±0.14 ±0.09 ±0.02 ±0.04 ±0.02
E
DES 60
258 243 12.53 5.16 0.73 0.30 0.18 0.07
Vit K 60 ±11 ±12 +0:89 ±0.22 ±0.07 ±0.03 ±0.03 ±0.01
F
Vit K 60
250 242 9.66 3.99 0.66 0.27 0.16 0.07
±  3 ±9 ±1.01 ±0.35 ±0.08 ±0.03 ±0.02 ±0.01
Abs = absolute organ weight
Rel = relative organ weight (% of body weight)
DES = diethylstilboestrol? Vit K = vitamin K^; dose rate, mg/kg/day
Figures represent mean ±SD of data from five animals.
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EXPERIMENT 3 Clotting inhibitor and factor VII activities in the plasma 
of female rats given diethylstilboestrol and the effects on oestrogen- 
induced changes in Thrombotest times of high dosages of vitamin K^ _
Twenty animals in the weight range 17O210g were assigned to 
four groups as follows.
Group Treatment Dose
(mg/kg/day)
Dose vehicle twice 
controls
Dose vehicle 
+
Diethylstilboestrol 80
Vitamin K3 (Daily) 80
+
Diethylstilboestrol 80
Dose vehicle 
+
Diethylstilboestrol 80
+
Vitamin K3 (Day 4) 80
Vitamin K3 was dissolved in water at 80mg/ml and administered by 
intraperitoneal injection. The animals of Group C received this
compound one day before the start of dosing and on each day thereafter
for the four-day study period. All the other animals received the 
dosing vehicle, water, at the corresponding times. On Day 4, one hour 
after the two doses had been given, blood samples were taken for a 
Thrombotest determination. Immediately afterwards vitamin K3 was given 
to the Group D animals, and water to the others. Three hours later 
another blood sample was taken for a second Thrombotest determination.
Blood obtained at the first sampling from the rats of Groups A 
and B was used to estimate plasma factor VII activity in the manner of 
Austen and Rhymes (1975). This clotting protein was chosen for 
measurement because it has the shortest plasma half-life (less than 4 
hours) of the vitamin K-dependent clotting factors (Dodds et al, 1967). 
The circulating levels of this protein thus rapidly reflect alterations
A
B
C
D
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in hepatic synthesis (Hellemans et al, 1963).
Blood specimens acquired from Groups A and B rats during the 
first sampling were selectively mixed according to the schedule outlined 
in Table 4, and the Thrombotest times of the mixed samples determined. 
This was in order to determine the effect of putative normal blood on 
any clotting abnormalities in the blood of the treated animals.
RESULTS
On Day 4, the initial and final Thrombotest times of all the 
rats treated with diethylstilboestrol were significantly increased 
(p<0.02 or better) compared to controls (Table 2). There was some 
variation between the first and second determinations but in no case was 
the difference significant. The clotting times at the second 
determination, however, were markedly different in the two groups of 
rats which received vitamin K3 (Groups C and D).
In the rats of Group B the levels of plasma factor VII were 
lower, though variably so, than in the controls (Table 3). The clotting 
times of the pooled blood samples (Table 4) were moderately above 
control values (Table 2). This probably indicates below normal levels 
of one or more of the clotting factors in the blood of the treated 
animals, partially made good by the normal samples, rather 
than abnormally high levels of inhibitors, diluted.
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Table 2. Thrombotest times of female rats given diethylstilboestrol and
vitamin and of controls
Treatment Thrombotest time
group (sec)
Initial Final
A 53 55
Controls ± 2 ± 2
B 6 8 71
DES ±7 ±4
C
DES 6 6 63
Vit K3 (Day 1-4) ± 6 ± 1
D
DES 69 76
Vit K3 (Day 4) + 6 ±5
Figures represent mean ±£D of data from five animals. 
Thrombotest determinations on 10VQ. whole blood added to 0.5ml 
reconstituted reagent.
Table 3. Factor VII activity in the plasma of female rats given 
diethylstilboestrol compared to controls
Rat No. Factor VII
(% of mean control)
B1
B2
B3
B4
B5
54
±25
Mean
±SD
36
84
60
66
22
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Table 4. Thrombotest times of pooled blood samples from female rats
given diethylstilboestrol and from controls
Rat Nos. 
Pooled sample
Thrombotest time 
(sec)
Al + B1 59
A2 + B2 60
A3 + B3 58
A4 + B4 56
A5 + B5 59
Mean 58
±3D ± 2
Thrombotest determinations on lOpl whole blood added to 0.5ml 
reconstituted reagent.
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EXPERIMENT 4 Thrombotest times of female rats given hexoestrol and 
clomiphene citrate
Twenty animals in the weight range 220-250g were assigned to
four groups as follows.
Group Treatment Dose
(mg/kg/day)
A Dose vehicle twice
(controls)
B Dose vehicle
+
Hexoestrol 60
C Clcmiphene citrate 60
+
Hexoestrol 60
D Clcmiphene citrate 60
+
Dose vehicle
After four days the animals were anaesthetized with ether and 
exsanguinated from the vena cava. A post-mortem examination was 
performed and organ weights were determined. Faeces were collected on 
the final day of the study and subjected to a qualitative analysis for 
the presence of blood (Peroheme 40-C, BDH Chemicals, Poole, Dorset).
RESULTS
Hie Thrombotest times were slightly prolonged in the Group D 
animals compared to controls, moderately prolonged in the Group B 
animals, and markedly prolonged in the Group C animals (Table 5). These 
effects were, respectively, non-significant, narrowly non-significant, 
and significant (p<0.01). Hiere were no marked signs of toxicity among 
the treated animals except in the rats of Group C. One of these latter 
became moribund and was electively killed shortly before the termination 
of the study on Day 4. Hie terminal Hirombotest time of this rat was in 
excess of 300 seconds. Morbidity was associated with blood around the 
nose and mouth, a decline in physical activity, and incontinence. Post­
mortem examination revealed erosion of the gastric mucosa. Hie other 
rats in Group C showed similar, though less severe, external signs of
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Table 5. Thrombotest times of female rats given hexoestrol and
clomiphene citrate, and of controls
Treatment
group
Thrombotest time 
(sec)
A 53
Controls ± 2
B 60
Hex ± 6
C 142
cc ±34
Hex
D 57
CC ±3
Figures represent mean ±$D of data from five animals. Thrombotest 
determinations on 10yl whole blood added to 0.5ml reconstituted reagent. 
Data from Rat No. C3 omitted (see text).
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morbidity but no gross abnormalities at post-mortem. The faeces of 
these animals showed a moderate increase in blood compared to controls. 
The amount of faecal blood in the other treated animals may also have 
been elevated slightly.
The organ weight analysis is not presented in detail; the 
findings were of sufficient interest to prompt a more comprehensive 
investigation which is reported in Chapter 6 . The findings in the 
hexoestrol-treated rats (Group B) included increases in the absolute and 
relative weights of the liver, pituitary, and reproductive organs. Such 
effects were absent in the animals treated with clomiphene citrate (Group 
D) and absent or reduced in the rats given both hexoestrol and the 
antioestrogen (Group C).
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EXPERIMENT 5 Effects of age on the changes in Thrombotest times 
and body weights of female rats given hexoestrol
Thirty female rats in three age groups (50, 80, and 115 days) 
were assigned to six groups as follows.
Group Treatment
A Hexoestrol
B Dose vehicle
(controls)
C Hexoestrol
D Dose vehicle
(controls)
E Hexoestrol
F Dose vehicle
Dose
(mg/kg/day)
60
60
60
Mean 
body weights
(g)
175
172
242
249 '
286
284
RESULTS
Fig. 3a-c illustrates the biphasic pattern of clotting changes 
which occurred in all the treated animals over the seventeen-day study 
period. The second phase of these changes (Days 7-17) tended to be 
least severe in the youngest animals (Group A).
Most of the treated animals lost weight over the course of the 
study (Fig. 4). This effect was age-dependent, the reductions being 
greater in the older animals. Conversely, the controls of Groups B and 
D showed gains in body weight and this effect was also related to 
initial body weight. The Group F controls maintained their body 
weights. By the end of the study the treated animals in each age group 
tended to be about 25% lighter than their controls. In absolute terms 
the weight differences were greater in the older animals.
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Fig. 3a-c Effect of age on Thrombotest times of female rats 
treated with hexoestrol/ and of controls. a, age 50 days 
(175g) : •, hexoestrol (Group A); O, controls (Group B) . 
b, age 80 days (245g); A, hexoestrol (Group C); A, controls 
(Group D). c, age 115 days (285g): ■ , hexoestrol (Group E);
O, controls (Group F). Points represent mean + SD of data 
from five animals. Thrombotest determinations on lOyl whole 
blood added to 0.5ml reconstituted reagent.
*p< 0.05; **p< 0.02; ***p<0.01.
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Fig. 4 Effect of age on the changes in body weight of female
rats treated with hexoestrol and of controls: #, hexoestrol
(age 50 days) (Group A); O, controls (age 50 days) (Group B); 
A, hexoestrol (age 80 days) (Group C); A, controls (age 80 
days) (Group D); ■, hexoestrol (age 115 days) (Group E) ;
P 7 controls, (age 115 days) (Group F). Each column represents
mean + SD of data from five animals.
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DISCUSSION
The picture that emerges from these studies is of an oestrogen- 
induced clotting defect probably arising from a decrease in one or more 
of the vitamin K-dependent clotting factors, rather than from the 
formation of an inhibitor to any one of these proteins. In rats treated 
with oestrogens alone the clotting changes were not associated with 
external signs of bleeding, tended to be biphasic and self-limiting over 
a twenty-day study period, and were resistant to parenteral vitamin K 
administration either before or after oestrogen treatment. These 
observations argue against a coumarin-like vitamin K antagonism, as this 
tends not to be self-limiting under continuous treatment or resistant to 
vitamin K administration (e.g. Clark and Halliwell, 1963).
While testosterone had only questionable effects on the clotting 
changes provoked by oestrogens, clomiphene exaggerated these - in a 
number of cases to lethal effect (Experiment 1). Morbidity in some of 
these animals was associated with signs of haemorrhage, some degree of 
liver damage, and bone marrow changes consistent with a compensatory 
response to blood loss. The Thrombotest clotting changes caused by 
hexoestrol were less rapidly exacerbated by clomiphene at a dose of 
2Qmg/kg/day (Experiment 1) than at a dose of 60mg/kg/day (Experiment 4). 
This effect of the antioestrogen may 'therefore be dose-dependent.
A striking feature of the rats which received the higher dose of 
clomiphene together with hexoestrol was the absence of the customary 
oestrogen-induced liver enlargement (Experiment 4). In a previous study 
(Chapter 3), the antioestrogen at a dose of 2mg/kg/day was shown to have 
a similar, though less marked, effect on rats treated with 
diethylstilboestrol at a dose of 6mg/kg/day. This effect may thus also 
be dose-related and may represent a lethal antagonism of adaptive 
hepatic growth.
There was some tendency for the oestrogen-induced blood clotting 
changes to be less severe in younger animals (Experiment 5). This 
effect and the age-dependency of the changes in body weight induced by 
oestrogens have not been reported before.
Experiment 2 confirmed that vitamin K possesses oestrogenic 
activity and also showed that the vitamin, in the presence of an 
oestrogen, can somewhat reduce the response of the uterus compared to 
when the hormone is administered alone (Mellette, 1961). In this, 
vitamin K acts as an impeded oestrogen. It is probably also a pro-
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oestrogen (Emmens, 1941, 1942): the compound while possessing one of
the minimal requirements for oestrogenic activity, an aromatic ring, 
lacks the other, a hydroxyl group. In view of the fact that oestrogenic 
activity is one of the commoner biological properties, too much emphasis 
probably should not be laid on the finding that vitamin K displays 
reproductive activity; while the action of vitamin K in the oestrogen 
target tissues appears to be relatively straightforward, the same cannot 
be said of the interrelationship between oestrogens and vitamin K in 
blood coagulation.
ABSTRACT
Five experiments were performed on female rats.
Hexoestrol, dietbylstilboestrol and ethinyloestradiol, at a dose 
of 60mg/kg/day, were administered orally to groups of five rats each.
All the animals so treated showed decreases in vitamin K-dependent blood 
clotting as measured by the Thrombotest reaction. These changes were in 
most cases biphasic and self-limiting over a twenty-day study period and 
were probably due to reductions in one or more of the vitamin K-dependent 
clotting factors rather than to abnormal inhibitor activity.
There were no signs of bleeding in the treated animals.
Pretreatment with testosterone, vitamin Kj, and vitamin K3 , did 
not markedly affect the clotting changes, but clomiphene citrate 
exacerbated these, in several cases to lethal effect. Death was 
associated with haemorrhage. Other hexoestrol-treated rats receiving 
clomiphene citrate did not show the increases in the weights of the 
liver, pituitary, and reproductive organs which occurred in animals 
given hexoestrol alone.
Vitamin K^ was shown to display oestrogenic activity.
Rats from three age groups (50, 80 and 115 days) were treated 
with hexoestrol at a dose level of 60mg/kg/day. Most lost weight over 
the seventeen-day study period. This effect was age-dependent and was 
more marked in the older animals. Conversely, the younger animals may 
have shown less severe clotting disorders.
The clotting defects reported here are probably not due to 
changes in vitamin K availability.
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CHAPTER 5
HEPATOTOXICITY 
IN FEMALE RATS 
TREATED WUH 
HEXOESTRCL
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INTRCDGCriCN
The experiment reported here represents the second part of the 
inquiry into the nature of the defects in vitamin K-dependent blood 
clotting identified in female rats treated with oestrogens (Chapters 3 
and 4). The earlier studies indicated that the observed changes in 
Thrombotest times in these animals were probably due to a reduction in 
one or more of the vitamin K-dependent blood clotting factors but that 
an alteration in vitamin K availability was not involved. The other main 
possibility is that the changes were due to hepatic dysfunction. As the 
liver is the main site of synthesis of the blood clotting factors, 
damage to this organ can result in clotting disorders (Walter and 
Israel, 1979). Ihe study detailed below was designed to examine this 
possibility.
Oestrogens have been shown to cause degenerative changes in the 
livers of rats and mice in a number of studies. Loeser (1939) reported 
necrosis and fatty change in the livers of rats treated with 
diethylstilboestrol at a dose level of lmg/day for 44 to 54 days.
Similar findings were reported for the natural oestrogens by Korte and 
Brenner (1963). Selye (1939) found areas of necrosis and leucocytic 
infiltration in mice given diethylstilboestrol at lmg/day, and reported 
liver damage associated with jaundice as the cause of death of several , 
of the treated animals. A number of other investigators have described 
focal necrosis and fatty change in the livers of oestrogen-treated rats, 
but affecting only a few animals (Von Haam et al, 1941; Russell et al, 
1941; Page et al, 1941). Teague (1942), however, produced none of these 
effects in rats given diethylstilboestrol, even at a dose level of 
10Ctng/kg for 14 days, or at a dose level of 50mgAg for periods of up to 
8 6 days. This author described only glycogenic vacuolation. Several 
others have reported no significant histological evidence of liver 
damage in rats treated with oestrogens (Grab, 1939; Blanchard and 
Stebbins, 1945; Gibson et al, 1967). In all but one of the foregoing 
studies biochemical parameters of liver toxicity were not assessed. In
the exception, that of Gibson et al (1967), no changes in clinical 
chemistry were found. Hey wood and Wadsworth (1980), however, have 
reported elevated serum alkaline phosphatase activities in rats treated 
with ethinyloestradiol at a dose of 0.5mg/kg/day together with increases 
in one-stage clotting reactions. Gopinath et al (1978) have also 
demonstrated that ethinyloestradiol can increase serum alkaline
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phosphatase levels in rats.
In toxicological studies liver integrity is customarily assessed 
by histopathological examination of the tissue and by a variety of 
biochemical tests on serum. Of these latter, those regarded as being 
the most sensitive parameters of liver damage include bilirubin, 
selected serum enzymes (e.g. alkaline phosphatase), and total and 
fractional proteins (Cutler, 1974). Accordingly, these parameters were 
measured in the present study, but in addition two novel markers of 
tissue damage were also assessed - namely, the serum concentrations of 
total glycoprotein and of o^-macrofoetoprotein. The former include the 
acute phase reactants - plasma proteins whose concentration increases 
significantly during the acute phase of inflammatory processes and in 
response to trauma, tissue breakdown, and infection (review, Cooper and 
Ward, 1979). The latter, o^-macrofoetoprotein, is a foetal protein 
which reappears in the adult rat after tissue damage (Van Gool and 
Ladiges, 1969). It has also been called o^-acute-phase globulin and 
slow-o^-globulin (Keyser, 1979)
In order to permit serial evaluation of any histopathological 
lesions, groups of rats were autopsied at intervals during this 
experiment. The results of these investigations and of the biochemical 
tests indicated the presence in hexoestrol-treated rats of a 
significant, but self-limiting, impairment of liver function.
EXPERIMENTAL DESIGN AND METHODS
Fifty female rats weighing between 225g and 275g were randomly 
assigned to two groups according to the following treatment schedule.
Group Treatment Dose
(mg/kg/day)
A Dose vehicle only
B Hexoestrol 60
The drug dosage was adjusted to body weights at weekly 
intervals. The animals were housed in groups of five and maintained 
under standard conditions. Their food consumption and overall condition 
were monitored daily, their body weights twice-weekly.
At regular intervals during the experiment (after 4, 12, 20, 30
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and 40 days of treatment) five animals from each group were 
anaesthetized with ether and exsanguinated from the vena cava. After a 
general macroscopic examination the liver was removed and weighed, and 
samples of this tissue were preserved in 1 0 % buffered formal-saline. 
Sections were prepared and subjected to a full histological analysis. 
This included an assessment of the mitotic index (total hepatocytes and 
mitotic figures counted in ten fields at a magnification xlOO).
Ihe serum from the terminal blood samples was used for the 
estimation of alkaline phosphatase, bilirubin, total protein, albumin, 
glycoprotein (Goncanavalin A nephelometry), and o^-macrofoetoprotein 
(radial immune diffusion).
RESULTS
General observations
There were no mortalities during the study. The treated animals 
tended to be less active than controls but there were otherwise no 
external signs of toxicity.
The body weights of all the rats treated with hexoestrol 
declined during the study. Ihe extent of these weight reductions 
depended on the time of exposure to the oestrogen. Thus, those animals 
autopsied on Day 4 tended to show losses of below 5% (i.e. 12g) of their 
initial body weights, those on Day 12 up to 1C% (i.e. 25g), and those 
after this time, 1015% (i.e. 25-40g). Ihe controls maintained their 
weights or showed slight gains. Food consumption was lower in all the 
treated animals than in the controls. This effect was particularly 
obvious in the first week of the experiment.
Serum proteins
The results of the serum protein analysis are presented in 
Table 1. Ihe terminal serum of the Day 4 animals compared to the serum 
of controls showed significantly lower levels of total protein (p<0.05). 
This was due to decreases in albumin, the globulin fraction being 
unchanged. Ihe total serum proteins of the treated animals autopsied 
after Day 4, on the other hand, were increased compared to controls, 
significantly so in the Day 30 animals (p<0.05). These changes resulted 
from increases in the serum globulins (evident by Day 12) and, to a
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Table 1. Serum proteins of female rats treated with hexoestrol and of
controls
Parameter Treatment
group
Day of 
4
treatment 
1 2 2 0 30 40
Total A 69.4 68.3 6 8 . 8 64.7 7 2 . 0
protein Controls +2 . 0 ±3.6 ±4.3 ±2 . 0 ±4.7
(g/D
B 66.5 74.5 74.4 7 6 . 8 77.6
HEX ±0 . 6 ±4.8 ±8.4 ±7.8 ±4.3
Albumin A 35.9 34.9 34.7 35.6 34.3
(g/1 ) Controls ±1.1 ±1.3 ± 1.1 ±1.5 ±2.5
B 32.4 34.5 3 6 . 2 3 8 . 0 34.9
HEX ±0 . 8 ±1.5 ±0 . 1 ±3.9 ± 1 . 0
(%) A 51.7 51.1 50.4 55.0 47.6
Controls ±1 . 6 ±1.9 ± 1 . 6 ±2.3 ±3.5
B 48.7 46.3 48.7 49.5 45.0
HEX ±1.5 ±2 . 0 ±0. 1 ±5.1 ±1.3
Globulin A 33.5 34.9 34.1 29.1 37.7
(g/1 ) Contrpls ±1 . 2 ±6 . 2 ±4.2 ± 1 . 6 ±3.1
B 34.0 40.0 43.0 38.9 42.7
HEX ±0.4 ±3.2 ±0 . 6 ±4.8 ±4.3
{%) A 48.3 51.1 49.6 45.0 52.4
Controls ±1.7 ±9.1 ±6 . 1 ±2.5 ±4.3
B 51.1 53.7 57.8 50.7 55.0
HEX ±0 . 6 ±4.3 ±0 . 8 ±6.3 ±5.5
Albumin/ A 1.1 1 . 0 1 . 0 1 . 2 0.9
globulin Controls ±0 . 1 ±0 . 2 ±0 . 1 ±0 . 1 ±0 . 1
ratio
B 1 . 0 0.9 0.9 1 . 0 0 . 8
HEX ±0 . 1 ±0 . 1 ±0 . 1 ±0 . 1 ±0 . 1
Glycoprotein A 97 95 111 109 1 0 2
Controls ±19 ±9 ±9 ±35 ±9
B 134 263 171 181 164
HEX ± 2 2 ±30 ±47 ±27 ±42
% - % of total protein 
Globulin = total protein albumin
Glycoprotein estimated by Concanavalin A nephelometry (arbitrary units). 
Figures represent mean ±SD of data from five animals.
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lesser extent, from increases in the albumin fraction (evident on Days 
20 and 30). In most of the treated rats the albumin/globulin ratio was 
lower than controls.
Hexoestrol provoked increases in the serum glycoproteins. This 
effect was most significant in the serum of the animals autopsied on Day
1 2  (p<0 .0 0 1 ).
The data on the serum proteins of the control animals were 
unremarkable, except for a certain inconsistency in the glycoproteins.
Serum chemistry
The data from the alkaline phosphatase, bilirubin, and '^-macro- 
foetoprotein determinations are given in Table 2. There were time- 
related changes in each of these parameters.
Serum alkaline phosphatase levels were elevated in most of the 
treated animals. This was particularly striking in the rats killed on 
Day 4 (p<0.02). Animals autopsied at the other time-points showed 
progressively lower increments in this enzyme. A rather similar pattern 
emerged from the bilirubin estimations except that here the peak values 
occurred on Day 12 (p<0.01). The serum of the Day 12 animals, in fact, 
was grossly icteric, that of the other rats, much less so. The control 
data for bilirubin were considered to be within normal limits.
No c^-macrofoetoprotein was detectable in the serum of the 
control animals or in the serum of the test animals killed before Day 
30. This protein, however, was readily identified in the serum of the 
treated rats autopsied on Day 30 and to a lesser degree in the serum of 
those autopsied on Day 40.
Liver studies
Organ weight
Oestrogen treatment caused increases in the absolute and 
relative liver weights of all the test animals (Table 3). In all cases 
these increases we re highly significant (p<0.001). The pattern which 
emerged was of a progressive increase in the liver weights up to 
Day 20, followed by a relative decline thereafter. The relative liver 
weights of the Day 4 and Day 20 rats were increased by over 50% and 60%, 
respectively.
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TABLE 2. Serum chemistry of female rats treated with hexoestrol and of
controls
Parameter Treatment
group
Day of treatment 
4 12 2 0 30 40
Alkaline A 67 63 59 61 61
phosphatase
(U/l)
Controls ±5 ±9 ± 1 ± 1 1 ± 1 0
B 129 104 90 71 65
HEX ±33 ±39 ±5 ±13 ±28
Bilirubin A 0.09 0.08 0.06 0.03 0.06
(mg/dl) Controls ±0.05 ±0.06 ±0.03 ± 0 . 0 2 ±0.04
B 0.19 3.82 0.36 0.16 0.38
HEX ± 0 . 0 2 ±1.39 ±0.17 ± 0 . 1 1 ±0.29
o^-Macro A 
foetoprotein Controls
- - - - -
B
HEX
c^-Macrofoetoprotein estimated by radial immune diffuse (arbitrary 
units).
- = undetectable
Figures represent mean ±SD of data from five animals.
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Table 3 Liver weight and mitotic index of female rats treated with 
hexoestrol and of controls
Parameter Treatment
group
Day of treatment 
4 12 2 0 30 40
Liver weight A 9.17 9.26 9.09 9.45 9.91
Absolute Controls ±0.28 ±0.62 ±0.36 ±1.25 ±0.77
(g)
B 11.45 12.37 14.13 13.03 12.38
HEX ±1.07 ±0.76 ±1.35 ±1 . 2 2 ±1.29
Relative A 3.67 3.79 3.51 3.80 3.76
(% of body Controls ±0 . 1 1 ±0.19 ±0.14 ±0.43 ±0.23
weight)
B 5.60 6.13 6.27 5.74 5.40
HEX ±0.37 ±0.44 ±0.26 ±0.64 ±0.26
Mitotic index A 6 2 1 2 0
Controls ±4 ± 2 ± 1 ± 2 —
B 98 26 2 9 1
HEX ±49 ± 1 0 ± 2 ± 6 ± 2
Mitotic index = mitotic figures per 10,000 hepatocytes. 
Figures represent mean ±3D of datafrom five animals.
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Mitotic activity
Amongst the Day 4 and Day 12 animals there were significantly 
higher levels of mitotic activity in the livers of the treated rats than 
in those of controls (p<0.02 and p<0 .0 1 , respectively). Hie level of 
mitotic activity showed a downward trend from Day 4 onwards until a 
second, smaller/ peak of activity around Day 30. This, however, was not 
significant.
Histopatholocry
There were no macroscopic liver abnormalities identified at 
autopsy. There were, however, a number of histological findings.
All sections of liver examined, particularly those after Day 4, 
showed variations in cell size associated with cellular hypertrophy.
This was most obvious around the centrilobular veins. The early 
sections also showed abundant mitotic figures.
The liver sections of the control animals were normal in 
appearance and only showed a weak diffuse positive reaction for fat.
There was a tendency for this latter effect to be more obvious in the 
treated animals particularly in the early sections. In addition, in the 
Day 12 sections and after, there were scattered individual cells showing 
fatty change (Figs. 1 and 2). In many of these cells the fat was present 
as an aggregate of discrete small- and medium-sized droplets. The 
affected cells preponderated in the midzonal region and the incidence of 
these intensified from Day 12 to Day 30, but they were present in 
approximately similar numbers in the Day 30 and Day 40 sections. In 
some sections, especially the Day 30 ones, there was a modest increase 
in midzonal glycogen. Occasional sections showed sinusoidal dilatation 
and others an increase in dark cells.
DISCUSSION
Hexoestrol administered in high dosages to female rats provoked 
an appreciable degree of hepatotoxicity. The pathological abnormalities 
were of both a structural and functional kind, but the changes were 
self-limiting and non-lethal over a 40-day study period. The evidence 
indicated an initial period of marked liver impairment superseded by a 
more stable, adaptive phase thereafter.
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%* 0
Fig. 1. Fatty change in the liver of a rat treated with 
hexoestrol, Day 30. Oil Red 0 & haematoxylin, x 100
Fig. 2. Liver of a control rat, Day 30. Oil Red 0 & 
haonatoxylin, x 100
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Pathokinetics
The early data (Days 4 and 12) showed that hexoestrol caused a 
progressive liver enlargement due to both cellular hypertrophy and 
hyperplasia* At the same time a degree of hepatic dysfunction was 
evident from the identification of both hypoalbuminaemia (Day 4 only) 
and hyperbilirubinanaemia (throughout). Concomitant elevations in 
alkaline phosphatase and in the levels of the putative acute phase 
reactants (Concanavalin A-binding glycoproteins) probably implied some 
structural damage. Ihe histological evidence of damage in the Day 4 
liver sections, however, was minimal but fatty change was identified in 
the livers of the animals autopsied on Day 12 and after. The 
intensification of this effect coincided somewhat paradoxically with 
the observed regressions from peak values of most of the biochemical 
parameters of toxicity. The evidence from these latter seems to suggest 
the occurrence of a process of adaptation during the second half of the 
experiment. Such homeostatic responses to non-lethal toxicity are quite 
common (La Via and Hill, 1971).
Serum proteins
The assertion that the sequential changes in the liver 
culminated in a adaptive phase finds some support from the results of 
the serum protein analysis. As the liver is the source of nearly all of 
the serum proteins alterations in these can reflect changes in hepatic 
function.
The serum globulin levels were significantly elevated in most of 
the treated rats killed after Day 4, while the albumin levels - after 
initially being depressed (Day 4) - were above control values on Days 20 
and 30. The differences in the extent and onset of these changes in the 
two fractions argue against these alterations being due to haemodynamic 
effects. Elevations in the serum globulins often occur in liver 
disorders. These changes may be due to increases in the total 
globulins, or more usually, increases in the gamma-globulins (Gray and 
Howarth, 1979, pp. 89). In retrospect, zonal electrophoresis of the 
serum proteins would, have enabled these effects to be more fully 
characterized. Decreases in albumin also arise from liver disorders but 
elevations in this protein are less common (Spector, 1980). The 
observed increases in albumin were probably not merely a reflection of
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increased liver size; phenobarbitone, for example, while also having 
this effect does not alter serum albumin levels (Schulte-Hermann, 1974). 
As the serum albumin levels of the Day 40 animals were similar to those 
of controls the earlier increases may represent a modest 'rebound1 
effect within a phase of adjustment.
The initial reductions in serum albumin observed in the treated 
rats in this experiment appear to correlate with observations regarding 
the hepatic synthesis of proteins reported elsewhere in this thesis 
(Chapter 4); oestrogens produce in rats clotting disorders which may 
arise from alterations in clotting factor synthesis. These latter 
effects, however, may be of longer duration (up to 2 0  days) and of 
greater severity (factor VII decreased by about 5C% after 4 days) than 
the changes in the serum albumin outlined here. While the clotting 
factors are glycoproteins, albumin is a relatively simple polypeptide. 
The disruption of hepatic synthesis caused by hexoestrol may affect 
different classes of export proteins to different degrees.
Serum chemistry
The increases in serum bilirubin may have been due to changes in 
biliary excretion or to hepatocellular damage, or both, but are unlikely 
to have been due to haemolysis. Jaundice has been reported in mice 
treated with mestranol (Imai and Hayashi, 1970) and in these animals 
canalicular bile plugs were observed. No histological evidence of 
cholestasis was noted in the present study but oestrogens are known to 
decrease hepatic excretory function in the rat (Gumicio and Valdivieso, 
1970; Plaa and Priestly, 1976). Ethinyloestradiol and oestrone, for 
example, have been reported to reduce bile output by about 50% (see 
Dixit, 1980).
As in the present study, increses in serum alkaline phosphatase 
have been noted in female rats given ethinyloestradiol (Gopinath et al, 
1974). It was concluded that this was in part attributable to new 
synthesis by the liver. Heywood and Wadsworth (1980) have repx)rted 
similar alterations in alkaline phosphatase in oestrogen-treated rats.
c^-Macrofoetoprotein is a foetal glycoprotein of macromolecular 
structure which reappears in the adult rat after injury (Van Gool and 
Ladiges, 1969). It has been shown to display acute-phase 
characteristics and usually rises rapidly after tissue injury (Keyser, 
1979, pp. 142). In view of this, the long-delayed rise in this protein
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noted in the current experiment was unexpected. Such an effect has not 
hitherto been described.
Liver enlargement
Many drugs, insecticides, food additives, and other chemical 
compounds are known to induce liver enlargement in the rat. In terms of 
organ weight changes, most of these compounds affect only the liver 
(Schulte-Hermann, 1974). Oestrogens, on the other hand, affect the 
weights of a number of organs besides the liver, including the pituitary 
and adrenal glands and the reproductive tissues (Teague 1942; Chapter 
3). The induction of liver growth by the chemical inducers is often 
accompanied by an increased ability of the liver to metabolize 
lipophilic compounds via the mixed-function oxidase system. For this 
reason liver growth is usually regarded as an adaptation to increased 
functional load.
The character of the oestrogen-induced liver enlargement seems 
to have resembled that commonly associated with the chemical inducers, 
that is, a combination of hypertrophy and hyperplasia. As in the 
present experiment these responses tend to be localized in different 
zones of the liver lobule - hypertrophy predominating around the 
centrilobular veins, lyperplasia in the periportal and midzonal areas 
(Schulte-Hermann, 1974). These zonal differences were particularly 
marked in the livers of the Days 30 and 40 rats, and indeed the lower 
liver weights in these animals compared to those of the Day 20 group 
appeared to be due to a partial regression of the periportal hypertrophy.
Hi stopathology
While fatty change has been noted in rats treated with 
oestrogens (Loeser, 1939; Korte and Brenner, 1963), the pattern seen in 
the present study - involving individual cells in the midzonal region - 
has not been reported before. In addition, the necrosis seen in these 
earlier studies was not reproduced here. There was an increase in 
glycogen in some sections of liver examined. This was the principle 
finding of Teague (1942), but this author reported no fatty change.
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Pathogenesis
The degree of liver dysfunction described here is probably 
sufficient to explain the clotting defects identified previously in 
oestrogen-treated rats (Chapters 3 and 4). The liver is involved in the 
synthesis of almost all the blood clotting factors and it is therefore 
quite common for liver damage to be associated with coagulation 
disorders. The cause of the biphasic pattern of these clotting defects 
in rats, however, remains conjectural; the only parameter which showed a 
biphasic pattern of change was the mitotic index. In the present 
experiment, several lines of evidence seem to indicate the involvement 
of the endoplasmic reticulum in the observed hepatotoxicity. Fatty 
change is often related to inhibition of the biosynthesis of the protein 
moiety of hepatic lipoproteins. This can be due to direct interference 
with the subcellular site of lipoprotein synthesis itself, the 
endoplasmic reticulum. Damage to this organelle would also account for 
the alterations in export protein synthesis, and the selectivity of this 
damage (e.g. alterations in ribosomal attachment) might account for the 
apparent differences in the time-course of the changes in albumin and 
clotting factor VII. An effect on protein synthetic activity is 
regarded as one of the main actions of oestrogens on the liver 
(Adlercreutz and Tenhunen, 1970).
ABSTRACT
Assessments have been made of the hepatotoxic effects of 
administering hexoestrol to the female rat. Twenty-five animals were 
treated daily with hexoestrol at a dose of 60mg/kg. Twenty-five more 
acted as controls. Five animals from each group were killed after 4,
12, 20, 30, and 40 days of treatment. This was to permit serial 
evaluations of liver histopathology to complement serum biochemical 
investigations.
There were no mortalities during the study and only modest 
external signs of toxicity. All the treated rats showed reductions in 
body weight and appetite and gains in liver weight. This last-mentioned 
effect was due to both cellular hypertrophy and hyperplasia.
The principal finding of the liver histopathology was fatty 
change. This affected scattered individual cells mainly in the midzonal 
region.
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All of the serum parameters of toxicity - which consisted of 
bilirubin, total protein, albumin, glycoprotein, o^-macrofoetoprotein, 
and alkaline phosphatase - indicated liver impairment. Most of these 
variables also showed time-related changes consistent with an initial 
phase up to Day 20 of marked liver dysfunction superseded by a more 
adaptive phase thereafter.
Hie hepatotoxicity described here is probably sufficient in 
extent and character to explain the clotting defects observed previously 
in oestrogen-treated rata Damage to the endoplasmic reticulum may be 
involved in the observed effects.
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CHAPTER 6
ORGAN WEIGHT 
CHANGES IN FEMALE 
RATS TREATED WITH 
HEXOESTROL
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IKCRCCOCTICK
Hexoestrol and diethylstilboestrol administered to the female 
rat caused increases in the weights of the pituitary, adrenals, uterus, 
and ovaries (Chapter 3). The endocrine contribution to some of these 
effects was emphasised by the finding that the pituitary, uterine and 
liver weight gains were partially prevented by pretreatment with 
clomiphene, an antioestrogen. This observation relating to the liver 
was reproduced in a later experiment (Chapter 4, Experiment 4). As the 
liver is not usually regarded as an oestrogen target organ this finding 
was somewhat unexpected. The present investigations, therefore, were 
designed to assess the endocrine contribution to the observed liver 
growth and also to indicate the cause or causes of the other organ 
weight changes induced by oestrogens.
In the three experiments described here the endocrine techniques 
of surgical ablation and chemical intervention were used. The three 
studies are presented separately but discussed together. In each case 
female rats were used and these were treated with hexoestrol. The 
rationale behind each of the experiments was as follows. The first was 
designed to confirm the organotrophic effects of hexoestrol and to 
reproduce and extend the earlier observations which indicated that 
clomiphene prevented some of the observed organ weight changes. The 
antioestrogen is known to compete with oestrogen for the high-affinity 
intracellular receptors through which the hormone is believed to act 
(Clark and Peck, 1979). The first study, therefore, examined the effect 
on the organ weight changes of attempting to ‘block1 the endocrine 
activity of hexoestrol. As a control, clomiphene was also administered to 
animals treated with phenobarbitone. This latter is the classical 
inducer of liver enlargement (Schulte-Hermann, 1974).
The second experiment used hypophysectomized rats in order to 
assess the role of the pituitary in the organ weight changes. There is 
some evidence that an intact pituitary is necessary in the oestrogen- 
dependent growth of the uterus (Sonnenschein and Soto, 1978), adrenal 
(Turner and Bagnara, 1971), and liver (Fraenkel-Oonrat et al, 1941).
The third experiment was directed towards defining the 
involvement, if any, of pituitary growth hormone in the hexoestrol- 
induced organ weight changes. To this end a monkey antiserum to rat 
growth hormone was used to neutralise the biological activity of the 
endogenous hormone. The use of an antiserum for this purpose is well-
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established (Hayashida, 1975). Oestrogens are known to increase plasma 
levels of growth hormone in the female rat (Dickerman et al, 1977), and 
growth hormone in turn has been shown to cause visceral enlargement 
(including liver growth) when administered to rodents (Reid, 1954). 
Enlargement of the soft tissues is also observed in man in such 
disorders as gigantism and acromegaly, and this is usually attributed to 
an excess of growth hormone (Anderson, 1976).
In the experiments described below hexoestrol caused a number of 
reproducible changes in the organ weights of the female rat. Most of 
these effects appeared to be mediated through the hypothalamic-pituitary 
axis and were thus susceptible to endocrine manipulation.
EXPERIMENTAL DETAILS
In the three studies reported here there were five rats in each 
of the experimental groups. Hie animals in each group were housed 
together and maintained under standard conditions. Unless otherwise 
stated the experimental compounds were dissolved in isopropyl myristate 
and administered orally. Pretreatment compounds or the dosing vehicle 
were given one hour before the treatment compound or the second dosing 
vehicle. Hie dosing period in each of the experiments was four days.
Hie animals were weighed at the start and end of this period. At the 
termination of the studies the rats were anaesthetized with ether and 
exsanguinated from the vena cava. Hie following organs were removed and 
weighed: liver, spleen, heart, kidneys, adrenals, ovaries, uterus, and
pituitary.
The experimental procedures adhered to in these investigations 
were as outlined in the Appendix.
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EXPERIMENT 1, Organ weight changes in female rats treated with 
hexoestrol, clomiphene citrate and phenobarbitone sodium
Forty adult female rats in the weight range 170-250g were 
assigned to eight groups as follows.
Group Treatment Dose
(mg/kg/day)
A Dose vehicles twice 
(controls)
B Dose vehicle 
+
-
Hexoestrol 60
C Clcmiphene citrate 
+
20
Hexoestrol 60
D Clcmiphene citrate 
+
40
Hexoestrol 60
E Clcmiphene citrate 
+
60
Hexoestrol 60
F Clcmiphene citrate 
+
60
Dose vehicle -
G Clcmiphene citrate 
+
60
Phenobarbitone sodium 80
H Dose vehicle 
+
-
Phenobarbitone sodium 80
The phenobarbitone sodium was dissolved in water and 
administered by intraperitoneal injection.
RESULTS
The initial and final body weights and the absolute organ 
weights are given in Table 1. Hie relative organ weights are presented
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graphically in Fig. la - c.
The controls showed modest gains in weight over the study 
period. The responses amongst the treated animals were more varied.
The animals receiving hexoestrol alone (Group B) or phenobarbitone alone 
(Group H) showed modest weight gains. The gains were less in those rats 
given hexoestrol and the lowest dose of clomiphene (Group C). Higher 
doses of clomiphene given in combination with either of the other 
compounds tended to reduce the weights of the animals so treated. This 
effect in the hexoestrol-treated animals (Groups D and E) was dependent 
on the dose of antioestrogen. The weights of the rats given clomiphene 
alone (Group F) were unchanged. Overall, the body weight changes were 
insufficient to complicate the organ weight analysis.
In the rats treated with hexoestrol alone (Group B), compared to 
controls, there were significant increases in the relative weights of 
the liver (p<0.01), pituitary (p<0.05), uterus (p<0.01), and ovaries 
(p<0.02). There were also moderate increases in the relative adrenal 
weights and decreases in the spleen weights but these changes were not 
significant. The kidney weights tended to be marginally above, and the 
heart weights marginally below control values.
Clomiphene administered alone (Group F) decreased most of the 
relative organ weights compared to controls. The direction and extent 
of the changes and their significance were as follows: liver (-18%, p<0.05), 
spleen (-17%, p<0.05), heart (-16%, p<0.01), kidneys (-11%, p<0.02), 
pituitary (-13%, non-significant), uterus (-25%, pKO.Ol), and 
ovaries (-4%, non-significant). In contrast to these findings, the 
adrenal weight was increased by 7%. This change was non-significant, 
however.
The relative organ weights of the animals treated with both the 
antioestrogen and oestrogen (Groups C, D and E) were generally lower 
than those of animals receiving the oestrogen alone (Group B), and in 
some cases were comparable to those of rats given the antioestrogen 
alone (Group F). The antioestrogen appeared to antagonize in a dose- 
dependent manner the oestrogen-induced increases in the liver, 
pituitary, uterus, and ovaries, while also reducing - again in an 
approximately dose-dependent manner - the spleen, heart and kidney 
weights. The adrenal weights of the Groups D and E rats were 
exceptional in being, higher than those of the hexoestrol-only rats of 
Group B.
The liver and kidney weights of the rats treated with
140
phenobarbitone alone (Group H) were above, and the spleen and uterine 
weights were below, control values. Compared to these rats, the animals 
which received clomiphene as well as phenobarbitone (Group G) had 
similar liver, kidney and heart weights, higher spleen, adrenal and 
ovarian weights, and lower pituitary and uterine weights. None of these 
differences, however, was significant.
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Fig. lc Relative pituitary, uterine and ovarian 
weights of female rats treated with hexoestrol, 
clomiphene citrate, and phenobarbitone sodium, and 
of controls: eight treatment groups, A-H;
HEX = hexoestrol; CC = clomiphene citrate,
PE = phenobarbitone sodium; figures give dose 
rate, mg/kg/day. Each column represents mean + SD 
of data from five animals.
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EXPERIMENT 2. Organ weight changes in hvpophysectomized and intact
female rats treated with hexoestrol
Hie rats used in this experiment were Wistar albinos 
(Crl:(WI)BR) supplied by Charles River UK Ltd., Margate, Kent. The 
operative procedures were carried out by the supplier and this 
experiment was performed within three weeks of surgery. Hypopbysectomy 
caused a virtual cessation of growth. This and the three week post­
operative period account for the differences in the initial body weights 
of the hypophysectomized and sham-operated animals.
Ten hypophy sect omized and ten sham-operated (i.e. intact) female 
rats were assigned to four groups as follows.
Group Status Treatment Dose
(mg/kg/day)
A Intact Dose vehicle only 
(controls)
B Intact Hexoestrol 60
Hypox Hexoestrol 60
D
RESULTS
Hypox Dose vehicle only 
(controls)
Hie body weights and the absolute organ weights are shown in 
Table 2. Hie relative organ weights are displayed in Fig. 2 a-c.
Hie intact controls (Group A) maintained their body weights over 
the four-day study period. All the rats of Groups B, C, and D, however, 
showed moderate reductions in weight.
All the organ weights determined were lower in the 
hypophysectomized controls (Groups D) than in the intact controls (Group 
A). Hypopbysectomy in the adult rat, besides leading to the arrest of 
body growth, also gives rise to splanchnomicria (Jacobsohn, 1966).
Hexoestrol provoked in the intact rats of Group B significant 
increases in the relative weights of the liver (p<0.001),
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adrenals (p<0.02), pituitary (p<0.05), and uterus (p<0.01), compared to 
the intact controls (Group A). The spleen weights on the other hand 
were significantly decreased (p<0.05). Some of the individual kidney 
and ovarian weights were moderately above control values but the group 
means were not significantly increased. The heart weights appeared to 
be unchanged. In contrast to the foregoing, hexoestrol caused fewer 
changes in the relative organ weights of hypophysectomized rats. The 
relative organ weights of the hypophysectomized, hexoestrol-treated rats 
(Group C) differed from those of hypophysectomized controls (Group D) as 
follows: liver (+11%), Spleen (0%), heart (-2%), adrenals (+7%),
kidneys (-5%), uterus (+2%), and ovaries (-1%). None of these 
differences was significant.
EXPERIMENT 3. Organ weight changes in female rats treated with 
hexoestrol and a monkey antiserum to rat growth hormone
Twenty adult female rats in the weight range 190-220g were 
assigned to four groups as follows.
Group Treatment Dose
(mg/kg/day)
A Dose vehicles Only -
(controls)
B Dose vehicle
+
Hexoestrol 60
C GH antiserum
+
hexoestrol 60
D GH antiserum
+
Dose vehicle
Ihe monkey antiserum to rat growth hormone (see Appendix for 
details) was diluted (1 in 60) with physiological saline and 
administered by intravenous injection into the tail vein at lml/kg/day.
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The antiserum or, in the case of controls, saline, was administered 
immediately before the oestrogen or dosing vehicle.
RESULTS
The body weights and absolute organ weights are shown in Table 3 
and the relative organ weights in Fig. 3a- c.
Most of the experimental animals either maintained their body 
weights or showed modest gains over the study period.
Hexoestrol caused a significant increase in the weights of the 
liver (p<0.01), adrenals (p<0.01), pituitary (p<0.05), and uterus 
(p<0.02). There were non-significant rises in the kidney and ovarian 
weights and a modest reduction in the spleen weight (-4%) was also non­
significant. The heart weights were unchanged.
The growth hormone antiserum admininstered alone (Group D) /
increased the weights of the adrenals (+8%) and uterus (4-7%), and 
decreased the weight of the ovaries (-14%). These changes were not 
significant but may imply a role for growth hormone in the maintenance 
of the sizes of these organs in the normal animal - inhibitory for the 
adrenals and uterus, stimulatory for the ovaries.
Most of the organ weight changes seen in the oestrogen-treated 
rats (Group B) also occurred in those which received the growth hormone 
antiserum as well (Group C). The Group C animals, however, had higher 
pituitary and uterine weights and lower liver and adrenal weights than 
the -Group B rats. Of these findings, only the difference in liver weight 
was significant (p<0.02). The ovarian, heart, and spleen weights of the 
two groups were similar. Compared to controls (Group A), the kidney 
weights of the Group B rats were increased while those of the Group C 
animals were decreased. The difference in kidney weights between Groups 
B and C was not quite significant (p<0.1).
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DISCUSSION
The results described here demonstrate that hexoestrol when 
administered in high doses to the female rat causes reproducible 
alterations in the weights of a number of the principal organs. Ihe 
organotrophic activity of hexoestrol is thus more marked than that of 
most other foreign compounds; these latter, if effective in this 
regard, usually only alter the weights of one or two organs and often 
only that of the liver (Schulte-Hermann, 1974). Furthermore, the 
hexoestrol-induced changes were mainly mediated through the 
hypothalamic-pituitary axis. This implies that the observed liver 
enlargement, for example, cannot be regarded as a manifestation of the 
"toxicity" of hexoestrol as such, but as an exaggeration of 
pharmacological activity.
Hexoestrol
There was good agreement between the results of the three 
studies as to the organ weight changes provoked by hexoestrol, though 
the extent of these effects varied somewhat and the effects though 
reproducible were not invariably significant. Ihe results of the organ 
weight analyses have been collated in Table 4. Of the eight organs whose 
weights were determined, six tended to show weight gains, one (the 
spleen) weight reductions, and one (the heart) no consistent changes. The 
average weight changes in the three studies were as follows: liver 
(+37%), spleen (-11%), adrenals (+43%), kidneys (+3%), pituitary (+23%), 
uterus (+49%), and ovaries (+13%). An essentially similar pattern of 
organ weight changes was found in hexoestrol-treated rats in an earlier, 
longer-term, experiment - in animals moreover which, unlike those in the 
present studies, showed significant and progressive reductions in body 
weight (Chapter 3). Ihe alterations in organ weights caused by 
hexoestrol are therefore consistent, sustained, and are not artefacts of 
body weight changes. No repx>rt in the literature on the effects of high 
doses of oestrogens carries a fully comprehensive organ weight analysis 
but the more striking changes - pituitary, uterine, liver and adrenal 
enlargements - are common observations (Teague, 1942; Gibson et al, 1967; 
Heywood and Wadsworth, 1980). In contrast to the current findings, 
however, the ovarian weights of oestrogen-treated rats are usually found 
to be lower than controls (Heywood and Wadsworth, 1980). The reason for
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Table 4. Collated results of three experiments on the organ weight 
changes in female rats treated with hexoestrol
Relative organ weight 
(% of body weight)
Hexoestrol Contributory
Pituitary
factors
Other
Role of growth hormone 
Hexoestrol Controls
Experiment 
1 2  3 2 3
Liver + + + + (+) + 0
Spleen (-) - (-) - 0 0 O
Heart (-) 0 0 0 0 0 0
Adrenals ( + ) + + + (+) (+) (-)
Kidneys (+) ( + ) ( + ) (+) (-) ( + ) o
Pituitary + + + NA NA (-) o
Uterus + + + + (+) (-) (-)
Ovaries + (+) (+) ( + ) 0 0 (+)
+ = increase
= decrease 
0 = no change
NA = not applicable
Brackets indicate that the observed effect did not achieve statistical significance 
at the 5% confidence level.
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this discrepancy may be related to the duration of treatment: the
ovarian weights of hexoestrol-treated rats in the longer-term study 
mentioned above were similar to those of controls and below those of 
rats treated with a lower dose of diethylstilboestrol (Chapter 3).
There may thus be an incremental changes in ovarian weights prior to a 
decline in rats treated with the highest doses of oestrogens.
No histological evaluations were made in these experiments but 
tentative deductions can perhaps be made as to the character of some of 
the organ weight changes from the results reported elsewhere in this 
thesis and from the literature. Most of these changes appear to involve 
hypertrophic or hyperplastic processes. Hie probable changes are as 
follows. Pituitary - chromophobic proliferation in the anterior lobe 
(Chapter 3; Heywood and Wadsworth, 1980); uterus - endometrial 
hypertrophy and hyperplasia and myometrial hypertrophy (Chapter 3); 
liver-hepatocyte hypertrophy and hyperplasia (Chapter 5); kidneys - no 
obvious cause (Chapter 3); adrenals - cortical cell hypertrophy 
(Chapter 3; Turner and Bagnara, 1971) spleen - no obvious cause 
(Chapter 3); and ovaries - luteotrophic effects (see below).
Pituitary mediation
The data from Experiment 2 showed that in otherwise untreated 
hypophysectomized rats there is a general reduction in the body tissues. 
This is mainly due to the loss of anterior pituitary hormones, but may 
also be due in part to derangements of the general metabolism 
(Jacobsohn, 1966). The elimination in hypophysectomized rats of the 
ability to display the organ weight changes normally induced by 
oestrogens demonstrates that these effects are probably mediated through 
the pituitary. This applies to the uterine weights gains and also to 
the trophic effects on the liver, kidneys, adrenals, and ovaries, and 
the modest reductive effect on the spleen. These findings confirm that 
in the rat an intact pituitary is necessary for full oestrogen-dependent 
growth of the uterus (Sonnenschein and Soto, 1978), adrenal (Turner and 
Bagnara, 1971) and liver (Fraenkel-Conrat et al, 1941), but extend these 
observations by showing that this pituitary mediation is operative even 
at the highest dose levels of oestrogen. The possible mechanisms 
underlying these effects will be considered below.
Experiment 2 also provided evidence for several organ-specific 
effects not mediated through the pituitary (Table 4). Thus, in
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hypophy sect om iz ed animals given hexoestrol, the liver and adrenal 
weights were increased by 11% and 7%, respectively, and the kidney 
weights were decreased by 5%. The corresponding figure for the uterine 
weight was just +2%. None of these changes was significant. These 
effects may represent direct actions on the organs concerned.
Growth hormone
An increase in the secretion of pituitary growth hormone in 
hexoestrol-treated rats appeared to be one of the main causes of the 
liver weight gains, the sole cause of the modest kidney weight gains, 
and a contributory factor in the adrenal weight gains. The increases in 
the weights of the pituitary, ovaries and uterus, and the reduction in 
the weight of the spleen were not caused by growth hormone - and, 
indeed, the pituitary and uterine gains, if anything, appeared to be 
inhibited by this hormone (Table 4). These various observations 
regarding the role of growth hormone in the organ weight changes are 
consistent with the known effects of administering large doses of this 
hormone to rodents (Reid, 1954). In one study (Mirand, 1954), male mice 
which had* received 0.4mg of growth hormone showed increases in the 
following relative organ weights: liver (25%), spleen (62%), adrenals
(3%) and kidneys (14%). Conversely, growth hormone had an inhibitory 
effect on the organs of the male reproductive tract (e.g. prostate, 
seminal vesicles, testes). This was also the case in male rats in the 
same' study. The results of Experiment 3 corresponded to these findings 
in some respects but not others. Thus, growth hormone appeared to have 
inhibitory effects on the uterine weights of both control and treated 
animals, and this hormone was also implicated in the liver, kidney and 
adrenal weight gains caused by hexoestrol. The spleeen weight changes, 
however, were in the opposite direction to what might have been 
predicted and the extent of the adrenal gains (over 4C%) also do not 
appear explicable in terms of alterations in growth hormone secretion 
alone - a conclusion supported by the findings of Experiment 3. 
Experiment 2 demonstrated that the spleen weight changes only occurred 
in the presence of an intact pituitary. The reason for the changes in 
the weight of this organ is not readily apparent, though there are 
reports of similar effects occurring in rodents after treatment with 
ACTH (Reid, 1954). This hormone may also play a role in the adrenal 
changes; ACTH is well established as the primary regulator of
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adrenocortical growth and function, and secretion of this hormone may be 
increased after oestrogen administration (Trenkle, 1969). Ihe net 
changes in adrenal weight may thus be due to the combined effects of (i) 
a modest stimulatory effect not mediated through the pituitary (see 
above), (ii) growth hormone, and (iii) ACTH. Growth hormone is known to 
potentiate the effects of ACTH on adrenocortical function in adults 
(Colby et al, 1973; Kramer et al, 1977). The interpretation of the 
roles of growth hormone and ACTH in these effects is somewhat 
complicated, however, by the paradoxical finding that in the untreated 
animal growth hormone appears to exert a modest inhibitory effect on 
the adrenal weights.
The renal weights in the animals in Experiment 3 which received 
both hexoestrol and the growth hormone antiserum were below control 
values. This correlates with the finding in Experiment 2 that in the 
absence of the pituitary, hexoestrol has an inhibitory action on the 
kidneys. The nature of this latter effect is unclear and has not been 
reported previously. Ihe net gain in the kidney weights is thus the 
resultant of this unspecified inhibitory effect and of the stimulatory 
effects of growth hormone. This latter is known to have renotrophic 
effects: it produces an increase in both the size and function of the
kidneys (Jensen, 1980).
Although oestrogens induce enlargement of the liver, this organ 
is far less sensitive in this regard than the uterus. For example, a 
single dose of 0.5mg of oestradiol in mice does not alter the liver 
weight appreciably, in contrast to a marked effect on the uterus (Song 
et al, 1969). Ihe evidence presented here indicates that the oestrogen- 
induced liver enlargement in the rat is due to at least two influences: 
a mild stimulatory effect not mediated through the pituitary (see above) 
and an increase in pituitary growth hormone. Whether the action of 
growth hormone is direct or merely permissive is not clear; 
operationally, in experiments like the present ones, these alternatives 
are indistinguishable. High affinity intracellular oestrogen receptors 
have been identified recently in the rat liver and it has been shown 
that for the levels of these to be maintained an intact pituitary is 
required (Eisenfeld et al, 1980). The current findings prompt the 
suggestion that growth hormone may be the active principle involved 
here. Ihe opposite may hold true in male mice - oestradiol increases 
the growth hormone binding sites in the liver, but again only in the 
presence of the pituitary (literature cited in Muller, 1979).
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Experiment 2 demonstrated that the pituitary was also required 
for full hexoestrol-dependent uterine growth. Ihe pituitary 
contribution in question has been named "uterotrophic factor" and there 
is evidence that it is not growth hormone (Sonnenschein and Soto, 1978).
This finding is consistent with the data from Experiment 3 on animals 
treated wTith the growth hormone antiserum. Uterotrophic factor also appears 
to be distinct from prolactin and the gonadotrophins. The present 
results suggest that oestrogens when administered in high doses not only 
exert a stimulatory effect on the uterus through the uterotrophic factor 
but also an inhibitory one through growth hormone. Though this latter 
effect was non-significant in Experiment 3, the 70% uterine growth in 
the rats treated with both the antiserum and hexoestrol was appreciably 
more than the average of just over 50% in the rats given hexoestrol 
alone. In contrast to this, growth hormone in the normal female rat 
appeared to have a mild stimulatory effect on the ovaries. This may be 
a reflection of the suggested requirement for this hormone in the 
maintenance of gonadal integrity in both sexes (e.g. Pertezelan et al,
1978). The ovarian weight gains in hexoestrol-treated rats, however, 
were clearly not due to growth hormone. The gonadotrophins may have 
been involved here, though this seems an insufficient explanation as 
oestrogens in high doses usually inhibit gonadotrophin secretion (Labrie 
et al, 1979). High oestrogen levels, however, enhance prolactin 
secretion (Forrest, 1974), and this pituitary hormone is established as 
being luteotrophic in the rat (Greep, 1978). An increase in the number 
and size of the corpora lutea was, indeed, held to explain the ovarian 
weight gains in rats treated with diethylstilboestrol in an earlier 
study (Chapter 3).
Although the anterior pituitary is regarded as a target tissue 
for oestrogens, its normal physiological response to oestrogenic 
stimulation does not involve enlargement (Clark and Peck, 1979). This, 
however, is a very common finding in experimental animals exposed to 
unphysiological doses of oestrogens (Heywood and Wadsworth, 1980) and 
this effect is related to dose and duration of exposure. The pituitary 
is known to vary in size in line with the changing levels of oestrogens 
during the oestrous cycle in the female and differences in the levels of 
these hormones are also believed to be the physiological basis of the 
greater size of the female pituitary compared to that of the male 
(Russfield, 1967). The in vivo approach of the present experiments does 
not permit the effects of hexoestrol at the hypothalamus and pituitary
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to be dissociated but the present finding that growth hormone partially 
inhibits the oestrogen-induced pituitary enlargement suggests the 
possibility that other anterior pituitary hormones may also be involved 
these effects.
Clomiphene
Ihe increases in the organ weights observed when hexoestrol was 
administered alone were largely prevented in a dose-dependent manner by 
pretreatment with clomiphene. A similar, though less marked, effect was 
observed in rats treated with lower doses of diethystilboestrol and 
clomiphene in an earlier experiment (Chapter 3). Clomiphene has been 
reported previously to inhibit oestrogen-induced growth of the rat 
pituitary (Schreiber et al, 1972) and uterus (Clark and Peck, 1979), and 
it has also been shown to inhibit the anabolic effects of oestrogen on 
the mouse liver (Schwarzlose and Heim, 1970), though the precise 
mechanism of this latter effect has not been determined. As the 
organotrophic effects of hexoestrol were shown by one of the present 
studies (Experiments) to be mediated through the hypothalamic-pituitary 
axis, it seems likely that the observed effects of clomiphene were due 
to competitive antagonism at this level. This would imply that the 
antioestrogen acted centrally to prevent, for example, the oestrogen- 
dependent increases in the secretion of growth hormone and the putative 
uterotrophic factor. A single site of action would also account for the 
rather similar dose-dependent pattern of stepwise decrements in the 
weights of most of the organs measured. There is evidence that the 
oestrogen receptors in the rat pituitary shows affinity for clomiphene 
and that this compound can thus block the uptake of oestrogens (Skidmore 
et al, 1972). It is perhaps surprising that a dose-dependent antagonism 
should have been seen in Experiment 1 in view of the fact that the doses 
of the active compounds used were well in excess of those required to 
saturate the oestrogen receptor pathways. It was also a somewhat 
unexpected finding that clomiphene administered alone decreased almost 
all the organ weights. The depressant effect of high .doses of 
clomiphene has been reported for the rat pituitary, uterus, and ovaries 
(Newberne et al, 1966) and for the mouse liver (Schwarzlose and Heim,
1970), but changes in the other organ weights have not been described.
In reducing the size of the viscera, clomiphene treatment resembled in 
character though not in degree the effects of hypopbysectomy. This is
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circumstantial evidence that the antioestrogen is acting centrally. 
Antagonism of the endogenous oestrogen may be involved here or an 
unrelated mechanism.
Adrenal
Clomiphene administered alone caused a non-significant increase 
in the weight of the adrenal glands and in high doses this compound also 
markedly augmented the hexoestrol-induced adrenal enlargement. Both 
these findings were in contrast to the decremental effect of clomiphene 
on all the other organ weights, and the latter observation confirms 
similar results from a study on rats treated with diethylstilboestrol 
and clomiphene (Chapter 3). In rats treated with both clomiphene and 
hexoestrol the reductions in the other organs tended to be dependent on 
the dose of antioestrogen and proportional to the reduction in pituitary 
size. Ihe increases in the adrenals, however, were less clearly 
dependent on dose and the relationship to pituitary size was not 
straightforwardly inverse. Ihe absence of adrenal weight reductions in 
clomiphene-treated rats was the only qualitative difference between the 
effects of this antioestrogen and the effects of hypopbysectomy. These 
various observations indicate marked differences between the influences 
on adrenal size and those on the sizes of the other organs.
Ihe adrenal weight gains caused by hexoestrol were shown to be 
probably due to at least three factors, of which two were growth hormone 
and ACTH. As clomiphene prevented the liver enlargement caused by an 
oestrogen-induced increase in growth hormone secretion it might have 
been expected that the antioestrogen would reduce the adrenal 
enlargement. This was not so however. Alterations in the levels of 
ACTH seem not to be involved here as clomiphene is believed not to 
affect the secretion of this hormone (Van Maanen et al, 1961).
Clomiphene may be having a direct action on the adrenals but this would 
not fully explain the synergistic effect of clomiphene and hexoestrol. 
There remains the possibility that some additional factor is involved in 
the interactions of clomiphene and the adrenals.
Phenobarbitone
Hexoestrol proved to be more hepatotrophic than phenobarbitone 
(Experiment 1). It is known that the phenobarbitone-induced liver
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growth is due to a direct effect on the hepatic parenchyma and can occur 
in the absence of the pituitary (Schult e-Hermann, 1974). Ihe 
hexoestrol-induced liver changes on the other hand are mainly mediated 
through the hypothalamic-pituitary axis, and are thus reduced fcy 
hypopbysectomy (Experiment 2; Fraenkel-Conrat, 1941). Clomiphene did 
not modify the liver enlargement caused fcy phenobarbitone, but reduced 
that caused by hexoestrol (Experiment 1). These findings are 
consistent, firstly, with the postulation made above that the main 
action of clomiphene in this context is at the hypothalamic-pituitary 
axis, and secondly, with the presence and absence, respectively, of a 
pituitary involvement in the hepatic weight changes elicited by 
hexoestrol and phenobarbitone.
Besides causing liver enlargement, phenobarbitone caused an 
increase in the size of the kidneys and some other (non-significant) 
changes in the organ weights - more indeed than are usually reported for 
this compound (Schulte-Hermann, 1974). In addition, some of the organ 
weights (e.g. adrenals, ovaries) of the rats treated with both 
phenobarbitone and clomiphene did not correspond to those of the rats 
receiving either compound alone. The differences were not significant, 
however, and the causes of these effects are unclear.
ABSTRACT
Three experiments were performed to determine the organ weight 
changes in adult female rats treated with hexoestrol at a dose level of 
60mg/kg/day. In order to assess the endocrine contribution to 
the observed effects the following experimental procedures were used: 
hypopbysectomy, antioestrogen treatment (i.e. clomiphene citrate), and 
immunisation with a monkey antiserum to rat growth hormone. Each of the 
expriments lasted four days and there were five animals in each 
experimental group. In none of the studies were there any deaths.
The rats receiving hexoestrol in the three studies showed a 
number of significant changes in their relative organ weights compared 
to cntrols. The average values from the three studies were: liver
(+37%), spleen (-11%), adrenals (+43%), kidneys (+3%), pituitary (+23%), 
uterus (+49%), and ovaries (+13%). The heart weights were generally 
unchanged. The histological character of these changes was not 
determined.
The relative organ weights of fcypophysectomized, hexoestrol-
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treated rats differed from those of hypophysectomized controls as 
follows: liver (+11%), spleen (0%), heart (-2%), adrenals (+7%),
kidneys (-5%), uterus (+2%), and ovaries (-1%). None of these 
differences was significant. It was concluded that the organ weight 
changes provoked by hexoestrol in intact rats - including the uterine 
weight gains - were mainly mediated through the hypothalamic-pituitary 
axis,
Ihe probable causes of the observed organ weight changes can be 
summarized thus: liver increase - partly due to a modest stimulatory
effect (possibly direct) not mediated through the pituitary, and mainly 
due to the stimulatory effect of an increase in pituitary growth 
hormone; kidney increase - resultant of a modest inhibitory effect 
(possibly direct) not mediated through the pituitary, and the 
stimulatory effect of pituitary growth hormone; uterine increase - 
mainly due to pituitary stimulation ('uterotrophic factor1 - a novel 
pituitary hormone), but also partly due to a modest pituitary inhibition 
(growth hormone); ovarian increase - pituitary stimulation (unspecified
- possibly gonadotrophins or prolactin); adrenal increase - partly due 
to a modest stimulatory effect (possibly direct) not mediated through 
the pituitary, but mainly due to pituitary stimulation (in part growth 
hormone but mainly unspecified - possibly ACTH); and pituitary increase
- stimulation (possibly direct) and inhibition (pituitary growth hormone).
Clomiphene citrate pretreatment prevented in a dose-dependent 
manner most of the organ weight changes induced by hexoestrol when 
administered alone. Ihe exception was the adrenal weight which was 
enhanced by antioestrogen pretreatment. Rats treated with 
phenobarbitone showed liver enlargement but this was not affected by 
prior administration of claniphene citrate.
Clomiphene citrate administered alone changed the weights of all 
the organs measured. The results were as follows: liver (-18%), spleen
(-17%), heart (-16%), kidneys (-11%), adrenals (+7%), pituitary (-13%), 
uterus (-25%), and ovaries (-4%). Antagonism of the endogenous 
oestrogen may be involved here or an unrelated mechanism.
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CHAPTER 7
ORGAN WEIGHT CHANGES 
IN FEMALE FERRETS 
TREATED WITH HEXOESTROL 
AND CLOMIEHENE CITRATE
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INTRODOCTICN
In the rat, hexoestrol caused increases in the absolute and 
relative weights of the liver, adrenals, kidneys, pituitary, uterus and 
ovaries, and a decrease in the weight of the spleen (see Chapter 6). 
These effects were mainly mediated through the hypothalamic-pituitary 
axis. In the ferret, a rather similar though less consistent pattern of 
changes occurred after oestrogen treatment (Chapters 1 and 2) but the 
role of the hypothalamic-pituitary axis was less clear; in contrast to 
the effect in the rat, the organ weight changes in the anoestrous ferret 
(Chapter 2) were not obviously reduced by pretreatment with clomiphene 
citrate - an antioestrogen known to act at the level of the hypothalamus 
and pituitary (Schulz et al, 1971). The purpose of the present study, 
therefore, was to clarify the response of the oestrogen-treated ferret 
to pretreatment with the antioestrogen and hence to determine if a 
genuine species difference exists between the ferret and the rat in this 
regard.
The experimental design used here was such as to permit 
comparisons between the present study and those previously reported in 
the rat (Chapter 6). Animals in oestrus were used because the ferret 
appears to show more marked organ weight changes in response to 
oestrogens when in this condition (Chapter 1) than when in anoestrus 
(Chapter 2). Ihe opportunity was also taken to make haematological and 
histopathological assessments of toxicity.
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EXPERIMENTAL DESIGN AND METHODS
Eight adult, female ferrets (albino and polecat, 1 - 2  years,
710 - 1360g, in early oestrus) were randomly assigned to three treatment 
groups as follows.
Group Animal Treatment Dose
(mg/kg/day)
A 22, 23* Dose vehicle twice
B 24, 26, 28* Dose vehicle
+
Hexoestrol 60
25, 27, 29 Clcmiphene citrate 60
+
Hexoestrol 60
*lhese animals were not in oestrus.
The test compounds were dissolved in isopropyl myristate. 
Clomiphene citrate was administered one hour before the oestrogen. At 
this time the other animals received the dosing vehicle only.
The animals were housed singly and maintained under standard 
conditions. Food consumption was monitored daily and the body weights 
were determined at the start and end of the dosing period.
After 4 days treatment the animals were anaesthetized with 
intraperitoneal pentobarbitone sodium and exsanguinated from the vena 
cava. After macroscopic examination, the liver, spleen, heart, kidneys, 
adrenals, ovaries, uterus, and pituitary were removed and weighed. 
Samples of these tissues were preserved in 10% buffered formal-saline, 
and subsequently subjected to histological analysis. Femoral marrow 
smears were prepared at autopsy.
The blood samples collected at post-mortem were used for the 
following haematological investigations: total and differential white
cell counts, packed cell volume, haemoglobin, and Thrombotest time (lGpl 
whole blood added to 0.5ml reconstituted reagent).
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RESULTS
General observations
There were no deaths during the study. The condition of all of 
the treated ferrets did, however, show some deterioration. They all 
showed a general malaise, and a decrease in physical activity was 
particularly noticeable in two animals (Nos. 25 and 26). There was a 
moderate decline in food consumption (all) and four animals (Nos. 24,
25, 26, and 29) showed a reduction in body weight (Table 2). Some 
mammary stimulation (nipple enlargement) was evident in one ferret (No. 
24). The two controls remained in general good health throughout the 
experiment though both lost weight.
Five of the six treated ferrets were in oestrus at the start of 
the study. The vulval swelling in these animals was enhanced by 
oestrogen treatment. The sixth treated ferret (No. 28) was not in 
oestrus at the start of dosing but by Day 4 this animal displayed 
moderate vulval oedema. The controls showed no qualitative change in 
reproductive status.
Haematology
The haematological findings are presented in Table 1. The data 
from the controls were within the expected normal range.
All of the treated ferrets showed a neutrophil leucocytosis.
The severity of this varied and there were no obvious group trends. The 
red cell data were considered to be within normal limits, and blood film 
analysis revealed no morphological abnormalities among the red cells.
The Thrombotest times of all the treated ferrets were longer 
than controls, in one case (No. 25) markedly so.
Organ weight analysis
The control data compared favourably with that from the two 
earlier ferret studies (Chapters 1 and 2) - though the data from one 
(No. 23) tended to be at the lower end of the normal range. There were 
numerous differences between the relative organ weights of the treated 
animals and those of controls (Table 2, Fig. la - c). The extent of 
many of these differences suggest that they were not artefacts of
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Table 1. Pre-terminal haematological data of female ferrets treated
with hexoestrol and clomiphene citrate, and of controls
Treatment
group
Ferret
No.
Hb
(g/di)
PCV
(%)
WBC
(lCp/mm^ )
ty/L
ratio
Thrcmbotest
time
(sec)
A 22 15.5 51 10.9 0.7 50
Controls 23 17.3 50 10.4 0.6 54
Mean 16.4 51 10.7 0.7 52
24 16.8 51 16.7 4.2 60
B
HEX 26 17.2 49 32.8 6.2 57
28 21.4 62 21.1 1.9 59
Mean 18.5 54 23.5 4.1 59
±SD +2.5 ±7 ±8.3 ±2.1 ±L
C 25 17.5 54 34.1 3.2 81
CC
HEX 27 15.5 49 43.8 5.1 56
29 14.3 44 13.2 4.8 62
Mean 15.8 49 30.4 4.4 66
±SD ±L.6 +5 +15.6 ±1.0 ±L3
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and hexoestrol. Points represent, and numbers identify, 
individual animals. Bars represent group means.
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variations in body weight among the treated animals or of body weight 
losses during the experiment. All of the organs measured were affected 
though not in every animal. No group trends emerged - clomiphene 
citrate had no obvious effects on the organ weight changes. The 
relative liver, heart, adrenal, kidney, pituitary and uterine weights 
were either unchanged or increased compared to controls. The spleen 
weights were more variable, some being above the control range (Nos. 24, 
26, and 27), some below (Nos. 25 and 28). One (No. 29) was unchanged. 
The ovarian weights were generally decreased. The exception was the 
ovarian weight of No. 29 which was above control values. In some cases 
(pituitary, uterus) the maximum organ weights among the treated animals 
were two or three times those of controls. Four animals (Nos. 24, 27,
28 and 29) tended to show changes in all of the organ weights while two 
(Nos. 25 and 26) did so only in a few cases. These two animals were the 
heaviest of the treated animals.
Histopatholoaical changes
There were no obvious group trends in the histopathological 
findings.
The livers of three of the treated ferrets (Nos. 24, 25, and 28) 
showed moderate fatty change. This was mainly periportal in 
distribution, the fat occurring as both coarse and fine droplets. In 
the other treated animals occasional hepatocytes showed fat vacuoles but 
the effect was not marked. There were no other obvious liver 
abnormalities.
The right adrenal of Ferret No. 24 showed multiple colloid- 
filled spaces obliterating the medulla and part of the cortex (Fig. 2). 
appearance of the left adrenal was normal. The abnormalities in the 
right adrenal accounted for the high adrenal weight in this 
animal. Given the short duration of the study and the absence of 
reports of such adrenal abnormalities in oestrogen-treated animals, this 
lesion may not be associated with drug treatment. Similar changes to 
this have been noted as background pathology in a population of ageing 
rats (Burek, 1978).
The adrenals of Ferret No. 25 were haemorrhagic.
The anterior pituitaries of two animals (Nos. 28 and 29) showed 
an increase in acidophils. The pituitaries of the other ferrets were 
comparable in appearance to those of controls.
The
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Fig. 2. Above: multiple colloid-filled spaces in the right
adrenal of a ferret (No. 24) treated with hexoestrol.
Below: Left adrenal of the same animal. H & E, x 25
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The uterine changes were indicative of modest stimulation and 
consisted of hyperplastic and hypertrophic changes in the endometrium 
and some myometrial hypertrophy. In one case (No. 29), there was cystic 
glandular dilatation. The ovarian changes were mainly inhibitory.
There was a decrease in viable follicles (all) and stromal thinning 
(Nos. 26 and 27). Two ferrets showed follicular cysts (Nos. 27 and 29). 
The high ovarian weight noted in one animal (No. 29) was due to 
smooth muscle hyperplasia in the medullary stroma. As such lesions have 
been reported in the ovaries of untreated ferrets (Cotchin, 1980), the 
present findings may be unrelated to oestrogen administration. The 
provenance of the smooth muscle is uncertain but may be in part the 
adventitial muscle of blood vessels and in part the smooth muscle of the 
ovarian ligament.
The femoral marrow of two of the treated ferrets (Nos. 24 and 
28) were normal. The bone marrow of the other animals showed myeloid 
hyperplasia. The other cell lines were unchanged.
At autopsy the lungs of several ferrets (Nos. 24, 25, and. 27) 
showed the surface plaques which were described in the earlier ferret 
studies (Chapters 1 and 2) and which have been reported elsewhere 
(Hammond and Chesterman, 1976).
The other tissues examined were considered to be normal in 
appearance.
DISCUSSION
Toxicity
In spite of the very high doses of hexoestrol administered here 
there were no deaths during this study. In the dog - another animal 
which like the ferrets shows a haemopoietic sensitivity to oestrogens - 
the survival time though to some extent dose-dependent, cannot be 
shortened below about 10 days (Castrodale et al, 1941).
Group trends
There were no consistent differences between the experimental 
groups either in terms of haematology or histopathology. This indicates 
that clomiphene, even when administered in high doses, does not alter 
the toxicological consequences of administering oestrogens to the female
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ferret. This observation is in agreement with the results of an earlier 
study in the ferret (Chapter 2) in which clomiphene (2mg/kg/day) and 
diethylstilboestrol (6mg/kg/day) were administered together, and in 
contrast to the findings in the rat. In this latter species, for 
example, the antioestrogen appears to exacerbate the adverse effects of 
oestrogens on liver-dependent blood clotting (Chapter 4).
Haematology
A neutrophil leucocytosis was observed in all of the treated 
animals. This was associated in some cases with an obvious degree of 
myeloid hyperplasia in the bone marrow. Similar changes to these have 
been reported in dogs treated with oestrogens for short periods (Hall, 
1972) and a neutrophil leucocytosis was also a finding of the earlier 
studies in the ferret (Chapters 1 and 2).
Liver
The liver abnormalities reported here were confined to moderate 
fatty change. This is in contrast to the longer ferret studies 
(Chapters 1 and 2) in which intrahepatic biliary lesions were also 
observed. This suggests that the parenchymal changes precede those in 
the biliary system.
In most of the treated animals the liver weight was above 
control values. Ihere was, however, no correlation between the liver 
weight and the extent of the fatty change. The results of the 
Thrombotest determinations probably indicate that there was some 
disturbance of liver function in all of the treated animals.
Ihrombotest is a one-stage clotting assay sensitive to alterations in 
three of the vitamin K-dependent clotting factor (II, VII, and X). It 
can therefore be regarded as a test of liver function (Owren, 1959). It 
may be of note that the clotting time was longest in the animal (No. 25) 
which showed no liver enlargement, and shortest in the one (No. 27) 
which showed the greatest enlargement. A similar, though more marked, 
relationship between liver size and Thrombotest time was also 
described in rats treated with hexoestrol and clomiphene citrate 
(Chapter 4).
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Reproductive organs
Hexoestrol elicited signs of uterine stimulation and in some 
cases uterine weight gains. The absence of gross uterine enlargement of 
the kind seen in the earlier studies (Chapters 1 and 2) is consistent 
with the view that these effects occur in the ferret only after 
sustained oestrogen treatment. Uterine weight gains are also not easily 
provoked in the dog by oestrogens (Dow, 1959). Both the ferret and dog, 
therefore, are in contrast to the rat in this respect.
The treated animals showed varying degrees of ovarian atrophy. 
This is also the usual finding in dogs treated with large doses of 
oestrogens (Heywood and Wadsworth, 1980).
Organ weights
The present findings are in agreement with those of the previous 
studies in the ferret (Chapters 1 and 2); the oestrogen increased the 
size of most of the principal organs. Furthermore, as in the second 
study (Chapter 2), pretreatment with clomiphene citrate was without 
effect on the observed changes. In the rat in contrast, the 
antioestrogen generally reduced the organotrophic effects of hexoestrol 
(Chapter 6).
As in the first experiment (Chapter 1), the smallest of the 
treated ferrets showed the most pronounced organ weight changes. Some 
of* the other animals in fact, showed only modest changes. This degree 
of individual variation was also seen in the second ferret study 
(Chapter 2), and is in contrast to the more predictable response of the 
female rat (Chapter 6). In both species, however, five organs tended to 
be increased in weight by short-term oestrogen administration - the 
liver, adrenals, kidneys, pituitary and uterus. The changes in the 
other organs diverged. Thus, the ovaries, heart and spleen weights in 
the rat were, respectively, increased, unchanged and decreased; the 
corresponding weights in the ferret were, respectively, decreased, 
increased, and variable. In the ferret the maximum organ weight changes 
were generally greater than those in the rat. In the latter, the organ 
weights, where these were increased, were up to 5C% above those of 
controls. In the oestrus ferret the corresponding values were between 
50 and 175%. This difference is even more accentuated when the results 
of the longer studies are compared (i.e. ferret - Chapter 1; rat -
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Chapter 3). The changes, when they occur, are thus more marked in the 
ferret than in the rat, and are progressive over a longer period. These 
observations are particularly true of the uterine weight gains.
In the rat the organotrophic effects of hexoestrol are mainly 
mediated through the hypothalamic-pituitary axis. This may also be the 
case in the ferret. This might explain the generality of the 
organotrophic effects of hexoestrol and would be consistent with the 
qualitative similarity of many of the organ weight changes in the ferret 
to those which occurred in the rat. It would also imply that the 
qualitative and quantitative differences are due to species variations 
in endocrinology. In support of a pituitary involvement in the organ 
weight changes was the finding that in those animals (i.e. the heaviest 
ones) which showed no pituitary weight gains the organ weight changes 
were few. Furthermore, there was a tendency among the other animals, 
notably in Group C, for the extent of the pituitary enlargement to be 
related to the extent of the changes in some of the other organs e.g. 
uterus, ovaries, and heart. Observations such as these are difficult to 
explain in terms of ad hoc organ-specific interpretations. That 
clomiphene is effective in preventing the oestrogen-induced organ weight 
changes in the rat but not in the ferret indicates that there are 
differences in the underlying mechanism of these changes in the two 
species. The species differences in the response to clomiphene between 
the rat and ferret may also hold between the rat and the dog. In female 
rats treated for 53 weeks with clomiphene in doses up to 40mg/kg/day the 
pituitary weights and body weights were significantly decreased 
(Newberne et al, 1966), This was not the case in dogs receiving similar 
treatment.
There were two main morphological differences in the response of 
the ferret and rat to short-term hexoestrol administration: the ferret
liver showed somewhat more evidence of damage (fatty change), and the 
anterior pituitary enlargement in the ferret was due, not to 
proliferation of the chromophobes as in the rat, but to proliferation of 
the acidophils. This latter difference in the response to oestrogens is 
also known to exist between the rat and the dog (Jabara, 1962; Heywood 
and Wadsworth, 1980).
The endocrine differences between the ferret and rat are 
emphasized by the control data from the organ weight analysis. While 
most of the organ weights when expressed in relative terms we re 
comparable in the two species the data for the endocrine organs were
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not. The relative adrenal weight of the ferret was between a half and a 
third that of the rat, the ovarian weight was less than a third, and the 
pituitary weight less than a tenth. Specifically, for the two control 
ferrets used here, both weighing over 1.2kg, the absolute pituitary 
weights were about 5mg. The corresponding value for rats weighing about 
200g was lOmg (Chapter 6). Both these figures are comparable to 
literature values (ferret - Thornton et al, 1979; rat - Verzar, 1966), 
and the ferret data also resembles that for the dog (Oboussier, 1979).
If there is some relation between the size of an organ and its relative 
functional significance (Oboussier, 1979), then these data imply 
endocrine differences which may have a bearing on the organ weight 
changes seen in the two species after exposure to oestrogens.
ABSTRACT
Assessments have been made of the organ weight changes and other 
effects associated with the short-term administration of hexoestrol and 
clomiphene citrate to the female ferret. Three animals were treated for 
a 4-day period with hexoestrol at a dose of 60mg/kg/day. Three others 
received clomiphene citrate at the same dose prior to hexoestrol. Two 
animals acted as controls. The animals were in early oestrus with two 
exceptions (one control, one treated with hexoestrol).
Hexoestrol induced a number of alterations in the organ weights 
of the treated animals. There was considerable individual variation in 
the extent of the observed changes. Pretreatment with clomiphene 
citrate was without apparent effect.
The relative weights of the liver, heart, adrenals, kidneys, 
pituitary and uterus were increased or, in some cases, unchanged. The 
ovarian weights were generally decreased. The spleen weights were in 
some cases increased, in others, decreased or unchanged. The heaviest 
animals tended to show the least marked changes in organ weights.
It is conjectured that in the ferret, as in the rat (Chapter 6), 
the oestrogen-induced organ weight changes are mainly mediated through 
the hypothalamic-pituitary axis. There must be differences in the 
underlying mechanism, however, because while clomiphene citrate reduces 
the oestrogen-induced changes in one (the rat), this compound is without 
effect in the other (the ferret).
There was a neutrophil leucocytosis in all of the treated 
animals and the Thrombotest clotting times were prolonged.
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The livers of several ferrets showed periportal fatty change. 
There was also evidence of uterine stimulation and ovarian inhibition.
Ihe anterior pituitaries of two animals showed acidophil 
proliferation.
184
CONCLUSIONS
MECHANISMS OF TCKICTIY AND SPECIES DIFFERENCES
Ihe synthetic oestrogens are unusual in a toxicological sense in 
that they are analogues of endogenous hormones. The toxic effects 
associated with their administration could be due to exaggerations of 
pharmacological activity and hence disturbances in endocrine control 
systems or to other mechanisms of toxicity (e.g. metabolic activation) 
less related to the hormonal milieu. Species variations in the pattern 
of toxicity could in turn originate from differences in endocrinology 
or, for example, from differences in pharmacokinetics.
The effects of administering oestrogens in high doses to female 
ferrets and rats are summarised in Table 1. These effects and their 
ostensible causes together with the species differences in toxicity will 
be considered first prior to a discussion of the pharmacokinetic and 
endocrine contributions to the observed toxicity.
Body weight
A reduction in growth rate is the usual finding in rats treated 
with oestrogens. Ihe growth-inhibiting effects of oestrogens are dose- 
related (Heywood and Wadsworth, 1980), and high doses can lead to a net 
loss in body weight. The severity of this latter effect increases with 
the age of te experimental animals (Chapter 4, Experiment 5). A 
decrease in food intake is involved (Gibson et al, 1967; Chapter 3), 
but there may also be an adjustment of the regulated body weight (Wade, 
1975). This is suggested by the observation that while the appetite may 
show a partial or complete recovery, the body weight reduction is 
persistent (Roy and Wade, 1976; Chapter 3). Ihe effects on growth and 
eating behaviour can be antagonized by progesterone (Ross and Zucker, 
1974) and by the antioestrogen clomiphene (Chapter 3) - but not, 
apparently, by other antioestrogens, for example, ethamoxytriphetol 
(MER-25), which like clomiphene is a triphenyethylene derivative (Roy 
and Wade, 1976). Ihe action of clomiphene in this regard has not been 
reported before.
In decreasing appetite, the oestrogen appears to be acting 
centrally, probably at the hypothalamus (Roy and Wade, 1976); implants 
of oestradiol near the ventromedial nucleus have been shown to decrease 
food intake (Beatty et al, 1974). This hypothesis, however, has been 
disputed (Thompson and Cox, 1979). Early investigators (e.g. Reichlin,
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Table 1. Effects of administering oestrogens in high doses to female 
ferrets and female rats
Parameter Ferret Rat
Body weight - -
Organ weights 
Liver 
Spleen 
Heart 
Kidneys 
Adrenals 
Uterus 
Ovary 
Pituitary
+
+
+
+
+
+
+
o
+
+
+
+
+
Histopathology
Liver Periportal fatty change; 
intrahepatic biliary 
lesions: early 
centrilobular necrosis
Scattered individual cells 
in the midzonal region 
showing fatty change
Kidneys Cloudy swelling of
tubular cells;
fatty change (2 animals)
No abnormalities
Adrenals Cortical enlargement Cortical enlargement
Uterus Stimulation;
marked fluid accumulaton
Stimulation;
modest fluid accumulation
Ovary Inhibition Inhibition
Pituitary Acidophil proliferation 
in the anterior lobe
Chromophobe proliferation 
in the anterior lobe
Bone
marrow
Myeloid hyperplasia then 
hypoplasia of all elements
Erythroid hypoplasia
Haematology and serum chemistry
Red blood cells
White blood cells + then -
Platelets -
Thrombotest time 0 then +
Fibrinogen + then -
Total protein + or -
Bilirubin '+
Serum enzymes +
Con A-binding 
glycoprotein +
c^-Macro-
foetoprotein nd
0
nd
+ then 0 
nd
+
+
+
+
+ = increase 0 = no change Con A = Concanavalin A
- = decrease nd = no data
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1966) postulated that the effects of oestrogens on appetite and body 
weight were due to a decrease in the secretion of pituitary growth 
hormone, but the evidence suggests that, at least in the short term, 
growth hormone secretion is actually increased (Chapter 6). Rats 
treated with hexoestrol at a dose of 6Qmg/kg/day or diethylstilboestrol 
at a dose of 6mg/kg/day (Chapter 3) showed almost identical losses in 
body weight but quite different degrees of liver enlargement. This 
latter effect is mainly due to an increase in growth hormone secretion 
(see below), Ihus while the alterations in liver weight and body weight 
are probably both mediated through the hypothalamus these effects appear 
to be distinct - the one related to growth hormone secretion the other 
not.
Food intake was decreased in ferrets treated with oestrogens but 
the effect on body weight was less consistent (Chapters 1 and 2). A net 
reduction in weight was observed in most of the treated ferrets but in 
some, particularly the heavier animals, there were net gains at some 
stage during treatment. Weight gains after oestrogen administration 
have been reported in hamsters (Manda and Matsumoto, 1973), gerbils (Roy 
et al, 1977), ruminants (Umberger, 1975), and guinea pigs (Preston et 
al, 1956). Differences in the hypothalamic-pituitary axis probably 
account for the interspecies variation in the effects of oestrogens on 
growth and body weight (Trenkle, 1969; Velle, 1978).
Organ weights
Oestrogens are basically organotrophic in both the rat (Chapter 
6) and the ferret (Chapter 7): most of the organs examined - whether
classical target organs such as the uterus and pituitary, or non-target 
organs such as the liver and kidney were increased in size by oestrogen 
treatment. These organ weight changes were not artefacts of alterations 
in body weight, but rather, where the cause could be determined, were 
the result of hyperplastic or hypertrophic processes. That the 
synthetic oestrogens cause such a diversity of organ weight changes 
distinguishes them from other foreign compounds, most of which - if 
effective in this regard - alter the weight of only one or two organs 
and usually only that of the liver (Schulte-Hermann, 1974).
In the rat, the oestrogen-induced organ weight changes were for 
the most part mediated through the hypothalamic-pituitary axis (Chapter
6). This was true of the trophic effects on the liver, kidneys,
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adrenals, uterus and ovaries, but also for the modest reductive effect 
on the spleen. In addition, however, there were several effects not 
mediated through the pituitary. These included modest incremental 
effects on the liver and adrenal weights and a decremental effect on the 
kidney weight. These effects may have been the result of direct actions 
on the organs concerned.
The involvement of the hypothalamic-pituitary system in the 
organ weight changes induced by oestrogens probably accounts for the 
dose-dependent antagonism of these effects by the antioestrogen 
clomiphene. Kato et al (1968) showed that in the rat this compound can 
depress the uptake of oestradiol by the anterior pituitary and anterior 
hypothalamus. The organ weight changes are probably due mainly to the 
action of oestrogens at the hypothalamus, though direct effects on the 
pituitary may also be involved (El Etreby et al, 1979; Gorski, 1980).
An increase in the secretion of pituitary growth hormone was a 
contributory factor in the liver, kidney and adrenal weight gains 
(Chapter 6, Experiment 3). The cause or causes of the other organ 
weight changes were not determined but probably involved the other 
trophic hormones of the anterior pituitary. A pituitary involvement in 
the oestrogen-stimulated growth of the liver (Fraenckel-Oonrat et al,
1941) and adrenal (Snair, 1963) is perhaps less surprising than the
*
recent demonstration by Sonnenschein and Soto (1978, 1980) that the 
pituitary is also required for full uterine growth. This was confirmed 
in the present work (Chapter 6, Experiment 2): hexoestrol given at a
dose of 6Qmg/kg/day for 4 days produced only a 2% increase in uterine 
growth in hypophysectomized rats compared to 49% in intact animals. The 
effect of hypophysectomy in the castrated rat is less severe, and leads 
to a reduction of only 20-4C% in oestrogen-induced uterine growth 
(Sonnenschein and Soto, 1978). The pituitary contribution in question 
is not prolactin, follicle stimulating hormone, luteinizing hormone, or 
growth hormone. This last conclusion is also supported by the present 
findings (Chapter 6, Experiment 3). On the basis of the failure to 
replicate in vitro the proliferative effects of oestrogens on uterine 
cells in vivo, and on the basis of their experiments, Sonnenschein and 
Soto (1978) have proposed the existence of a novel pituitary hormone 
which they have named "uterotrophic factor". This proposal warrants 
further investigation.
It was of interest that growth hormone appeared to partially 
inhibit the uterine growth elicited by high doses of oestrogens
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(Chapter 6, Experiment 3), and that, further, a similar effect was 
observed on the pituitary weight gain. These results indicate that, 
firstly, growth hormone can have both inhibitory and stimulatory effects 
on weight according to the organ examined, and that, secondly, and more 
generally, the pituitary influences on a particular organ can be 
multiple.
The interrelations of oestrogen, growth hormone and the liver, 
and the existence of the novel hormone uterotrophic factor may be of 
interest in another context, namely, drug metabolism. It is known that 
in the rat there are sex differences in the hepatic metabolism of drugs 
and steroids. These sex differences have been attributed to the actions 
of androgens and oestrogens but an intact pituitary is also required 
(Kramer et al, 1979). Based on the failure to identify the anterior 
pituitary hormone responsible for these effects the existence has been 
proposed of an additional pituitary hormone responsible for the 
feminizing effects of oestradiol on hepatic metabolism (Gustafsson et 
al, 1975, 1977? Skett and Gustafsson, 1979). This hormone has been 
named "femino tropin". Other work, however, supports the candidacy of 
growth hormone as the pituitary hormone responsible for these effects 
(Rumbaugh and Colby, 1980). While the present findings do not bear 
directly on these issues they do support the role of growth hormone as 
the mediator in at least one aspect of the interaction of oestrogens and 
the liver (i.e. organ size), but conversely they also support the 
existence of a novel female pituitary hormone distinct from growth 
hormone. The exact mechanism by which oestrogen influences hepatic 
metabolism remains uncertain, but the possibility is suggested that 
uterotrophic factor and femino tropin are the same hormone, and that, 
therefore, the effects of uterotrophic factor may not be confined to the 
reproductive tract.
In many respects the organ weight changes provoked in the female 
ferret by oestrogens (Chapter 7) resembled those seen in the female rat 
(Chapter 6). This observation suggests that in the ferret as in the rat 
the hypothalamic-pituitary axis is implicated in these effects, and that 
therefore, endocrinological differences at this level might account for 
the qualitative and quantitative differences in the organ weight changes 
seen in the two species.
In terms of uterine weight gains, the anoestrous ferret (Chapter 
2) proved to be less susceptible to the uterotrophic activity of 
oestrogen than the oestrous animal (Chapter 1), but even in the latter
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(Chapter 7) oestrogens were less predictably uterotrophic than in the 
rat (Chapter 6). It was also the case that clomiphene which is 
antioestrogenic in the rat (Chapter 3) did not display this activity in 
the ferret (Chapters 2 and 7). Oestrogens have also been reported to 
have relatively low uterotrophic activity in the hamster (Giannina,
1971) and possibly the dog (Dow, 1959), and clomiphene-type 
antioestrogens are also ineffective in these species (hamster - 
Giannina, 1971; dog - Newberne et al, 1966). On current knowledge, 
these various observations are difficult to integrate into a model of 
oestrogen action based on receptor kinetics in the uterus (e.g. Gorski, 
1980). The seasonal variation in the response of the ferret to 
oestrogens is probably a reflection of seasonal differences in pituitary 
activation relating to photoperiodic factors (Herbert et al, 1975) and 
the finding that oestrogens are unpredictably uterotrophic in the 
oestrous animal may bear, in part, on the observation that progesterone 
is an important additional factor in uterine growth in this animal and 
in the dog and hamster (Surani and Burling, 1979; Martin, 1980). The 
failure of clomiphene to display antioestrogenic activity in these 
species is more problematical but may relate to the recently postulated 
pituitary contribution to uterine growth, 'uterotrophic factor' 
(Sonnenschein and Soto, 1978) . . The antioestrogenic activity of 
clomiphene in the rat appears to include blockade at the hypothalamic- 
pituitary axis (Chapter 6). If oestrogen-induced uterine growth in the 
ferret, hamster, and dog, like that in the rat is mediated in part 
through the pituitary, then the interspecies variations in the response 
to clomiphene may denote differences in the control of the pituitary 
contribution to uterine growth. The need for lower doses of oestrogens 
in the rat to elicit uterine growth and the absence of seasonal effects 
suggests that these hormones play a more direct role in uterine 
proliferation in this species than in the ferret. The oestrogen-induced 
uterine growth process, however, once instigated in the ferret 
(Chapter 7) is more marked than in the rat (Chapter 6) and progressive 
over a longer period (Chapter 1). These observations, in fact, also 
apply to the other organ weight changes (Table 1). Granted the 
assumption that these effects are also mediated through hypothalamic- 
pituitary axis, then this might indicate that while oestrogens induce 
pituitary activation less predictably in the ferret than in the rat, the 
effects when this occurs are more emphatic. The responsiveness of the 
ferret pituitary appears to be dependent upon seasonal factors and body
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weight: oestrous animals (Chapter 1) were more susceptible to organ
weight changes than anoestrous animals (Chapter 2), and among oestrous 
animals, lighter animals were more susceptible than the heavier ones 
(Chapters 1 and 7). Pituitary enlargement itself was less predictably 
evoked in the ferret (Chapter 7) than in the rat (Chapter 6). In this, 
the ferret may resemble the dog (Heywood and Wadsworth, 1980), and this 
latter species is also less prone to pituitary tumours than the rat 
(El Etreby et al, 1979).
The endocrine effects underlying the organ weight changes in the 
ferret may resemble those in the rat, but if so, the observation that 
clomiphene is antiorganotrophic in the rat (Chapters 3 and 6) but not in 
the ferret (Chapters 2 and 7), indicates differences in the mechanism of 
oestrogen action at the hypothalamic-pituitary axis in the two species. 
In the rat the liver enlargement was mainly due to pituitary growth 
hormone. The liver changes were not consistently provoked in the ferret 
(Chapter 7). This latter species may resemble the dog in that 
oestrogens do not readily induce increases in growth hormone (El Etreby 
et al, 1979).
On the assumption that there is a relationship between the size 
of a tissue and the intensity of its function (Oboussier, 1979), the 
endocrine differences between the ferret and rat were emphasised by the 
finding that among the control animals the pituitary, adrenal, and 
ovaries of the ferret were markedly smaller in relative terms than the 
corresponding organs in the rat. Hie pituitary of the ferret (Chapter
7) proved in fact to be one tenth the size of that of the rat (Chapter 
6). This observation runs counter to the assertion that there is a 
standard relationship between pituitary and body size among mammalian 
species (Oboussier, 1979). In the rat, however, and less clearly in the 
ferret, there appeared to be some relationship between the extent of the 
pituitary weight changes after oestrogen and antioestrogen treatment and 
the size of the other organs. This was true even in rats in which the 
pituitary weight was reduced by antioestrogen treatment to below control 
values (Chapter 6, Experiment 1). Whether this is merely a reflection 
of the participation of the pituitary in the general organotrophic 
effects of oestrogens or a more fundamental relationship between the 
size of the pituitary and the sizes of the other organs is conjectural.
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H i stopatholoqy
The ferret appears to be as prone to liver damage caused by 
oestrogens as the cat (Grumbrecht and Loeserf 1940; Dow, 1958), and 
both these species appear to be more susceptible than either the dog 
(Heywood and Wadsworth, 1980) or the rat (Chapter 3). The periportal 
fatty change elicited in the ferret liver precedes the other hepatic 
lesions (intrahepatic biliary damage and early centrilobular necrosis) 
and also the modest renal disorders (Chapters 1, 2 and 7). The liver 
damage tended to be associated with a progressive and irreversible 
pathological process. In the rat, on the other hand, the functional 
impairment of the liver was self-limiting (see below) and the 
histological evidence of damage less marked (Chapter 5). The main 
finding consisted of individual cells mainly in the midzonal region 
showing fatty change. This phenomenon thus differed from the fatty 
change seen in the ferret liver in both extent and
distribution, but it also differed in intercellular appearance: the fat
occurred mainly as large vacuoles in the ferret but tended to be present 
as aggregates of discrete small- and medium-sized droplets in the rat. 
Also, unlike the ferret, the rat showed no identifiable renal lesions 
(Chapter 3).
The uterine changes in the two species were of two types: the
Type I changes consisted of stimulatory and proliferative effects, and 
these were superseded in some animals - notably the susceptible ferrets 
which survived longest (Chapters 1 and 2) and the rats which received 
hexoestrol in high doses (Chapters 3) - by the Type II changes which 
included luminal distension due to fluid accumulation and loss of 
mucosal folding. The Type I changes in the ferret represented an early 
phase of modest stimulation in which there was modest luminal epithelial 
hypertrophy, stromal cell hypertrophy, glandular dilatation, and 
myometrial hypertrophy. These effects were associated with little 
change in uterine weight. Moderate luminal epithelial hyperplasia was a 
feature of the Type II stage as was oedema of the endometrial stroma and 
large gains in uterine weight. In the rat, the presence of Type I or 
Type II changes was more dependent on dose of oestrogen than duration of 
treatment and both types of changes were associated with uterine weight 
gains (Chapter 3). Hypertrophy and hyperplasia of the luminal 
epithelium was seen in both types of response in the rat and these 
effects and epithelial abnormalities were more marked than in the
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ferret. In both animals, however, the Type II response was 
characterized by excessive glandular secretion. Ihe extent of this, 
effect was greater in the ferrets than in the rats but cystic 
abnormalities were noted in both species. Uterine changes similar to 
these have been reported in the dog (Jabara, 1962) and in other 
laboratory species (Heywood and Wadsworth, 1980), but the extent of the 
uterine weight gains and fluid accumulation seen amongst the ferrets of 
the present work surpassed the usual findings reported in studies on 
oestrogens.
The suppression of follicular development in the ovaries of the 
ferret and the rat is the usual finding after high-dose oestrogen 
treatment (Heywood and Wadsworth, 1980). The presence of corpora lutea
in the ovaries of the control and treated rats and the absence of these
in the ferrets, were consistent with the reproductive differences 
between these animals; the rat is a polycestrous animal and a 
spontaneous ovulator, the ferret is monoestrous and an induced ovulator. 
In this latter species, therefore, ovulation - and hence formation of 
corpora lutea - follows coitus. Follicular formation, and resorption, 
however, are virtually continuous processes (Young, 1957).
Species differences in endocrinology presumably account for the 
observation that the pituitary enlargement elicited in the ferret 
(Chapter 7) was due not to chromophobe proliferation in the glandular 
lobe as was the case with the rat (Chapter 3), but acidophil
proliferation as is the case with the dog (Heywood and Wadsworth, 1980).
Haematology and serum chemistry
A moderate normocytic normochromic anaemia and an associated 
diminution in erythropoietic activity in the bone marrow are common 
observations in oestrogen-treated rats (e.g. Piliero et al, 1968). The 
leucocytes are either unchanged (Chapter 3) or are decreased slightly 
(Teague, 1942). The changes in the peripheral blood of the ferret 
(Chapters 1, 2 and 7) and the dog (Hall, 1972), however, are quite 
different; a neutrophil leucocytosis gives way to leucopenia, 
thrombocytopenia, and anaemia, and there are correlated changes in the 
bone marrow consisting of myeloid hyperplasia followed by hypoplasia 
affecting all cell lines. Such effects are not seen in another species 
of carnivore, the cat (Dow, 1958). Ihe bleeding disorders in the ferret 
and dog are associated with thrombocytopenia, but in the former animal
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there are also disturbances of liver-dependent blood coagulation 
(Chapters 1 and 7).
Oestrogens probably act both directly and indirectly to inhibit 
erythropoiesis in the rat. These compounds depress the stem cell
response to erythropoietin just as androgens stimulate it (Jepson and 
Lowenstein, 1966) and they also decrease erythropoietin production 
(Piliero et al, 1968; Peschle et al, 1973), possibly or partly by an 
effect on the liver synthesis of the precursor protein (Mirand and 
Gordon, 1966; Gordon and Zanjani, 1971). The normal sex difference in 
haemoglobin concentration and red cell count is, in fact, attributable 
to the depressive effect of oestrogens on erythropoiesis (Thompson, 
1977). This is indicated by the observation that ovariectomy is 
followed by a rise in the red cell indices, an effect which is 
reversible by oestradiol administration (Steinglas et al, 1941). The 
rate of regeneration of erythrocytes following acute haemorrhage in 
normal rats is also decreased by oestrogens (Finkelstein et al, 1944).
Both steroidal and nonsteroidal oestrogens can cause blood 
dyscrasias in the ferret (Chapter 2) and the dog (MacBryde et al, 1942). 
The mechanisms underlying these effects are at present unknown. They 
occur in the dog regardless of the age and sex of the experimental 
animals (Tyslowitz and Dingemanse, 1941), and of their nutritional plane 
(Cruz et al, 1948), and irrespective of the route of administration 
(Lowenstine et al, 1972), and the disorders are not prevented by 
castration, hysterectomy or vaginectomy (Tyslowitz and Dingemanse,
1941), thyroidectomy or parathyroidectomy (Arnold et al, 1936, 1937), 
unilateral nephrectomy, jejunal resection, or the .presence of a gall 
bladder-renal fistula (Cruz et al, 1948), or by the administration of 
vitamin C (Bareuther and Schabbel, 1931), nicotinic acid (Schrade,
1938), androgens or liver extracts (Tyslowitz and Dingemanse, 1941), 
histamine or vitamins A, D and K (Cruz et al, 1948), vitamin E 
(Richtmeir et al, 1947), or 3-methylcholanthrene (Mulligan, 1947). 
Furthermore, the corresponding changes in the ferret were not altered by 
pretreatment with either phenobarbitone or clomiphene (Chapter 2).
The time-course of the bone marrow changes in the ferret and dog 
after oestrogen treatment is consistent with chenically and physically 
induced aplasia, but the phase of myeloid hyperplasia is not. There 
also tend not to be species differences in the response to chemical and 
physical agents (Doull et al, 1980). Amongst the chemical agents there 
are no common structural features or physicochonical properties
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(Lien, 1977) which could indicate the mechanism of action of oestrogens. 
The direct cytotoxic effect of many of the chemical toxins is commonly 
presumed to involve disturbances in DNA structure or function. While 
oestrogens are not usually regarded as genotoxic such effects cannot be 
ruled out: diethylstilboestrol is active in various in vitro assay
systems for genetic damage (Metzler et al, 1980) and has been shown to 
bind to calf thymus DNA in vitro (Blackburn et al, 1976), and 
ethinyloestradiol and oestrone have been shown to bind to rat liver DNA 
in vivo (Jaggi et al, 1978). However, oestrogens have usually been 
reported to be without effect on animal bone marrow cells in culture 
(review, Simonnet 1951; Fox, 1961), though there are some reports of an 
inhibitory action (Schlag and Boll, 1951; Chare and Baum, 1976). Human 
bone marrow in vitro has been reported to show an increse in 
granulocytic activity and a reduction in fibroblasts in response to 
oestrone (Israels and Delamare, 1976). Cn the basis of haematological 
investigations and studies on tritiated thymidine, Chiu (1974) 
postulated that in the dog oestrogens inhibit differentiation of the 
pluripotential stem cell while concurrently stimulating the 
differentiation and maturation of the committed stem cells. Oestrogens 
have also been shown to suppress the pluripotential stem cell in the 
mouse, resulting in falls in leucocytes and platelets and in 
compensatory splenic erythropoiesis (Fried et al, 1973; Adler and 
Trobaugh, 1978). Chrisman and Hinkle (1974) have reported the induction 
of aneuploidy in the bone marrow cells of mice treated with 
diethylstilboestrol diphosphate at a dose of lOOmg/kg. The authors 
suggest that this effect may be mediated through alterations in spindle 
formation.
In female rats treated with hexoestrol, diethylstilboestrol or 
ethinyloestradiol, at a dose level of 60mg/kg/day, the Ihrombotest 
clotting times were lengthened, an effect probably due to interference 
with the synthesis of one or more of the vitamin K dependent clotting 
factors rather than inhibitor activity (Chapter 4). These changes were 
not associated with overt bleeding, were reversible under continuous 
treatment, and were resistant to parenteral vitamin K administration.
For these reasons a coumarin-like vitamin K antagonism was discounted. 
The results of a subsequent study (Chapter 5) indicated that liver 
damage was the probable cause of the clotting disorders. In rats 
treated with hexoestrol at 6Qmg/kg/day, a phase up to Day 20 of marked 
liver impairment was superseded by a more stable, adaptive phase
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thereafter. The evidence from histology and serum chemistry pointed to 
the involvement of the endoplasmic reticulum in these effects. This 
would be consistent with fatty change in some cells (e.g. failure of 
lipoprotein synthesis) and with a reduction in the synthesis of 
extracellular proteins such as albumin and clotting factor VII. An 
effect on hepatic protein synthesis in the rough endoplasmic reticulum 
is known to be one of the main actions of oestrogens on the liver 
(Adlercreutz and Tenhunen, 1970). This is in contrast to the 
progestogens and androgens which mainly affect the smooth endoplasmic 
reticulum and drug-metabolizing enzymes. Oestradiol and testosterone 
have been postulated to be controlling substances in the attachment of 
the ribosomes to the endoplasmic reticulum in the rat liver (e.g.
Fielder et al, 1978, and literature therein). The attachment and 
removal of ribosomes probably regulates protein synthesis. This control 
mechanism may be disrupted by high doses of oestrogens or quite 
different effects may be involved. It was noticeable that in the rat 
oestrogens affected representatives of different classes of proteins to 
different degrees: the clotting disorders - which were associated with
a decrease in clotting factor VII, a glycoprotein - were of longer 
duration than the reductions in albumin, a relatively simple 
polypeptide.
The physiological role of oestrogens in hepatic protein 
synthesis probably accounts for the interrelations of these compounds 
and vitamin K in blood coagulation. The effects of dietary vitamin K 
deficiency are less severe in female rats than male rats (Metta et al, 
1959a, 1959b) and in oestrogen-treated rats than in untreated rats (e.g. 
Jolly et al, 1977). Vitamin K is a cofactor in the carboxylation of 
glutamyl residues during the synthesis of clotting factors II, VII, IX, 
and X (Gallop et al, 1980). This is believed to occur in the 
endoplasmic reticulum and be a postribosomal process. Recent work 
(Nishino, 1979), indicates that oestrogens enhance, and androgens 
depress, the sensitivity of liver microsomes to vitamin K. The action 
of oestrogens may be direct or via an increase in pituitary prolactin 
secretion.
In view of the very high doses of oestrogens used in these 
studies in the rat, the absence of mortalities, and the apparent 
reversibility of the observed effects, the hepatotoxicity of these 
compounds in this species must be regarded as low. Hie extent of the 
hepatotoxicity was greater, however, in the ferret. This was shown fcy
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the histopathological evidence and by the observation that while 
alterations in Thrombotest times occurred in oestrous ferrets treated 
with diethylstilboestrol at a dose of 6mg/kg/day (Chapter 1) no such 
changes were identified in rats receiving similar treatment (Chapter 3). 
Furthermore, the clotting changes in rats treated with higher doses of 
the same oestrogen were self-limiting (Chapter 4) but those in the 
ferrets were progressive and associated with the development of a 
terminal condition (Chapter 1). Death was associated with 
hyperbilirubinaemia and elevations in serum enzymes, and there was 
histological evidence of marked liver damage.
In anoestrous ferrets (Chapter 2) there were alterations in 
plasma fibrinogen levels and in the serum proteins. In those animals 
regarded as most susceptible to oestrogens in terms of uterine 
stimulation, body weight changes and clinical signs, there were 
increases in total serum protein and in the levels of most of the 
protein fractions. The increases in serum proteins in the susceptible 
anoestrous ferrets were surprising in view of the fact that histological 
evidence of liver damage was greatest in these animals. In the less 
susceptible animals the level of total protein was decreased, mainly due 
to reductions in albumin and $2-globulins. These various effects were 
markedly more severe than the changes in serum proteins observed in 
oestrogen-treated rats (Chapter 5) and this suggests major alterations 
in liver function. If direct effects on the endoplasmic reticulum are 
involved here as was postulated to be the case in the rat, then these 
findings indicate notable interspecies variations in the action of high 
doses of oestrogens on this subcellular organelle.
These various observations regarding the serum proteins endorse 
the conclusion that there are marked differences in the character and 
pathokinetics of oestrogen-induced hepatotoxicity in the ferret and rat.
PHARMOOKINEriCS AND METABOLIC ACTIVATION
Of the major effects of oestrogens discussed above, those which 
can perhaps be most readily characterized as "toxic" are the hepatic 
disorders in the ferret and rat and the haemopoietic and renal disorders 
in the ferret. Apart from endocrine factors, the interspecies variation 
in the response to oestrogens could derive from pharmacokinetic 
differences - that is, in the rate of absorption, the pattern of 
distribution, the rate and routes of metabolism, and the rate and routes
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of excretion. Such differences may increase the concentration of the 
test compound and hence exaggerate its effects. The character of the 
metabolites may also be important - many species differences arise 
because of interspecies variations in the amounts of "active" or toxic 
metabolites formed during the course of biotransformation. These 
metabolites may undergo covalent interactions with critical 
macromolecules and thus may cause disturbances of cellular biochemistry. 
This mechanism is believed to be of importance in some aspects of 
carcinogenesis, mutagenesis,, cytotoxicity, allergy, blood dyscrasias, 
and foetotoxicity (Gillette, 1977).
The comparative pharmacokinetics of oestrogens in carnivore and 
rodent species have not been extensively investigated. Some relevant 
studies are those of Pope (1978) working on bifluranol, a fluorinated 
bibenzyl. This compound is structurally related to hexoestrol and, like 
it, displays oestrogenic activity. The fate of bifluranol was found to 
be similar in the rat, mouse, ferret, and dog, and consisted of rapid 
absorption, low blood levels due to extensive hepatic uptake and biliary 
excretion, with predominantly faecal excretion of a single dose within 
96 hours. The major faecal metabolites were glucuronide conjugates. 
Autoradioradiographic and other studies indicated that the distribution 
of bifluranol was similar in the rat, mouse, and ferret. The overall 
pharmacokinetic pattern was therefore similar in the species studied and 
resembled that of diethylstilboestrol in rodents (Fischer et al, 1976). 
Examination of the biliary metabolites of bifluranol in the rat showed 
that 7% of an administered dose (2mg/kg) underwent oxidative metabolism. 
Ihere was no evidence of significant oxidation in the ferret or dog. If 
this latter finding also applies to related nonsteroidal oestrogens then 
this might argue against a metabolic basis to the species differences in 
toxicity. This view must be tentative, however, not least because of 
the lack of information on repeat-dose and high-dose kinetics. In the 
rat, for example, the proportion of polar metabolites of 
diethylstilboestrol rises with dose (Neumann, 1976). Ihere is also no 
data on organ-specific effects in the ferret and rat. However, the 
observation that the adverse effects of oestrogens can be replicated by 
both steroids and nonsteroids (Heywood and Wadsworth, 1980; Chapiters 2 
and 4) - that is, by structurally diverse compounds - might argue 
against the primacy of a metabolic contribution to the species 
differences in oestrogen toxicity.
The observation that stilbene derivatives such as
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4-aminostilbene and 4-dimethylaminostilbene are carcinogenic in several 
organs in the rat (Arcos and Angus, 1974), possibly due to metabolic 
activation, has prompted the speculation that diethylstilboestrol may be 
carcinogenic by a similar mechanism. Hie main examples cited are the 
production by this compound of cervicovaginal cancers in young women 
whose mothers were treated during pregnancy for threatened abortion, and 
the induction of renal tumours in hamsters (Metzler and McLachlan,
1979). In neither case, however, does the metabolic hypothesis appear 
to be applicable. Though the enzymes responsible for oxidative 
metabolism develop in the human foetus to around one third of adult 
levels during the first half of pregnancy (Pelkonen, 1977), these 
enzymes are confined primarily to the liver, intestine, ana kidney 
(Pelkonen et al, 1971). The observed lesions in the affected women were 
highly specific and it seems unlikely that the products of oxidative 
metabolism would affect only these cells. Recently, emphasis has been 
placed on the low binding affinity of diethylstilboestrol for 
alphafoetoprotein compared to that of the steroidal oestrogens (Clark 
and Peck, 1979). It has been suggested that this protein, by a trapping 
effect on oestrogens, reduces the local concentration of these hormones 
in the reproductive tract. The presence of high concentrations of 
unbound nonsteroidal oestrogens could lead to interference with the 
normal processes of reproductive development. As for the induction of 
renal tumours in hamsters, diethylstilboestrol is no more potent than 
oestradiol in this regard (Hamilton, 1975). Ihe susceptibility of 
hamsters to tumours of this kind may be related to species differences 
in the control of pituitary MSH secretion (El Etreby et al, 1979?
Saluja et al, 1979), and, furthermore, the development of these tumours 
can be inhibited by antioestrogens (Li et al, 1980). Most evidence, 
therefore, indicates that in this and other systems diethylstilboestrol 
is carcinogenic by dint of its oestrogenicity rather than its unique 
structural characteristics (Lingeman, 1979).
Covalent binding of active metabolites is also one of the 
possible mechanisms fcy which oral contraceptives cause liver tumours in 
exposed women (Westerholm, 1980). However, while the contraceptive 
oestrogen ethinyloestradiol has been shown to bind to rat liver DNA in 
vivo, the affinity with which it does so is about 10,000 times lower 
than that of typical liver carcinogens such as aflatoxin and 
dimethylnitrosamine (Jaggi et al, 1978).
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ENDOCRINE FACTORS
Rats
While rats treated with hexoestrol at a dose of 60mg/kg/day 
showed only moderate and self-limiting decreases in vitamin K-dependent 
blood clotting as assessed by the Thrombotest reaction, those treated 
with hexoestrol at the same dose together with clomiphene at 20mg/kg/day 
showed more severe changes which proved to be irreversible (Chapter 4, 
Experiment 1). Morbidity was associated with signs of a bleeding 
disorder. The presence of a gross liver-related clotting disorder in 
animals receiving both compounds was confirmed in a later study (Chapter 
4, Experiment 4), and the severity of these changes appeared to be 
dependent upon the dose of antioestrogen. This later study also 
indicated that in the treated animals the customary liver enlargement 
induced by oestrogens was absent. This effect was in turn also shown to 
be dependent upon the dose of antioestrogen (Chapter 6). This suggests 
an inverse relationship between liver size and vitamin K-dependent blood 
clotting in the anti oestrogen- and oestrogen-treated rat. A similar 
relationship is believed to exist between the viable liver mass in 
humans with liver disease and the clotting time as determined by 
Normotest, a one-stage clotting assay derived from Thrombotest (Fuji et 
al, 1980). On the basis of these various observations in the rat, it 
can be concluded that clomiphene - acting at the hypothalamic-pituitary 
axis (see Organ weights) - antagonises an oestrogen-induced liver 
enlargement and thereky exacerbates the hepatic insufficiency in the 
synthesis of at least one of the vitamin K-dependent blood clotting 
proteins. The corollary to this is that the resistance of the rat to 
the inhibitory effects of oestrogen on vitamin K-dependent blood 
clotting is due to a pituitary -^mediated hepatic adaptation. As these 
clotting changes, however, appeared to be only one aspect of the 
functional changes in the rat liver (Chapter 5) this generalization may 
be applicable to the range of inhibitory effects of oestrogens on liver 
function. The presence of hepatic insufficiency with respect to vitamin 
K-dependent clotting factor synthesis in oestrogen-only rats appears to 
indicate that the pituitary-related mechanism is, at least transiently, 
unable to cope. The most obvious reason for this might be that the 
responsive capacity of the rat pituitary is itself limited. The 
biphasic nature of the clotting changes (Chapter 4, Experiments 1 and 5)
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might, in this view, indicate a two-stage pituitary adaptation, possibly 
associated with two waves of mitotic activity in the liver (Chapter 5). 
The observation that the clotting disorders are somewhat more severe in 
older animals (Chapter 4, Experiment 5) may relate to a more effective 
pituitary-hepatic adaptation in younger animals which, in view of the 
role of growth hormone in the liver enlargement, may be due to age- 
dependent changes in the secretion of this hormone.
The foregoing analysis together with observations made elsewhere 
(see Mechanisms of toxicity and species differences) indicate that the 
pituitary is a major determinant of the character of oestrogen toxicity 
in the rat. This conclusion is endorsed by the results of the first rat 
study (Chapter 1) in which animals were treated with diethylstilboestrol 
at a dose of 6mg/kg/day or hexoestrol at a dose of 60mg/kg/day. Most of 
the group differences probably related directly or indirectly to 
hypothalamic-pituitary function: the differences in liver, pituitary,
and adrenal weights, uterine weight and morphology (given the pituitary 
contribution to uterine growth), ovarian morphology, and hepatic 
function including vitamin K-dependent blood clotting. The key role of 
the pituitary particularly as regards adaptive phenomena is shown by an 
early observation that the susceptibility of rats to oestrogen toxicity 
is enhanced by hypophysectomy (see Selye, 1939).
Ferret
A number of correlations emerged from the ferret studies.
1. The anoestrous ferrets (Chapter 2) which were most 
susceptible to the reproductive effects of oestrogens 
(as assessed by uterine morphology and weight) tended 
to show either more toxic effects than the other animals 
(in terms of clinical signs, body weight changes, and 
hepatic and renal histopathology) or a different pattern 
of changes (serum proteins).
2. The oestrous ferrets (Chapter 1) were more susceptible to 
both the reproductive and toxic effects (hepatic and 
haemopoietic) of oestrogens than were the anoestrous animals 
(Chapter 2).
3. Among the oestrous ferrets (Chapter 1) the external signs 
of oestrus were least marked in the longest surviving animals.
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4. The heavier oestrous ferrets (Chapter 1) tended to survive 
longer than the lighter animals.
5. The organ weight changes in oestrous ferrets were most 
marked in animals of low tody weight (Chapters 1 and 7).
From these observations it can be inferred that the 
susceptibility of the female ferret to the reproductive effects of 
oestrogens is related to its susceptibility to the toxic effects of 
these compounds, and that, at least among oestrous ferrets, body weight 
may be a determining factor in both kinds of susceptibility. The organ 
weights are of interest because, in view of the inter cor related 
character of the various changes induced by oestrogens, any factor that 
influences these may be of importance in the other effects. It was 
conjectured above, in fact, that the organ weight changes including the 
uterine weight gains were mediated through the hypothalamic-pituitary 
axis (see Organ weights). This suggests the tentative but testable 
hypothesis that the hypothalamic-pituitary axis may be of importance in 
the haemopoietic changes and may also be a factor in the seasonal and 
body weight effects.
Current evidence indicates that the effect of oestrogens on the 
bone marrow may involve inhibition of the pluripotential stem cell but 
that oestrogens probably do not act as cytoxic agents (see Haematology 
and serum chemistry). It is not possible to say if the alterations in 
the bone marrow cells of dogs given oestrogens is due to direct action or 
indirect action through, for example, humoral factors (Chiu, 1974).
Given the relatively disappointing correlation between the in vitro and 
the in vivo studies (e.g. Fox, 1961), it is plausible to supplement the 
existing concept of direct action with an indirect humoral contribution. 
Ihe proximate effectors involved here may well be the colony^stimulating 
factors which are believed to regulate haemopoiesis (Burgess et al,
1980), but there is nothing known at present about the effects of 
oestrogens on these. The correlative -evidence outlined above suggests a 
pituitary influence on the bone marrow changes - though since these 
changes occur in the absence of the ovaries (lyslowitz and Dingemanse, 
1941) and the thyroid (Arnold et al, 1936, 1937), the influence of the 
pituitary-ovarian and pituitary-thyroid axes can probably be discounted. 
Ihe role of the pituitary in haemopoiesis is shown by the observation 
that a moderate hypoproliferative anaemia is commonly seen with 
hypopituitarism and this represents the absence of growth hormone and
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the summation of the failure of end-organs such as the thyroid, gonads, 
and adrenals. Ihe anaemia results from decreased metabolic demands and 
decreased erythropoietin formation. Some studies have suggested that an 
additional primary pituitary factor may be involved in these effects 
(Eichner, 1980). In view of the postulated existence of a pituitary 
uterotrophic factor, and the intercorrelation noted above between the 
reproductive and toxic effects of oestrogens in the ferret, it may be 
that this novel hormone has actions, direct or indirect, on haemopoietic 
tissue. Alterations in the pituitary-adrenal axis may’also'be of 
relevance here. It is known, for example, that pharmacological doses of 
glucocorticoids result in neutrophilia due to an increased production of 
neutrophils by the bone marrow (Doull et al, 1980). In a study in dogs 
on the effects of corticotropine-(l-23)-tricusipeptideamide (also known 
as ACTH-C23”ami(3e), a synthetic ACTH analogue, three animals died in the 
high dose group (Kramer and Gunzel, 1979). Haematologically, these 
animals showed a marked increase in granulocytes, and a decrease in 
lymphocytes, red cells, and platelets. Decreases in the spleen and 
thymus weights and enlargement of the adrenals were other findings. Ihe 
resemblance of some of these findings to the present results need not be 
stressed. It may also be of interest in the present context that while 
blood neutrophil levels are unchanged in the pregnant rat (Benirschke et 
al, 1978), these are increased in the pregnant dog (Doxey, 1966) and the 
pseudopregnant ferret (data not shown).
Though it is known that the the circulating levels of endogenous 
oestrogens are higher when the ferret is in oestrus than when it is in 
anoestrus (Herbert and Klinowski, 1978), it is unlikely, given the 
enormous doses of oestrogens used in the present studies, that an
additive effect can account for the increased toxicity of oestrogens in
the oestrous ferret. Metabolic factors may be involved here but perhaps 
the more likely explanation of the variations in toxicity would involve
seasonal differences in the hormonal milieu. Such effects are not
confined to the pituitary-ovarian complex. For example, in the'sheep, 
another seasonally breeding animal sensitive to changes in photoperiod, 
there are seasonal cycles in the secretion of growth hormone and 
prolactin, and in the activity of the thyroid and adrenal glands 
(Lincoln and Short, 1980). The seasonal variations in oestrogen 
toxicity may thus relate to differences in endocrine, and particularly 
pituitary, status. The presence of body weight changes and uterine 
weight gains in some anoestrous ferrets (Point 1, above) may denote
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differences in pituitary activity between these and the other animals.
As there were characteristic differences in the serum proteins between 
the susceptible animals and the others, this might indicate a marked 
pituitary influence on hepatic protein synthesis. Ihe augmented levels 
of plasma fibrinogen in the anoestrous ferrets and in oestrogen-treated 
dogs (Bhargava et al, 1979) may also correlate with pituitary changes, 
and more particularly, pituitary-adrenal changes. It has been shown, 
for instance, that in rabbits a pronounced rise in fibrinogen synthesis 
is provoked by an injection of adrenocorticotrophic hormone (Atencio and 
Lorand, 1970). If the pituitary-adrenal axis is also involved in the 
haematological changes, then this would account for the observation in 
the anoestrous ferrets that the sequential changes in the neutrophil 
leucocytes and the changes in plasma fibrinogen were in phase with one 
another.
Ihe association between body weight and toxicity in the ferret 
(Points 4 and 5 above) was not an age-related effect; there was no 
consistent relation between the age and weight of the experimental 
animals. Ihe cause of the body weight correlation is unclear but 
effects linked to pituitary function cannot be excluded. For example, 
in humans, the clearance of pituitary growth hormone is a function of 
body size (MacGillivray et al, 1970).
POTENCY AND TOXICITY
In the oestrous ferret (Chapter 1), there appeared to be some 
relationship between the relative toxicity of diethylstilboestrol and 
hexoestrol, as judged by the survival times of the animals and the 
cumulative lethal dose, and the relative oestrogenic potency of these 
compounds, as determined in various species by bioassays of reproductive 
activity. For a number of reasons the interpretation of this finding is 
problematical - not least because a potency-toxicity relationship did 
not appear to hold in the rat (Chapter 3).
Ihe results of bioassays themselves can be inconsistent when 
different parameters and species are compared (Edgren and Sturtevant, 
1976) and this is illustrated by the oestrogenic potency of hexoestrol 
which has been variously estimated as between a third and a tenth that 
of diethylstilboestrol (lyden, 1951; Heftman, 1970). This level of 
agreement, however, is better than for many other oestrogens when 
compared in different bioassay systems (Edgren and Sturtevant, 1976) and
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this may be a reflection of the similarity of these compounds in terms 
of biological activity (see below). Potency differences probably relate 
to differences in binding affinity for the intracellular oestrogen 
receptor (Siiteri, 1979). Given the varied estimates of the relative 
potency of hexoestrol and diethylstilboestrol, rather a wide range of 
possible results from toxicity studies could be held to fit a spurious 
potency-toxicity relationship.
A second interpretative difficulty relates to the question of 
dose: the amount of oestrogens active in uterine and vaginal bioassays
is measured in micrograms; the doses used in the present studies were 
three or four orders of magnitude greater than this (i.e. 6-6Qmg/kg/day). 
Since oestrogenic activity - in target tissues at least - appears to 
depend upon specific and quantitative binding to intracellular 
receptors, suprathreshold doses might be expected to elicit rather 
similar effects. It should be noted also that the conclusion cannot be 
drawn from the receptor concept that all oestrogens share an identical 
spectrum of hormonal activity (Bolt, 1979). Some oestrogens, for 
example oestriol, are regarded as vaginotrophic and only weakly 
uterotrophic, while others are mainly uterotrophic. Ihe different 
attributes can be overstated, however, as when the various oestrogens 
are administered in high chronic doses the differences in activity are 
much less obvious than when they are administered in low single doses 
(Clark and Peck, 1979). Furthermore, this difficulty was met in the 
present case by using diethylstilboestrol and hexoestrol - two 
structurally similar, highly uterotrophic oestrogens, with agonist but 
no antagonist properties.
The final difficulty bears on the apparently dubious 
relationship between the relative potency of two oestrogens in 
reproductive bioassays and the relative toxicity of the same two 
compounds in terms of, say, bone marrow aplasia.
The results of the first ferret study may have been a fortuitous 
consequence of differences in the kinetic patterns of 
diethylstilboestrol and hexoestrol, but, with regard to the above 
discussion (see Pharmacokinetics and metabolic activation), it is not 
clear at present what the basis of this effect could be. An 
alternative explanation might be that potency and toxicity are related 
because there is an endocrine contribution to the toxic effects, 
including, for example, the bone marrow changes. This view would be 
consistent with an earlier analysis (see Endocrine factors).
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MacBryde et al (1942) found that oestrone, oestradiol benzoate and 
diethylstilboestrol dipropionate given to dogs in equipotent doses 
(lOmg, 1.66mg and 5mg, respectively) were equally toxic, and on the 
basis of a review of the literature another investigator (Chiu, 1974) 
formed the same impression. No speculations have teen offered, however, 
as to the possible nature of this effect.
It was conjectured above that pituitary function was of 
importance in determining the pattern of changes in oestrogen-treated 
ferrets. Oestrogen action at this level may explain the potency- 
toxicity relationship. Compounds of different oestrogenic activity 
might be expected to alter pituitary function to different extents; 
there is, for example, a reasonably good correlation in the rat between 
uterotrophic potency and the magnitude of the regulatory effect on 
gonadotrophin secretion (Fishman and Martucci, 1977). Ihe existence of 
a potency-response curve at the high doses under consideration would 
imply that the relevant aspects of pituitary function in the ferret are 
relatively insensitive to oestrogenic stimulation. This has teen argued 
elsewhere (see Organ weights).
If the potency-toxicity relationship in the ferret is not an 
artefact arising from other factors then this would imply that oestrogen 
toxicity tests in this species are de facto bioassays of oestrogenic 
activity. While this generalisation takes no account, for example, of 
the different patterns of biological activity of the various oestrogen, 
and may therefore be a considerable oversimplification, it does demand a 
new-approach to oestrogen toxicity testing in animals such as the ferret 
and the dog: compounds should be compared at equipotent doses as well 
perhaps as at equimolar doses. The absence of a potency-toxicity 
relationship in the rat (Chapter 3) would accord with the view that the 
pituitary of this species is highly responsive to oestrogens - at high 
doses saturation or threshold effects might be expected to be operative.
OESTROGEN TOXICITY
The picture that has emerged from the present studies is one in 
which the species differences in the toxicity of oestrogens appear to be 
attributable in large part to differences in the response of the 
pituitary. In the rat, ex hypothesi, the pituitary changes which occur 
are reasonably well tolerated and apparently compatible with, and 
conducive to, adaptation (for example, of the liver) and hence low
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toxicity. In the ferret and dog, on the other hand, the pituitary 
changes are not well tolerated and give rise directly or indirectly to 
sequential and ultimately lethal changes in the blood and bone marrow.
In the ferret there are, in addition, liver abnormalities which may also 
be influenced by hypothalamic-pituitary function. The pituitary thus 
plays as important a role in oestrogen toxicity as it does in oestrogen 
endocrinology. The species variations in the pituitary response to 
oestrogens presumably relate to the differences in endocrinology between 
animals with different reproductive patterns - the rat, a polyoestrous 
rodent, the ferret and dog, monoestrous carnivores.
The evidence from the present experiments indicates that in the 
ferret and rat, diethylstilboestrol, hexoestrol and ethinyloestradial, 
when administered in high doses, have qualitatively similar toxic 
effects. As these compounds also tend to have similar toxic effects to 
the natural oestrogens (Heywood and Wadsworth, 1980), the possibility is 
that various oestrogens are toxic primarily by virtue of their hormonal 
activity. In this view, the extrar-oestrogenic toxicity of the synthetic 
compounds may not be appreciable, and furthermore, it may not be 
possible to dissociate the toxic and hormonal effects of oestrogens.
VITAMIN K AND CLOMIPHENE
When administered to rats at a dose of 6Cmg/kg/day for five 
days, vitamin K displayed moderate uterotrophic activity (Chapter 4, 
Experiment 2). Administered with diethylstilboestrol, vitamin K 
appeared to act as a weak antagonist. These effects have been described 
previously (Mellette, 1961). Uterine growth depends on sustained 
nuclear occupancy of the oestrogen-receptor complexes in the target 
cells (review: Clark and Peck, 1979). Compounds with weak oestrogenic
activity such as oestriol, dimethylstilboestrol, and, probably, vitamin 
K, induce only short nuclear occupancy compared to stronger oestrogens 
such as diethylstilboestrol and oestradiol. Given in combination w7ith 
one of these latter compounds, a weak oestrogen competes for the 
cytoplasmic receptor and thus reduces the overall nuclear occupancy 
time. Competition for receptor sites is also the basis of the 
antioestrogenic action of clomiphene but here there is long nuclear 
occupancy. Other factors such as interference with the process of 
receptor replenishment may also be involved (Katzenellenbogen et al, 
1979). Given in single or low doses to immature or ovariectcmized
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rodents, clomiphene can in fact display partial oestrogenic activity 
(Clark and Peck, 1979), but given in high chronic doses to mature 
animals clomiphene, unlike vitamin K, shows no uterotrophic activity 
(Chapter 6). A further difference between these compounds was that 
whereas vitamin K elicited liver growth in rats (Chapter 4, Experiment 
2) - though to a lesser extent than diethylstilboestrol - liver weights 
were decreased by clomiphene (Chapter 6). Many foreign compounds cause 
liver growth (Schulte-Hermann, 1974) and it is therefore unlikely that 
vitamin K is hepatotrophic by virtue of oestrogenic activity at the 
hypothalamic-pituitary axis (see Organ weights). This remains a 
possibility, however.
The compounds of interest in the current work can be 
characterized thus: diethylstilboestrol and hexoestrol, strong
agonists; vitamin K, moderate agonist, weak antagonist; clomiphene, 
weak agonist, strong antagonist. It is perhaps noteworthy that many of 
the properties of oestrogens and antioestrogens can be readily 
discriminated in the course of high-dose studies.
Clomiphene prevented most of the organ weight changes which 
occurred when hexoestrol was administered alone to the rat, and, in 
fact, in high doses the anti oestrogen reduced the organ weights in rats 
treated with both compounds to below control levels (Chapter 6, 
Experiment 1). This latter effect occurred even when the antioestrogen 
was administered alone; the weights of all the organs measured, except 
that of the adrenals, were decreased. The decremental effect of 
clomiphene on the organ weights has been reported for the rat pituitary, 
uterus, and ovaries (Newberne et al, 1966), and mouse liver (Schwarzlose 
and Heim, 1970), but corresponding changes in the spleen, heart, and 
kidneys have not. Cue interpretation of these effects is that 
clomiphene acts to antagonise the endogenous oestrogens at the 
hypothalamic axis, and that therefore in the hexoestrol-treated rat 
there are the combined effects of antagonism of both endogenous and 
exogenous oestrogens. While there is evidence that clomiphene does 
antagonise endogenous oestrogens (Clark and Peck, 1979), this, if 
accepted as the basis of the organ weight changes (Schwarzlose and Heim, 
1970), would imply that the endogenous oestrogens have a more marked 
regulatory influence on the size of the principle organs than has 
hitherto been recognized. Ihis hypothesis would predict that in the 
rat, ovariectomy - that is, the removal of the major source of 
endogenous oestrogen - would markedly decrease the size of the main
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visceral organs. While a decrease in the size of the reproductive organs 
is usual (Young, 1957), there would appear to be no reports of 
ovariectomy leading to the 10-201 decreases in kidney, heart, spleen, 
and liver weights seen after clomiphene treatment. Ihe possibility 
therefore arises that clomiphene may be interfering in some other way 
with the mechanisms determining organ size, rather than, or in addition 
to, antagonising the endogenous oestrogens. The biochemical 
basis of this effect is unclear. Clomiphene has no apparent 
progestational, androgenic, or antiandrogenic effects and does not 
interfere with pituitary-thyroid (TSH) or pituitary-adrenal (ACTH) 
function (Van Maanen et al, 1961). This last-mentioned observation is of 
interest because the adrenal, was the only organ of those weighed which 
was not reduced in size by clomiphene and, furthermore, was the only 
organ which weighed more in rats treated with clomiphene and hexoestrol 
than in those animals treated with hexoestrol alone (Chapter 6, 
Experiment 1). Why the adrenal should behave differently to the other 
organs is unclear. Clomiphene does not affect all animals: it does not
alter the organ weights of male rats or of dogs of either sex (Newberne 
et al, 1966) or, in all probability, the organ weights of female ferrets 
(Chapter 7).
Recently, a high-affinity, intracellular binding site for non­
steroidal antioestrogens has been described in oestrogen target tissues 
(Sutherland et al, 1980). This is distinct from the oestrogen receptor. 
Ihe possibility that the antioestrogen binding site has a natural ligand 
and that clomiphene and other triphenylethylene derivatives mimic the 
effects of this warrants investigation.
FERRET IN TOXIOG&QGY
On the basis of the studies reported in this thesis (Chapters 1, 
2, and 7) a preliminary assessment can be made on the suitability of the 
ferret as a replacement for the beagle dog in toxicological studies (see 
Introduction). Aside from considerations of pharmacokinetic similarity 
to man - which must be the subject of ad hoc studies (Smith, 1978) - the 
outstanding advantages of the ferret over the dog are those of cost and 
convenience: it is more economical to purchase (where breeding
facilities are unavailable) and it is also easier and more economical to 
house and maintain. A further advantage is that the use of the ferret 
is not an emotive issue with the public as is the use of the dog. Both
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species, however, share the attributes of tolerating captivity well, of 
reaching adult weight rapidly, and of being large enough for individual 
clinical monitoring. Notwithstanding these observations there are a 
number of practical difficulties associated with the use of the ferret: 
for example, it is less docile than the beagle dog, it is markedly less 
easy to bleed, and it is less easy to obtain an uncontaminated urine 
sample from it by non-surgical cannulation techniques.
Both the ferret and dog are relatively easy to breed in captivity 
though the shorter oestrous cycle of the latter is an advantage. Hie 
availability of laboratory-bred ferrets would eliminate the current need 
to use animals which are of unknown genetic origin, which have 
heterogeneous body weights, and which are not invariably free of disease 
and parasites (Chapters 1 and 2? Andrews et al, 1979). There is 
probably less individual variation in the physiology of the reproductive 
cycle in the ferret than in the dog (Christie and Bell, 1971) and this 
makes the former species particularly suitable for reproductive studies. 
On present evidence it is not possible to determine if the ferret or the 
dog is more prone to hormone-induced uterine disorders and mammary 
tumours, but the susceptibility of the ferret to neoplastic disorders in 
general, both spontaneous (Cotchin, 1980) and induced by chemical 
carcinogens (Figg, 1944), is regarded as low.
* A major difficulty with the ferret is the relative paucity of 
background information on physiology, pharmacology, pathology, and so 
on. Furthermore, what information is available is widely scattered in 
the literature. Hie ferret has been used in studies in virology (Shaver 
et al, 1964), drug metabolism (Ioannides et al, 1977), respiratory 
histology (Hyde et al, 1979), gastroenterology (Shillingford et al,
[ 1974), ethology (Kaufman, 1980), cardiology (Truek et al, 1974),
genetics (Pitt, 1921), teratogenesis (Beck et al, 1976), and 
reproductive physiology (Donovan and Haar, 1977). Hie haematology, 
biochemistry, and gross pathology of the ferret have also recently been 
investigated (Thornton et al, 1979), as have its growth characteristics 
(Shump and Shump, 1978). General information on the biology and 
laboratory use of the ferret can be obtained from several sources 
(Pyle, 1940; Willis and Barrow, 1971; Hammond and Chesterman, 1976).
Overall, the ferret has considerable cost advantages over the 
beagle dog, but there is less background information on the use of 
this species, and it also lacks the dog's balance of practical assets.
The ferret may thus be unsuitable for routine use in safety evaluation,
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but nevertheless appears to represent a useful second non-rodent species 
where additional toxicological characterization of a drug , or chemical is 
required - particularly if the alternative is a primate. The germane 
example here is the atypical haematological response of the dog to 
oestrogens. Ihe cat, another carnivore, does not display the same 
reaction to oestrogens, but the ferret does. Supplementary information 
can thus be obtained from studies on this latter species.
RELEVANCE OF ANIMAL STUDIES TO HOMANS
A prediction from animal studies that the clinical use of 
oestrogens would be associated with few serious toxic effects has been 
proved correct (Drill, 1974). Of the reported adverse effects (see 
Introduction) some could not be expected to be revealed in the course of 
preclinical animal studies either because they are peculiar to humans 
(e.g. anxiety, depression) or because they occur in such low incidence. 
This association of oral contraceptives with hypertension was 
predictable, but was not predicted - it received retrospective 
confirmation only (Leonard, 1974). Metabolic and liver disorders (e.g. 
jaundice) were predictable from experimental work but cardiovascular and 
thromboembolic disorders were not. Oestrogens do not cause thrombosis 
in animals and in fact the data on the rat, dog, and ferret indicate 
prolongation of clotting times secondary to alterations in liver and 
bone marrow function. The only indication from the present studies of a 
tendency towards increased coagulation was a transient increase in 
fibrinogen in oestrogen-treated ferrets (Chapter 2). Such experiments 
as these have thus failed to illuminate the problem of thromboembolism, 
have not suggested treatments, or served to identify at-risk 
individuals. It is of interest in this context that during the 1950s, 
at about the time the oral contraceptives were undergoing clinical 
trials, oestrogens were used as haemostatic agents in the treatment of 
spontaneous haemorrhage (e.g. epistaxis) and to curtail bleeding 
following such surgical procedures as tonsillectomy and prostatectomy 
(Herr et al, 1970). The mechanism of action of oestrogens in this 
regard was not established but their effectiveness in promoting blood 
coagulation was such as to lead one investigator (Jacobson, 1955) to 
postulate that oestrogen deficiency was a causative factor in the 
various manifestations of spontaneous haemorrhage in both men and wcmen.
Oestrogens have been described as causative factors in the
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development of breast and genital neoplasms in humans (Westerholm, 1980). 
Such effects have been frequently reported in animals but oestrogens do 
not have the general biological property of increasing the occurrence of 
tumours across the laboratory species. Ihe neoplastic effect of 
oestrogens in animals is typically dependent upon strain or species 
susceptibility and the use of high doses for protracted periods. For 
these reasons, while tumour studies have sensibly prompted a cautious 
approach to the clinical use of oestrogens, they have not been regarded 
as having detailed predictive value. Among oral contraceptive users 
there is in any case a decreased incidence of benign lesions of the 
breast and ovary (Laurence and Bennet, 1980), and of endometrial 
carcinoma (Weiss and Sayvetz, 1980). The risk of liver neoplasms, 
however, is probably increased in these women (Westerholm, 1980). This 
might have been predicted from the results of toxicity tests performed 
in the 1960s, but these findings received little attention at the time 
(Lingeman, 1979).
There is an increased prevalence of adenocarcinoma of the 
genital tract among young women exposed to nonsteroidal oestrogens 
in utero. These effects were not predicted but have received tentative 
experimental corroboration (Heywood and Wadsworth, 1980).
Oestrogens produce such widespread changes in experimental 
animals, even in general toxicity studies, that*it is difficult to 
separate pharmacological from toxicological effects. The present 
studies,indeed, have indicated that the 'toxicity' of oestrogens in 
animals is more fruitfully regarded as 'endocrine pathology' - with all 
that that implies for an interpretative emphasis on the species 
differences in endocrinology and for the experimental approach adopted 
in follow-up studies. Because of species differences, 
pathological changes which occur in a selected animal species, 
particularly if as in the present instance the doses of oestrogens are 
high, may have dubious relevance for the human experience. Examples of 
•such effects in studies in oestrogen toxicity would include tumours at 
various sites (e.g. renal tumours in hamsters), osteosclerosis in mice 
(Crandall et al, 1980), and the haematological abnormalities in dogs and 
ferrets. None of these effects have been observed in humans even after 
prolonged treatment with daily doses of up to 500mg (Karnaky, 1945).
There is one case on record, however, of nyelodyspoietic syndrome 
(characterized by pancytopenia and an excess of myeloblasts in the bone 
marrow) developing in a patient treated for prostatic cancer with
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diethylstilboestrol at a daily dose of 150mg for 7 years (Andersen and 
Lynch, 1980) - though whether the oestrogen actually caused this 
haematological disorder was unclear. The recognition, albeit tentative, 
that the haematological changes in the dog and ferret may result, in 
part, from species-specific disturbances in endocrine homeostasis would 
represent a rational basis for the long-held opinion that these effects 
are irrelevant to an assessment of the risk to humans of oestrogens.
The analogy here is the dog's susceptibility to mammary nodules and 
tumours after exposure to progestational steroids. This is believed to 
be due mainly to species differences in endocrinology; oestrogens and 
prolactin are the most important hormones involved in mammary 
tumourigenesis in the rat, mouse, and perhaps humans, but progesterone 
and possibly growth hormone appear to fulfill this role in the dog 
(Meites, 1979; El Etreby and Graf, 1979).
The foregoing observations indicate that the predictive value, 
hitherto somewhat disappointing, of studies in hormonal toxicology will 
be improved by advances in comparative endocrinology - but also, 
conversely, that fundamental advances in endocrinology can be prompted 
by findings in hormonal toxicology.
SUGGESTIONS FOR FURTHER WORK
Several lines of enquiry can be suggested on the basis of the 
work presented in this thesis. These are as follows.
1. The existence or otherwise of pituitary 'uterotrophic factor'.
2. The species differences between the ferret and the rat in the 
hepatotoxicity of oestrogens.
3. The endocrine contribution to the oestrogen-induced 
haematological disorders in the dog and ferret - for example, 
the effects of hypopbysectomy and adrenalectomy on the observed 
changes.
4. The nature of the decremental effect of clomiphene on the 
organ weights of the female rat - for example, treatment of 
ovariectcmized rats with clomiphene to assess the role of the 
endogenous oestrogens.
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APPENDIX
MATERIALS
AND
METHODS
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CHEMICALS
The following chemicals were obtained from Sigma London Chemical 
Co. Ltd., Poole, Dorset:
diethylstilboestrol
(4,4'-dihydroxy- a, 3-diethylstilbene)
17a-ethinyloestradiol
(17a-ethinyl- l,3,5(10)-estratriene 3, 173-diol) 
hexoestrol
(4,4*-dihydroxy- a, 3-diethyldiphenylethane) 
testosterone
(17 3-hydroxy-4-androsten-3-one) 
vitamin
(phytamenadione; 2-methyl-3-phytyl-I,4-napthoquinone) 
vitamin k3
(menadione; 2-methyl-l, 4-napthoquinone) 
warfarin
(3-(a-acetonylbenzyl)-4-hydroxy coumarin)
Unless otherwise stated the dosing vehicle for these compounds 
was isopropyl iryristate (myristic acid isopropyl ester; Sigma). 
Phenobarbitone sodium was obtained from BIB Chemicals Ltd., Poole, 
Dorset, and clomiphene citrate (2-(p-(2-chloro-l, 2-diphenyl- 
vinyl) phenoxy) triethylamine dihydrogen citrate) (mixed isomers) from 
Merrell Division, Richardson-Merrell Ltd., Slough, Berkshire. 
Ooncanavalin A was supplied by Miles Laboratories, Slough, Berkshire.
The antiserum to rat o^-macrofoetoprotein was supplied by 
Professor J. van Gool, Department of Experimental Medicine, University 
of Amsterdam, The Netherlands. The monkey antiserum to rat growth 
hormone was supplied under the National Institute of Arthritis, 
Metabolism and Digestive Diseases (NIAMDD) Rat Pituitary Hormone 
Distribution Program by Dr. A.F.Parlow, Harbor General Hospital,
Torrance, California, U.S.A. The designation of the antiserum 
preparation was NIAMI>-Anti-Rat GH-serum-4. This preparation does not 
cross-react with rat TSH, FSH or LH, and only approximately 1.6% with 
rat prolactin.
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ENVIRCNMENTRL CONDITICNS
Ventilation 
Temperature 
Humidity 
Light schedule
ANIMALS
Rat
Species
Strain
Sex
Description
Age
Source
Housing
Bedding
Diet
Water
Drug
administration 
Blood sampling
2030 air changes per hour
22±2°C
505%
12hr light (7am - 7pn)
12hr dark
Rattus norvegicus, L.
Wistar albino, closed colony, random-bred 
Female
Sexually mature, nulliparous; healthy 
175g, 50 days; 200g, 65 days;
225g, 75 days; 250g, 95 days;
275g, >100 days
Rodent Breeding Unit, University of Surrey 
Polycarbonate cages, 5 rats per cage 
Wood shavings, sterilised with ethylene 
oxide
Spratts Laboratory Diet No. 1, Expanded 
Provided without restriction 
Oral by gastric intubation needle
Conscious animal; amputation of tail-tip 
after warming by light bulb; sealed
with Nobecutane, EOT Pharmaceuticals Spray
Ltd., London
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Ferret
Species
Forir/markings
Sex
Description
Age
Source
Holding period
Housing
Bedding
Diet
Water
Drug
administration 
Blood sampling
Reproductive
status
Mustela putorius furo, L.
Albino and polecat (pigmented)? 
genetically undefined
Fenale
Sexually mature, nulliparous; healthy
9 months to 2 years
A. S. Roe, Little Fakenham, Thetfora,
Norfolk
6 weeks acclimatization? baseline data
Galvanised cages, one ferret per cage
Wood shavings, sterilised with ethylene 
oxide
Laboratory
Diet B (Purr), BP Nutrition Ltd.
Provided without restriction 
Oral by gastric intubation needle
Conscious animal? tail clipped free of 
hair? warmed in water? venepuncture
(Bleakley, 1980)
Vaginal smear and estimation of vulval 
swelling (for discussion, see Marshall, 1966)
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AUTOPSY PROCEDURES
Autopsies were performed in fulfilment of the requirements of 
experimental protocols and on animals found dead or moribund. Ihe rats 
were anaesthetized either with intraperitoneal pentobarbitone sodium 
(Sagatal, May and Baker, Dagenham, Essex) at 6Qmg/kg body weight, or 
with ether. Ihe ferrets were anaesthetized with intraperitoneal 
pentobarbitone sodium (Sagatal) at 60mgA9 body weight. Ihe animals 
were exsanguinated from the inferior vena cava. Ihe organs were removed 
in a standard order, trimmed free of connective tissue and fat, and 
weighed. The tissues were preserved in buffered 10% formal-saline. 
Femoral marrow was obtained by dissecting out the femur and cracking it 
longitudinally with bone forceps.
HISTOLOGICAL TECHNIQUES
The tissues ;were routinely processed by paraffin wax embedding 
techniques (Culling, 1974), sectioned at 7 y, and stained with 
haematoxylin and eosin. Sections of liver and kidney were also stained 
with Periodic acid-Schiff (glycogen) and Oil Red 0 (lipid). Where 
required, additional pieces of tissue were stained with Perl's Prussian 
Blue (ferric iron). Pieces of fixed sternum were decalcified in Gooding 
and Stewart's Fluid, and then routinely processed and stained with 
haematoxylin and eosin. Femoral marrow smears were fixed and stained 
with May-Grunwald/Giemsa. Vaginal smears were stained with Leishman's.
Ehrlich's haonatoxylin Snith and Bruton (1977,pp. 122-3) 
and eosin
Periodic acid-Schiff 
Oil Red 0
Perl's Prussian Blue
Gooding and 
Stewart's Fluid
Culling (1974,pp.361) 
Culling (1974,pp.378) 
Culling (1974,pp.63)
Culling (1974,pp.267-8)
May-Grunwald/Giansa
Leishman's
Dacie and Lewis (1975) 
Culling (1974, pp. 406)
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BAEMMX3L0GY
Whole blood for haematology was dispensed onto the potassium 
salt of ethylenediamine tetracetic acid as anticoagulant. Ihe 
haematological tests were carried out according to the general 
principles advocated by Dacie and Lewis (1975).
Packed cell volume (PCV) 
Haonoglobin (Hb)
Red cell count (RBC)
White cell count (WBC)
Differential white cell count 
and red cell morphology
Microhaenatocr it
Cyanmethaemoglobin
Coulter Counter Model 
Dn Medical
Coulter Counter Model 
Dn Medical
Stained blood film; 
May-Grunwald/Giemsa
Reticulocyte count 
(Reties)
Platelet count (Pitit)
Red cell osmotic fragility
Mean cell volume (MCV)
r
Mean cell haemoglobin (MCH)
Mean cell haemoglobin 
concentration (MCHC)
Supravitally stained film?
0.5% New methylene blue
Haamocytcmeter
Colorimetry
(Anticoagulant:lithium heparin)
PCV(%)_ x 10
RBC (10^ /nrn3)
■HblgZdJLl x IQ
RBC (10^ /nm3)
Bb.,(..g/dJD. x IQQ 
PCV(%)
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BDOCD CCVGUIATION
Whole blood was dispensed into tubes containing 3.8% (w/v) 
trisodium citrate for Ihrombotest and the assay of factor VII.
Thrcmbotest Commercial reagent
(Product code no. 25630 3E) from BEti 
Chenicals Ltd., Poole, Dorset.
10yl whole blood added to 0.5ml reconsti­
tuted reagent (i.e. a final dilution of 1 
in 51), or 2Qil whole blood added to 0.75ml 
reconstituted reagent (1 in 37.5)
(Spurling et al, 1974).
Factor VII One-stage assay of citrated plasma using
the method of Austen and Rhymes (1975) 
modified as follows.
Thromboplastin: saline extract of rat
brain. Substrate: factor Vll-deficient
plasma obtained from female rats treated 
with warfarin (Sigma) at a dose of 
2mg/kg/day for 4 days.
Fibrinogen Estimated in the microhaemtocrit plasma by
the heat precipitation method of Blaisdell 
and Dodds (1977).
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SERDM CHEMISTRY
Blood was collected in glass centrifuge tubes, allowed to clot, 
centrifuged at 2500rpn for 15 minutes, and the serum removed*
Total proteins
Albumin
Differential
proteins
Glycoproteins
Biuret
Brcmocresol green
Cellulose acetate electrophoresis
Measurement of binding to the plant lectin 
Concanavalin A: either, Laurell rocket
electrophoresis (Laurell, 1966) using agarose
gel containing 0.1% (w/v) of lectin;
or, nephelcmetry (Kallestad LSA 290
Nephelometer) using lOmg lectin in
100ml phosphate-buffered saline (pH7.2)
containing 30g/l polyethylene glycol
(MW 6000) (Kohn et al, 1980; Warren et al,
1980)
Alkaline
phosphatase
(EC 3.1.3.1)
Chapter Is method of Bergmeyer (1974, pp. 
856-864): Boehringer
Test-Combination (Cat. no. 123 889),
Boehringer Corporation Ltd., (London),
L^es, East Sussex.
Alanine Method of Bergmeyer (1974, pp. 752-767)
aminotransferase
(EC 2.6.1.2)
Isocitric
dehydrogenase
(EC 1.1.1.42)
Method of Bergmeyer (1974, pp. 624-631)
Bilirubin Boehringer Test-Combination 
(Cat. no. 123 927)
o^-Macro-
foetoprotein
Radial immune diffusion (Mancini, 1965) using 
a rabbit antiserum to rat c^-macrofoetoprotein
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Quality
control
Validate-Af Quality Assurance Serum 
(Product no. 30183), General Diagnostics,
Morris Plains, New Jersey, U.S.?Precinorm U
Control Serum, Boehringer
(Cat. no. 171 735)
URINALYSIS
PH
protein
glucose
ketones
bilirubin
blood
Bili-Labstix, Ames Co., Stoke Poges, Slough
Sediment Centrifuged at 3000 rpm for 10 minutes and 
examined microscopically
FAECAL ANALYSIS
Blood
STATISTICAL ANALYSIS
Clinical assay set: Peroheme 40-C (Product
code no. 25029 4T), BDH Chemicals Ltd.,
Poole, Dorset.
_ _ j ... . Zx2-(Zx)2/n
Standard deviation (SD) = / ---— :— -^--
Student's t test
REFERENCE VALUES
Rat Mitruka and Rawnsley, 1977
Ferrets Thornton et al, 1979
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Letter to the Editor
The Effect of Oestrogens on Blood Clotting in the Rat
F. K. SCHATTAUER VERLAG ■ STUTTGART- NEW YORK
Thrombos. Haemostas. (Stuttgart)
Thrombos. Haemostas. (Stuttg.), 1979, 42. 1069
The Effect of Oestrogens on Blood Clotting in the Rat
Dear Sir,
We wish to draw your attention to a hitherto unreported relationship between oestrogens 
and the blood clotting mechanism of the rat which we have recently observed in current 
studies on comparative toxicity.
While it is well known that exposure of the dog to oestrogens leads to the development of 
a bleeding diathesis due to thrombocytopenia arising from bone marrow depression (Hall 
1972), in the rat clotting disorders of this nature have not been associated with oestrogen 
administration. We have observed, however, that the daily, oral administration of 60 mg/kg 
of hexoestrol (a non-steroidal oestrogen) to adult female rats, though not resulting in overt 
bleeding does give rise to a prolongation in the clotting times as measured by Thrombotest*, 
which is an index of the activity of three of the vitamin K-dependent liver group of clotting 
factors, namely II, VII and X. As can be seen from Table 1 the phenomenon may be 
transient, possibly arguing against a coumarin-like vitamin K antagonism which tends to be 
irreversible. The prolongation would also appear to be biphasic over the period of the study, 
the Thrombotest times of the oestrogen-treated animals being significantly increased as 
compared to controls in both the first (day 3) and second (day 13) phases (p <0.001 and 
p<0.05, respectively).
Although we have used a high dosage, in the light of these observations in dogs and rats 
the relevance of animal studies purporting to evaluate oestrogens for their safety-in-use in 
humans seem very questionable in view of the apparent contrary provocation of a tendency 
to thrombosis and other circulatory disorders in human female users of oral contraceptive 
formulations incorporating oestrogens (Vessey and Mann 1978).
Further investigations are underway in this laboratory to determine the nature of this 
effect in the rat.
J. E. Hart 
S. M. Loscombe 
D. E. Hall 
D. V. Parke
Department of Biochemistry
Table 1 Thrombotest clotting times in seconds (mean ±  1 S.D.) of hexoestrol treated and control 
animals.
Day number 
1 3 7 10 13 17
Hexoestrol 29.1 ±2.5 41.6+3.1 35.3±3.4 45.7 ±10.9 97.4 ±54.6 47.3 ±18.5
(n =  10) 
Control 31.0±2.1 30.6±2.0 30.7±2.8 33.0± 3.7 36.1 ±  8.2 34.2 ±  3.2
(n =  7)
* 20 p,l whole blood to 0.75 ml reconstituted Thrombotest reagent.
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